<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE sequence-cwu SYSTEM "us-sequence-listing-v1_3-2020-10-08.dtd" [ ]><sequence-cwu id="SEQLST-1"><publication-reference><document-id><country>US</country><doc-number>20230000842</doc-number><kind>A1</kind><date>20230105</date></document-id></publication-reference><number>1</number><sequence-list-new-rules><s100><s160>49</s160></s100><s200><s210>1</s210><s211>484</s211><s212>PRT</s212><s213>Artificial</s213><s220><s223>Human CLK1 protein isoform 1</s223></s220></s200><s400> 1Met Arg His Ser Lys Arg Thr Tyr Cys Pro Asp Trp Asp Asp Lys Asp1               5                   10                  15Trp Asp Tyr Gly Lys Trp Arg Ser Ser Ser Ser His Lys Arg Arg Lys            20                  25                  30Arg Ser His Ser Ser Ala Gln Glu Asn Lys Arg Cys Lys Tyr Asn His        35                  40                  45Ser Lys Met Cys Asp Ser His Tyr Leu Glu Ser Arg Ser Ile Asn Glu    50                  55                  60Lys Asp Tyr His Ser Arg Arg Tyr Ile Asp Glu Tyr Arg Asn Asp Tyr65                  70                  75                  80Thr Gln Gly Cys Glu Pro Gly His Arg Gln Arg Asp His Glu Ser Arg                85                  90                  95Tyr Gln Asn His Ser Ser Lys Ser Ser Gly Arg Ser Gly Arg Ser Ser            100                 105                 110Tyr Lys Ser Lys His Arg Ile His His Ser Thr Ser His Arg Arg Ser        115                 120                 125His Gly Lys Ser His Arg Arg Lys Arg Thr Arg Ser Val Glu Asp Asp    130                 135                 140Glu Glu Gly His Leu Ile Cys Gln Ser Gly Asp Val Leu Ser Ala Arg145                 150                 155                 160Tyr Glu Ile Val Asp Thr Leu Gly Glu Gly Ala Phe Gly Lys Val Val                165                 170                 175Glu Cys Ile Asp His Lys Ala Gly Gly Arg His Val Ala Val Lys Ile            180                 185                 190Val Lys Asn Val Asp Arg Tyr Cys Glu Ala Ala Arg Ser Glu Ile Gln        195                 200                 205Val Leu Glu His Leu Asn Thr Thr Asp Pro Asn Ser Thr Phe Arg Cys    210                 215                 220Val Gln Met Leu Glu Trp Phe Glu His His Gly His Ile Cys Ile Val225                 230                 235                 240Phe Glu Leu Leu Gly Leu Ser Thr Tyr Asp Phe Ile Lys Glu Asn Gly                245                 250                 255Phe Leu Pro Phe Arg Leu Asp His Ile Arg Lys Met Ala Tyr Gln Ile            260                 265                 270Cys Lys Ser Val Asn Phe Leu His Ser Asn Lys Leu Thr His Thr Asp        275                 280                 285Leu Lys Pro Glu Asn Ile Leu Phe Val Gln Ser Asp Tyr Thr Glu Ala    290                 295                 300Tyr Asn Pro Lys Ile Lys Arg Asp Glu Arg Thr Leu Ile Asn Pro Asp305                 310                 315                 320Ile Lys Val Val Asp Phe Gly Ser Ala Thr Tyr Asp Asp Glu His His                325                 330                 335Ser Thr Leu Val Ser Thr Arg His Tyr Arg Ala Pro Glu Val Ile Leu            340                 345                 350Ala Leu Gly Trp Ser Gln Pro Cys Asp Val Trp Ser Ile Gly Cys Ile        355                 360                 365Leu Ile Glu Tyr Tyr Leu Gly Phe Thr Val Phe Pro Thr His Asp Ser    370                 375                 380Lys Glu His Leu Ala Met Met Glu Arg Ile Leu Gly Pro Leu Pro Lys385                 390                 395                 400His Met Ile Gln Lys Thr Arg Lys Arg Lys Tyr Phe His His Asp Arg                405                 410                 415Leu Asp Trp Asp Glu His Ser Ser Ala Gly Arg Tyr Val Ser Arg Arg            420                 425                 430Cys Lys Pro Leu Lys Glu Phe Met Leu Ser Gln Asp Val Glu His Glu        435                 440                 445Arg Leu Phe Asp Leu Ile Gln Lys Met Leu Glu Tyr Asp Pro Ala Lys    450                 455                 460Arg Ile Thr Leu Arg Glu Ala Leu Lys His Pro Phe Phe Asp Leu Leu465                 470                 475                 480Lys Lys Ser Ile</s400><s200><s210>2</s210><s211>1455</s211><s212>DNA</s212><s213>Artificial</s213><s220><s223>Human CLK1 cDNA isoform 1</s223></s220></s200><s400> 2atgagacact caaagagaac ttactgtcct gattgggatg acaaggattg ggattatgga     60aaatggagga gcagcagcag tcataaaaga aggaagagat cacatagcag tgcccaggag    120aacaagcgct gcaaatacaa tcactctaaa atgtgtgata gccattattt ggaaagcagg    180tctataaatg agaaagatta tcatagtcga cgctacattg atgagtacag aaatgactac    240actcaaggat gtgaacctgg acatcgccaa agagaccatg aaagccggta tcagaaccat    300agtagcaagt cttctggtag aagtggaaga agtagttata aaagcaaaca caggattcac    360cacagtactt cacatcgtcg ttcacatggg aagagtcacc gaaggaaaag aaccaggagt    420gtagaggatg atgaggaggg tcacctgatc tgtcagagtg gagacgtact aagtgcaaga    480tatgaaattg ttgatacttt aggtgaagga gcttttggaa aagttgtgga gtgcatcgat    540cataaagcgg gaggtagaca tgtagcagta aaaatagtta aaaatgtgga tagatactgt    600gaagctgctc gctcagaaat acaagttctg gaacatctga atacaacaga ccccaacagt    660actttccgct gtgtccagat gttggaatgg tttgagcatc atggtcacat ttgcattgtt    720tttgaactat tgggacttag tacttacgac ttcattaaag aaaatggttt tctaccattt    780cgactggatc atatcagaaa gatggcatat cagatatgca agtctgtgaa ttttttgcac    840agtaataagt tgactcacac agacttaaag cctgaaaaca tcttatttgt gcagtctgac    900tacacagagg cgtataatcc caaaataaaa cgtgatgaac gcaccttaat aaatccagat    960attaaagttg tagactttgg tagtgcaaca tatgatgacg aacatcacag tacattggta   1020tctacaagac attatagagc acctgaagtt attttagccc tagggtggtc ccaaccatgt   1080gatgtctgga gcataggatg cattcttatt gaatactatc ttgggtttac cgtatttcca   1140acacacgata gtaaggagca tttagcaatg atggaaagga ttcttggacc tctaccaaaa   1200catatgatac agaaaaccag gaaacgtaaa tattttcacc acgatcgatt agactgggat   1260gaacacagtt ctgccggcag atatgtttca agacgctgta aacctctgaa ggaatttatg   1320ctttctcaag atgttgaaca tgagcgtctc tttgacctca ttcagaaaat gttggagtat   1380gatccagcca aaagaattac tctcagagaa gccttaaagc atcctttctt tgaccttctg   1440aagaaaagta tatag                                                    1455</s400><s200><s210>3</s210><s211>526</s211><s212>PRT</s212><s213>Artificial</s213><s220><s223>Human CLK1 protein isoform 2</s223></s220></s200><s400> 3Met Ala Ala Gly Arg Arg Pro Ala Ser Ala Leu Trp Pro Glu Arg Arg1               5                   10                  15Gly Ser Pro Leu Arg Gly Asp Leu Leu Gly Phe Gln Asn Val Arg Glu            20                  25                  30Pro Ser Ser Cys Gly Glu Thr Leu Ser Gly Met Arg His Ser Lys Arg        35                  40                  45Thr Tyr Cys Pro Asp Trp Asp Asp Lys Asp Trp Asp Tyr Gly Lys Trp    50                  55                  60Arg Ser Ser Ser Ser His Lys Arg Arg Lys Arg Ser His Ser Ser Ala65                  70                  75                  80Gln Glu Asn Lys Arg Cys Lys Tyr Asn His Ser Lys Met Cys Asp Ser                85                  90                  95His Tyr Leu Glu Ser Arg Ser Ile Asn Glu Lys Asp Tyr His Ser Arg            100                 105                 110Arg Tyr Ile Asp Glu Tyr Arg Asn Asp Tyr Thr Gln Gly Cys Glu Pro        115                 120                 125Gly His Arg Gln Arg Asp His Glu Ser Arg Tyr Gln Asn His Ser Ser    130                 135                 140Lys Ser Ser Gly Arg Ser Gly Arg Ser Ser Tyr Lys Ser Lys His Arg145                 150                 155                 160Ile His His Ser Thr Ser His Arg Arg Ser His Gly Lys Ser His Arg                165                 170                 175Arg Lys Arg Thr Arg Ser Val Glu Asp Asp Glu Glu Gly His Leu Ile            180                 185                 190Cys Gln Ser Gly Asp Val Leu Ser Ala Arg Tyr Glu Ile Val Asp Thr        195                 200                 205Leu Gly Glu Gly Ala Phe Gly Lys Val Val Glu Cys Ile Asp His Lys    210                 215                 220Ala Gly Gly Arg His Val Ala Val Lys Ile Val Lys Asn Val Asp Arg225                 230                 235                 240Tyr Cys Glu Ala Ala Arg Ser Glu Ile Gln Val Leu Glu His Leu Asn                245                 250                 255Thr Thr Asp Pro Asn Ser Thr Phe Arg Cys Val Gln Met Leu Glu Trp            260                 265                 270Phe Glu His His Gly His Ile Cys Ile Val Phe Glu Leu Leu Gly Leu        275                 280                 285Ser Thr Tyr Asp Phe Ile Lys Glu Asn Gly Phe Leu Pro Phe Arg Leu    290                 295                 300Asp His Ile Arg Lys Met Ala Tyr Gln Ile Cys Lys Ser Val Asn Phe305                 310                 315                 320Leu His Ser Asn Lys Leu Thr His Thr Asp Leu Lys Pro Glu Asn Ile                325                 330                 335Leu Phe Val Gln Ser Asp Tyr Thr Glu Ala Tyr Asn Pro Lys Ile Lys            340                 345                 350Arg Asp Glu Arg Thr Leu Ile Asn Pro Asp Ile Lys Val Val Asp Phe        355                 360                 365Gly Ser Ala Thr Tyr Asp Asp Glu His His Ser Thr Leu Val Ser Thr    370                 375                 380Arg His Tyr Arg Ala Pro Glu Val Ile Leu Ala Leu Gly Trp Ser Gln385                 390                 395                 400Pro Cys Asp Val Trp Ser Ile Gly Cys Ile Leu Ile Glu Tyr Tyr Leu                405                 410                 415Gly Phe Thr Val Phe Pro Thr His Asp Ser Lys Glu His Leu Ala Met            420                 425                 430Met Glu Arg Ile Leu Gly Pro Leu Pro Lys His Met Ile Gln Lys Thr        435                 440                 445Arg Lys Arg Lys Tyr Phe His His Asp Arg Leu Asp Trp Asp Glu His    450                 455                 460Ser Ser Ala Gly Arg Tyr Val Ser Arg Arg Cys Lys Pro Leu Lys Glu465                 470                 475                 480Phe Met Leu Ser Gln Asp Val Glu His Glu Arg Leu Phe Asp Leu Ile                485                 490                 495Gln Lys Met Leu Glu Tyr Asp Pro Ala Lys Arg Ile Thr Leu Arg Glu            500                 505                 510Ala Leu Lys His Pro Phe Phe Asp Leu Leu Lys Lys Ser Ile        515                 520                 525</s400><s200><s210>4</s210><s211>1581</s211><s212>DNA</s212><s213>Artificial</s213><s220><s223>Human CLK1 cDNA isoform 2</s223></s220></s200><s400> 4atggcggctg ggcggaggcc ggcttcggcc ctgtggccgg aaaggcgagg ctccccgttg     60aggggggatt tgctggggtt ccagaatgtg cgtgagccaa gcagctgtgg ggaaacgttg    120tctggaatga gacactcaaa gagaacttac tgtcctgatt gggatgacaa ggattgggat    180tatggaaaat ggaggagcag cagcagtcat aaaagaagga agagatcaca tagcagtgcc    240caggagaaca agcgctgcaa atacaatcac tctaaaatgt gtgatagcca ttatttggaa    300agcaggtcta taaatgagaa agattatcat agtcgacgct acattgatga gtacagaaat    360gactacactc aaggatgtga acctggacat cgccaaagag accatgaaag ccggtatcag    420aaccatagta gcaagtcttc tggtagaagt ggaagaagta gttataaaag caaacacagg    480attcaccaca gtacttcaca tcgtcgttca catgggaaga gtcaccgaag gaaaagaacc    540aggagtgtag aggatgatga ggagggtcac ctgatctgtc agagtggaga cgtactaagt    600gcaagatatg aaattgttga tactttaggt gaaggagctt ttggaaaagt tgtggagtgc    660atcgatcata aagcgggagg tagacatgta gcagtaaaaa tagttaaaaa tgtggataga    720tactgtgaag ctgctcgctc agaaatacaa gttctggaac atctgaatac aacagacccc    780aacagtactt tccgctgtgt ccagatgttg gaatggtttg agcatcatgg tcacatttgc    840attgtttttg aactattggg acttagtact tacgacttca ttaaagaaaa tggttttcta    900ccatttcgac tggatcatat cagaaagatg gcatatcaga tatgcaagtc tgtgaatttt    960ttgcacagta ataagttgac tcacacagac ttaaagcctg aaaacatctt atttgtgcag   1020tctgactaca cagaggcgta taatcccaaa ataaaacgtg atgaacgcac cttaataaat   1080ccagatatta aagttgtaga ctttggtagt gcaacatatg atgacgaaca tcacagtaca   1140ttggtatcta caagacatta tagagcacct gaagttattt tagccctagg gtggtcccaa   1200ccatgtgatg tctggagcat aggatgcatt cttattgaat actatcttgg gtttaccgta   1260tttccaacac acgatagtaa ggagcattta gcaatgatgg aaaggattct tggacctcta   1320ccaaaacata tgatacagaa aaccaggaaa cgtaaatatt ttcaccacga tcgattagac   1380tgggatgaac acagttctgc cggcagatat gtttcaagac gctgtaaacc tctgaaggaa   1440tttatgcttt ctcaagatgt tgaacatgag cgtctctttg acctcattca gaaaatgttg   1500gagtatgatc cagccaaaag aattactctc agagaagcct taaagcatcc tttctttgac   1560cttctgaaga aaagtatata g                                             1581</s400><s200><s210>5</s210><s211>499</s211><s212>PRT</s212><s213>Artificial</s213><s220><s223>Human CLK2 protein isoform 1</s223></s220></s200><s400> 5Met Pro His Pro Arg Arg Tyr His Ser Ser Glu Arg Gly Ser Arg Gly1               5                   10                  15Ser Tyr Arg Glu His Tyr Arg Ser Arg Lys His Lys Arg Arg Arg Ser            20                  25                  30Arg Ser Trp Ser Ser Ser Ser Asp Arg Thr Arg Arg Arg Arg Arg Glu        35                  40                  45Asp Ser Tyr His Val Arg Ser Arg Ser Ser Tyr Asp Asp Arg Ser Ser    50                  55                  60Asp Arg Arg Val Tyr Asp Arg Arg Tyr Cys Gly Ser Tyr Arg Arg Asn65                  70                  75                  80Asp Tyr Ser Arg Asp Arg Gly Asp Ala Tyr Tyr Asp Thr Asp Tyr Arg                85                  90                  95His Ser Tyr Glu Tyr Gln Arg Glu Asn Ser Ser Tyr Arg Ser Gln Arg            100                 105                 110Ser Ser Arg Arg Lys His Arg Arg Arg Arg Arg Arg Ser Arg Thr Phe        115                 120                 125Ser Arg Ser Ser Ser Gln His Ser Ser Arg Arg Ala Lys Ser Val Glu    130                 135                 140Asp Asp Ala Glu Gly His Leu Ile Tyr His Val Gly Asp Trp Leu Gln145                 150                 155                 160Glu Arg Tyr Glu Ile Val Ser Thr Leu Gly Glu Gly Thr Phe Gly Arg                165                 170                 175Val Val Gln Cys Val Asp His Arg Arg Gly Gly Ala Arg Val Ala Leu            180                 185                 190Lys Ile Ile Lys Asn Val Glu Lys Tyr Lys Glu Ala Ala Arg Leu Glu        195                 200                 205Ile Asn Val Leu Glu Lys Ile Asn Glu Lys Asp Pro Asp Asn Lys Asn    210                 215                 220Leu Cys Val Gln Met Phe Asp Trp Phe Asp Tyr His Gly His Met Cys225                 230                 235                 240Ile Ser Phe Glu Leu Leu Gly Leu Ser Thr Phe Asp Phe Leu Lys Asp                245                 250                 255Asn Asn Tyr Leu Pro Tyr Pro Ile His Gln Val Arg His Met Ala Phe            260                 265                 270Gln Leu Cys Gln Ala Val Lys Phe Leu His Asp Asn Lys Leu Thr His        275                 280                 285Thr Asp Leu Lys Pro Glu Asn Ile Leu Phe Val Asn Ser Asp Tyr Glu    290                 295                 300Leu Thr Tyr Asn Leu Glu Lys Lys Arg Asp Glu Arg Ser Val Lys Ser305                 310                 315                 320Thr Ala Val Arg Val Val Asp Phe Gly Ser Ala Thr Phe Asp His Glu                325                 330                 335His His Ser Thr Ile Val Ser Thr Arg His Tyr Arg Ala Pro Glu Val            340                 345                 350Ile Leu Glu Leu Gly Trp Ser Gln Pro Cys Asp Val Trp Ser Ile Gly        355                 360                 365Cys Ile Ile Phe Glu Tyr Tyr Val Gly Phe Thr Leu Phe Gln Thr His    370                 375                 380Asp Asn Arg Glu His Leu Ala Met Met Glu Arg Ile Leu Gly Pro Ile385                 390                 395                 400Pro Ser Arg Met Ile Arg Lys Thr Arg Lys Gln Lys Tyr Phe Tyr Arg                405                 410                 415Gly Arg Leu Asp Trp Asp Glu Asn Thr Ser Ala Gly Arg Tyr Val Arg            420                 425                 430Glu Asn Cys Lys Pro Leu Arg Arg Tyr Leu Thr Ser Glu Ala Glu Glu        435                 440                 445His His Gln Leu Phe Asp Leu Ile Glu Ser Met Leu Glu Tyr Glu Pro    450                 455                 460Ala Lys Arg Leu Thr Leu Gly Glu Ala Leu Gln His Pro Phe Phe Ala465                 470                 475                 480Arg Leu Arg Ala Glu Pro Pro Asn Lys Leu Trp Asp Ser Ser Arg Asp                485                 490                 495Ile Ser Arg</s400><s200><s210>6</s210><s211>1500</s211><s212>DNA</s212><s213>Artificial</s213><s220><s223>Human CLK2 cDNA isoform 1</s223></s220></s200><s400> 6atgccgcatc ctcgaaggta ccactcctca gagcgaggca gccgggggag ttaccgtgaa     60cactatcgga gccgaaagca taagcgacga agaagtcgct cctggtcaag tagtagtgac    120cggacacgac ggcgtcggcg agaggacagc taccatgtcc gttctcgaag cagttatgat    180gatcgttcgt ccgaccggag ggtgtatgac cggcgatact gtggcagcta cagacgcaac    240gattatagcc gggatcgggg agatgcctac tatgacacag actatcggca ttcctatgaa    300tatcagcggg agaacagcag ttaccgcagc cagcgcagca gccggaggaa gcacagacgg    360cggaggaggc gcagccggac atttagccgc tcatcttcgc agcacagcag ccggagagcc    420aagagtgtag aggacgacgc tgagggccac ctcatctacc acgtcgggga ctggctacaa    480gagcgatatg aaatcgttag caccttagga gaggggacct tcggccgagt tgtacaatgt    540gttgaccatc gcaggggtgg ggctcgagtt gccctgaaga tcattaagaa tgtggagaag    600tacaaggaag cagctcgact tgagatcaac gtgctagaga aaatcaatga gaaagaccct    660gacaacaaga acctctgtgt ccagatgttt gactggtttg actaccatgg ccacatgtgt    720atctcctttg agcttctggg ccttagcacc ttcgatttcc tcaaagacaa caactacctg    780ccctacccca tccaccaagt gcgccacatg gccttccagc tgtgccaggc tgtcaagttc    840ctccatgata acaagctgac acatacagac ctcaagcctg aaaatattct gtttgtgaat    900tcagactatg agctcaccta caacctagag aagaagcgag atgagcgcag tgtgaagagc    960acagctgtgc gggtggtaga ctttggcagt gccacctttg accatgagca ccatagcacc   1020attgtctcca ctcgccatta ccgagcacca gaagtcatcc ttgagttggg ctggtcacag   1080ccttgtgatg tgtggagtat aggctgcatc atctttgaat actatgtggg attcaccctc   1140ttccagaccc atgacaacag agagcatcta gccatgatgg aaaggatctt gggtcctatc   1200ccttcccgga tgatccgaaa gacaagaaag cagaaatatt tttaccgggg tcgcctggat   1260tgggatgaga acacatcagc tgggcgctat gttcgtgaga actgcaaacc gctgcggcgg   1320tatctgacct cagaggcaga ggaacaccac cagctcttcg atctgattga aagcatgcta   1380gagtatgaac cagctaagcg gctgaccttg ggtgaagccc ttcagcatcc tttcttcgcc   1440cgccttcggg ctgagccgcc caacaagttg tgggactcca gtcgggatat cagtcggtga   1500</s400><s200><s210>7</s210><s211>498</s211><s212>PRT</s212><s213>Artificial</s213><s220><s223>Human CLK2 protein isoform 2</s223></s220></s200><s400> 7Met Pro His Pro Arg Arg Tyr His Ser Ser Glu Arg Gly Ser Arg Gly1               5                   10                  15Ser Tyr Arg Glu His Tyr Arg Ser Arg Lys His Lys Arg Arg Arg Ser            20                  25                  30Arg Ser Trp Ser Ser Ser Ser Asp Arg Thr Arg Arg Arg Arg Arg Glu        35                  40                  45Asp Ser Tyr His Val Arg Ser Arg Ser Ser Tyr Asp Asp Arg Ser Ser    50                  55                  60Asp Arg Arg Val Tyr Asp Arg Arg Tyr Cys Gly Ser Tyr Arg Arg Asn65                  70                  75                  80Asp Tyr Ser Arg Asp Arg Gly Asp Ala Tyr Tyr Asp Thr Asp Tyr Arg                85                  90                  95His Ser Tyr Glu Tyr Gln Arg Glu Asn Ser Ser Tyr Arg Ser Gln Arg            100                 105                 110Ser Ser Arg Arg Lys His Arg Arg Arg Arg Arg Arg Ser Arg Thr Phe        115                 120                 125Ser Arg Ser Ser Ser His Ser Ser Arg Arg Ala Lys Ser Val Glu Asp    130                 135                 140Asp Ala Glu Gly His Leu Ile Tyr His Val Gly Asp Trp Leu Gln Glu145                 150                 155                 160Arg Tyr Glu Ile Val Ser Thr Leu Gly Glu Gly Thr Phe Gly Arg Val                165                 170                 175Val Gln Cys Val Asp His Arg Arg Gly Gly Ala Arg Val Ala Leu Lys            180                 185                 190Ile Ile Lys Asn Val Glu Lys Tyr Lys Glu Ala Ala Arg Leu Glu Ile        195                 200                 205Asn Val Leu Glu Lys Ile Asn Glu Lys Asp Pro Asp Asn Lys Asn Leu    210                 215                 220Cys Val Gln Met Phe Asp Trp Phe Asp Tyr His Gly His Met Cys Ile225                 230                 235                 240Ser Phe Glu Leu Leu Gly Leu Ser Thr Phe Asp Phe Leu Lys Asp Asn                245                 250                 255Asn Tyr Leu Pro Tyr Pro Ile His Gln Val Arg His Met Ala Phe Gln            260                 265                 270Leu Cys Gln Ala Val Lys Phe Leu His Asp Asn Lys Leu Thr His Thr        275                 280                 285Asp Leu Lys Pro Glu Asn Ile Leu Phe Val Asn Ser Asp Tyr Glu Leu    290                 295                 300Thr Tyr Asn Leu Glu Lys Lys Arg Asp Glu Arg Ser Val Lys Ser Thr305                 310                 315                 320Ala Val Arg Val Val Asp Phe Gly Ser Ala Thr Phe Asp His Glu His                325                 330                 335His Ser Thr Ile Val Ser Thr Arg His Tyr Arg Ala Pro Glu Val Ile            340                 345                 350Leu Glu Leu Gly Trp Ser Gln Pro Cys Asp Val Trp Ser Ile Gly Cys        355                 360                 365Ile Ile Phe Glu Tyr Tyr Val Gly Phe Thr Leu Phe Gln Thr His Asp    370                 375                 380Asn Arg Glu His Leu Ala Met Met Glu Arg Ile Leu Gly Pro Ile Pro385                 390                 395                 400Ser Arg Met Ile Arg Lys Thr Arg Lys Gln Lys Tyr Phe Tyr Arg Gly                405                 410                 415Arg Leu Asp Trp Asp Glu Asn Thr Ser Ala Gly Arg Tyr Val Arg Glu            420                 425                 430Asn Cys Lys Pro Leu Arg Arg Tyr Leu Thr Ser Glu Ala Glu Glu His        435                 440                 445His Gln Leu Phe Asp Leu Ile Glu Ser Met Leu Glu Tyr Glu Pro Ala    450                 455                 460Lys Arg Leu Thr Leu Gly Glu Ala Leu Gln His Pro Phe Phe Ala Arg465                 470                 475                 480Leu Arg Ala Glu Pro Pro Asn Lys Leu Trp Asp Ser Ser Arg Asp Ile                485                 490                 495Ser Arg</s400><s200><s210>8</s210><s211>1497</s211><s212>DNA</s212><s213>Artificial</s213><s220><s223>Human CLK2 cDNA isoform 2</s223></s220></s200><s400> 8atgccgcatc ctcgaaggta ccactcctca gagcgaggca gccgggggag ttaccgtgaa     60cactatcgga gccgaaagca taagcgacga agaagtcgct cctggtcaag tagtagtgac    120cggacacgac ggcgtcggcg agaggacagc taccatgtcc gttctcgaag cagttatgat    180gatcgttcgt ccgaccggag ggtgtatgac cggcgatact gtggcagcta cagacgcaac    240gattatagcc gggatcgggg agatgcctac tatgacacag actatcggca ttcctatgaa    300tatcagcggg agaacagcag ttaccgcagc cagcgcagca gccggaggaa gcacagacgg    360cggaggaggc gcagccggac atttagccgc tcatcttcgc acagcagccg gagagccaag    420agtgtagagg acgacgctga gggccacctc atctaccacg tcggggactg gctacaagag    480cgatatgaaa tcgttagcac cttaggagag gggaccttcg gccgagttgt acaatgtgtt    540gaccatcgca ggggtggggc tcgagttgcc ctgaagatca ttaagaatgt ggagaagtac    600aaggaagcag ctcgacttga gatcaacgtg ctagagaaaa tcaatgagaa agaccctgac    660aacaagaacc tctgtgtcca gatgtttgac tggtttgact accatggcca catgtgtatc    720tcctttgagc ttctgggcct tagcaccttc gatttcctca aagacaacaa ctacctgccc    780taccccatcc accaagtgcg ccacatggcc ttccagctgt gccaggctgt caagttcctc    840catgataaca agctgacaca tacagacctc aagcctgaaa atattctgtt tgtgaattca    900gactatgagc tcacctacaa cctagagaag aagcgagatg agcgcagtgt gaagagcaca    960gctgtgcggg tggtagactt tggcagtgcc acctttgacc atgagcacca tagcaccatt   1020gtctccactc gccattaccg agcaccagaa gtcatccttg agttgggctg gtcacagcct   1080tgtgatgtgt ggagtatagg ctgcatcatc tttgaatact atgtgggatt caccctcttc   1140cagacccatg acaacagaga gcatctagcc atgatggaaa ggatcttggg tcctatccct   1200tcccggatga tccgaaagac aagaaagcag aaatattttt accggggtcg cctggattgg   1260gatgagaaca catcagctgg gcgctatgtt cgtgagaact gcaaaccgct gcggcggtat   1320ctgacctcag aggcagagga acaccaccag ctcttcgatc tgattgaaag catgctagag   1380tatgaaccag ctaagcggct gaccttgggt gaagcccttc agcatccttt cttcgcccgc   1440cttcgggctg agccgcccaa caagttgtgg gactccagtc gggatatcag tcggtga      1497</s400><s200><s210>9</s210><s211>271</s211><s212>PRT</s212><s213>Artificial</s213><s220><s223>Human CLK2 protein isoform 3</s223></s220></s200><s400> 9Met Phe Asp Trp Phe Asp Tyr His Gly His Met Cys Ile Ser Phe Glu1               5                   10                  15Leu Leu Gly Leu Ser Thr Phe Asp Phe Leu Lys Asp Asn Asn Tyr Leu            20                  25                  30Pro Tyr Pro Ile His Gln Val Arg His Met Ala Phe Gln Leu Cys Gln        35                  40                  45Ala Val Lys Phe Leu His Asp Asn Lys Leu Thr His Thr Asp Leu Lys    50                  55                  60Pro Glu Asn Ile Leu Phe Val Asn Ser Asp Tyr Glu Leu Thr Tyr Asn65                  70                  75                  80Leu Glu Lys Lys Arg Asp Glu Arg Ser Val Lys Ser Thr Ala Val Arg                85                  90                  95Val Val Asp Phe Gly Ser Ala Thr Phe Asp His Glu His His Ser Thr            100                 105                 110Ile Val Ser Thr Arg His Tyr Arg Ala Pro Glu Val Ile Leu Glu Leu        115                 120                 125Gly Trp Ser Gln Pro Cys Asp Val Trp Ser Ile Gly Cys Ile Ile Phe    130                 135                 140Glu Tyr Tyr Val Gly Phe Thr Leu Phe Gln Thr His Asp Asn Arg Glu145                 150                 155                 160His Leu Ala Met Met Glu Arg Ile Leu Gly Pro Ile Pro Ser Arg Met                165                 170                 175Ile Arg Lys Thr Arg Lys Gln Lys Tyr Phe Tyr Arg Gly Arg Leu Asp            180                 185                 190Trp Asp Glu Asn Thr Ser Ala Gly Arg Tyr Val Arg Glu Asn Cys Lys        195                 200                 205Pro Leu Arg Arg Tyr Leu Thr Ser Glu Ala Glu Glu His His Gln Leu    210                 215                 220Phe Asp Leu Ile Glu Ser Met Leu Glu Tyr Glu Pro Ala Lys Arg Leu225                 230                 235                 240Thr Leu Gly Glu Ala Leu Gln His Pro Phe Phe Ala Arg Leu Arg Ala                245                 250                 255Glu Pro Pro Asn Lys Leu Trp Asp Ser Ser Arg Asp Ile Ser Arg            260                 265                 270</s400><s200><s210>10</s210><s211>816</s211><s212>DNA</s212><s213>Artificial</s213><s220><s223>Human CLK2 cDNA isoform 3</s223></s220></s200><s400> 10atgtttgact ggtttgacta ccatggccac atgtgtatct cctttgagct tctgggcctt     60agcaccttcg atttcctcaa agacaacaac tacctgccct accccatcca ccaagtgcgc    120cacatggcct tccagctgtg ccaggctgtc aagttcctcc atgataacaa gctgacacat    180acagacctca agcctgaaaa tattctgttt gtgaattcag actatgagct cacctacaac    240ctagagaaga agcgagatga gcgcagtgtg aagagcacag ctgtgcgggt ggtagacttt    300ggcagtgcca cctttgacca tgagcaccat agcaccattg tctccactcg ccattaccga    360gcaccagaag tcatccttga gttgggctgg tcacagcctt gtgatgtgtg gagtataggc    420tgcatcatct ttgaatacta tgtgggattc accctcttcc agacccatga caacagagag    480catctagcca tgatggaaag gatcttgggt cctatccctt cccggatgat ccgaaagaca    540agaaagcaga aatattttta ccggggtcgc ctggattggg atgagaacac atcagctggg    600cgctatgttc gtgagaactg caaaccgctg cggcggtatc tgacctcaga ggcagaggaa    660caccaccagc tcttcgatct gattgaaagc atgctagagt atgaaccagc taagcggctg    720accttgggtg aagcccttca gcatcctttc ttcgcccgcc ttcgggctga gccgcccaac    780aagttgtggg actccagtcg ggatatcagt cggtga                              816</s400><s200><s210>11</s210><s211>497</s211><s212>PRT</s212><s213>Artificial</s213><s220><s223>Human CLK2 protein isoform 4</s223></s220></s200><s400> 11Met Pro His Pro Arg Arg Tyr His Ser Ser Glu Arg Gly Ser Arg Gly1               5                   10                  15Ser Tyr Arg Glu His Tyr Arg Ser Arg Lys His Lys Arg Arg Arg Ser            20                  25                  30Arg Ser Trp Ser Ser Ser Ser Asp Arg Thr Arg Arg Arg Arg Arg Glu        35                  40                  45Asp Ser Tyr His Val Arg Ser Arg Ser Tyr Asp Asp Arg Ser Ser Asp    50                  55                  60Arg Arg Val Tyr Asp Arg Arg Tyr Cys Gly Ser Tyr Arg Arg Asn Asp65                  70                  75                  80Tyr Ser Arg Asp Arg Gly Asp Ala Tyr Tyr Asp Thr Asp Tyr Arg His                85                  90                  95Ser Tyr Glu Tyr Gln Arg Glu Asn Ser Ser Tyr Arg Ser Gln Arg Ser            100                 105                 110Ser Arg Arg Lys His Arg Arg Arg Arg Arg Arg Ser Arg Thr Phe Ser        115                 120                 125Arg Ser Ser Ser His Ser Ser Arg Arg Ala Lys Ser Val Glu Asp Asp    130                 135                 140Ala Glu Gly His Leu Ile Tyr His Val Gly Asp Trp Leu Gln Glu Arg145                 150                 155                 160Tyr Glu Ile Val Ser Thr Leu Gly Glu Gly Thr Phe Gly Arg Val Val                165                 170                 175Gln Cys Val Asp His Arg Arg Gly Gly Ala Arg Val Ala Leu Lys Ile            180                 185                 190Ile Lys Asn Val Glu Lys Tyr Lys Glu Ala Ala Arg Leu Glu Ile Asn        195                 200                 205Val Leu Glu Lys Ile Asn Glu Lys Asp Pro Asp Asn Lys Asn Leu Cys    210                 215                 220Val Gln Met Phe Asp Trp Phe Asp Tyr His Gly His Met Cys Ile Ser225                 230                 235                 240Phe Glu Leu Leu Gly Leu Ser Thr Phe Asp Phe Leu Lys Asp Asn Asn                245                 250                 255Tyr Leu Pro Tyr Pro Ile His Gln Val Arg His Met Ala Phe Gln Leu            260                 265                 270Cys Gln Ala Val Lys Phe Leu His Asp Asn Lys Leu Thr His Thr Asp        275                 280                 285Leu Lys Pro Glu Asn Ile Leu Phe Val Asn Ser Asp Tyr Glu Leu Thr    290                 295                 300Tyr Asn Leu Glu Lys Lys Arg Asp Glu Arg Ser Val Lys Ser Thr Ala305                 310                 315                 320Val Arg Val Val Asp Phe Gly Ser Ala Thr Phe Asp His Glu His His                325                 330                 335Ser Thr Ile Val Ser Thr Arg His Tyr Arg Ala Pro Glu Val Ile Leu            340                 345                 350Glu Leu Gly Trp Ser Gln Pro Cys Asp Val Trp Ser Ile Gly Cys Ile        355                 360                 365Ile Phe Glu Tyr Tyr Val Gly Phe Thr Leu Phe Gln Thr His Asp Asn    370                 375                 380Arg Glu His Leu Ala Met Met Glu Arg Ile Leu Gly Pro Ile Pro Ser385                 390                 395                 400Arg Met Ile Arg Lys Thr Arg Lys Gln Lys Tyr Phe Tyr Arg Gly Arg                405                 410                 415Leu Asp Trp Asp Glu Asn Thr Ser Ala Gly Arg Tyr Val Arg Glu Asn            420                 425                 430Cys Lys Pro Leu Arg Arg Tyr Leu Thr Ser Glu Ala Glu Glu His His        435                 440                 445Gln Leu Phe Asp Leu Ile Glu Ser Met Leu Glu Tyr Glu Pro Ala Lys    450                 455                 460Arg Leu Thr Leu Gly Glu Ala Leu Gln His Pro Phe Phe Ala Arg Leu465                 470                 475                 480Arg Ala Glu Pro Pro Asn Lys Leu Trp Asp Ser Ser Arg Asp Ile Ser                485                 490                 495Arg</s400><s200><s210>12</s210><s211>1494</s211><s212>DNA</s212><s213>Artificial</s213><s220><s223>Human CLK2 cDNA isoform 4</s223></s220></s200><s400> 12atgccgcatc ctcgaaggta ccactcctca gagcgaggca gccgggggag ttaccgtgaa     60cactatcgga gccgaaagca taagcgacga agaagtcgct cctggtcaag tagtagtgac    120cggacacgac ggcgtcggcg agaggacagc taccatgtcc gttctcgaag ttatgatgat    180cgttcgtccg accggagggt gtatgaccgg cgatactgtg gcagctacag acgcaacgat    240tatagccggg atcggggaga tgcctactat gacacagact atcggcattc ctatgaatat    300cagcgggaga acagcagtta ccgcagccag cgcagcagcc ggaggaagca cagacggcgg    360aggaggcgca gccggacatt tagccgctca tcttcgcaca gcagccggag agccaagagt    420gtagaggacg acgctgaggg ccacctcatc taccacgtcg gggactggct acaagagcga    480tatgaaatcg ttagcacctt aggagagggg accttcggcc gagttgtaca atgtgttgac    540catcgcaggg gtggggctcg agttgccctg aagatcatta agaatgtgga gaagtacaag    600gaagcagctc gacttgagat caacgtgcta gagaaaatca atgagaaaga ccctgacaac    660aagaacctct gtgtccagat gtttgactgg tttgactacc atggccacat gtgtatctcc    720tttgagcttc tgggccttag caccttcgat ttcctcaaag acaacaacta cctgccctac    780cccatccacc aagtgcgcca catggccttc cagctgtgcc aggctgtcaa gttcctccat    840gataacaagc tgacacatac agacctcaag cctgaaaata ttctgtttgt gaattcagac    900tatgagctca cctacaacct agagaagaag cgagatgagc gcagtgtgaa gagcacagct    960gtgcgggtgg tagactttgg cagtgccacc tttgaccatg agcaccatag caccattgtc   1020tccactcgcc attaccgagc accagaagtc atccttgagt tgggctggtc acagccttgt   1080gatgtgtgga gtataggctg catcatcttt gaatactatg tgggattcac cctcttccag   1140acccatgaca acagagagca tctagccatg atggaaagga tcttgggtcc tatcccttcc   1200cggatgatcc gaaagacaag aaagcagaaa tatttttacc ggggtcgcct ggattgggat   1260gagaacacat cagctgggcg ctatgttcgt gagaactgca aaccgctgcg gcggtatctg   1320acctcagagg cagaggaaca ccaccagctc ttcgatctga ttgaaagcat gctagagtat   1380gaaccagcta agcggctgac cttgggtgaa gcccttcagc atcctttctt cgcccgcctt   1440cgggctgagc cgcccaacaa gttgtgggac tccagtcggg atatcagtcg gtga         1494</s400><s200><s210>13</s210><s211>638</s211><s212>PRT</s212><s213>Artificial</s213><s220><s223>Human CLK3 protein isoform 1</s223></s220></s200><s400> 13Met Pro Val Leu Ser Ala Arg Arg Arg Glu Leu Ala Asp His Ala Gly1               5                   10                  15Ser Gly Arg Arg Ser Gly Pro Ser Pro Thr Ala Arg Ser Gly Pro His            20                  25                  30Leu Ser Ala Leu Arg Ala Gln Pro Ala Arg Ala Ala His Leu Ser Gly        35                  40                  45Arg Gly Thr Tyr Val Arg Arg Asp Thr Ala Gly Gly Gly Pro Gly Gln    50                  55                  60Ala Arg Pro Leu Gly Pro Pro Gly Thr Ser Leu Leu Gly Arg Gly Ala65                  70                  75                  80Arg Arg Ser Gly Glu Gly Trp Cys Pro Gly Ala Phe Glu Ser Gly Ala                85                  90                  95Arg Ala Ala Arg Pro Pro Ser Arg Val Glu Pro Arg Leu Ala Thr Ala            100                 105                 110Ala Ser Arg Glu Gly Ala Gly Leu Pro Arg Ala Glu Val Ala Ala Gly        115                 120                 125Ser Gly Arg Gly Ala Arg Ser Gly Glu Trp Gly Leu Ala Ala Ala Gly    130                 135                 140Ala Trp Glu Thr Met His His Cys Lys Arg Tyr Arg Ser Pro Glu Pro145                 150                 155                 160Asp Pro Tyr Leu Ser Tyr Arg Trp Lys Arg Arg Arg Ser Tyr Ser Arg                165                 170                 175Glu His Glu Gly Arg Leu Arg Tyr Pro Ser Arg Arg Glu Pro Pro Pro            180                 185                 190Arg Arg Ser Arg Ser Arg Ser His Asp Arg Leu Pro Tyr Gln Arg Arg        195                 200                 205Tyr Arg Glu Arg Arg Asp Ser Asp Thr Tyr Arg Cys Glu Glu Arg Ser    210                 215                 220Pro Ser Phe Gly Glu Asp Tyr Tyr Gly Pro Ser Arg Ser Arg His Arg225                 230                 235                 240Arg Arg Ser Arg Glu Arg Gly Pro Tyr Arg Thr Arg Lys His Ala His                245                 250                 255His Cys His Lys Arg Arg Thr Arg Ser Cys Ser Ser Ala Ser Ser Arg            260                 265                 270Ser Gln Gln Ser Ser Lys Arg Ser Ser Arg Ser Val Glu Asp Asp Lys        275                 280                 285Glu Gly His Leu Val Cys Arg Ile Gly Asp Trp Leu Gln Glu Arg Tyr    290                 295                 300Glu Ile Val Gly Asn Leu Gly Glu Gly Thr Phe Gly Lys Val Val Glu305                 310                 315                 320Cys Leu Asp His Ala Arg Gly Lys Ser Gln Val Ala Leu Lys Ile Ile                325                 330                 335Arg Asn Val Gly Lys Tyr Arg Glu Ala Ala Arg Leu Glu Ile Asn Val            340                 345                 350Leu Lys Lys Ile Lys Glu Lys Asp Lys Glu Asn Lys Phe Leu Cys Val        355                 360                 365Leu Met Ser Asp Trp Phe Asn Phe His Gly His Met Cys Ile Ala Phe    370                 375                 380Glu Leu Leu Gly Lys Asn Thr Phe Glu Phe Leu Lys Glu Asn Asn Phe385                 390                 395                 400Gln Pro Tyr Pro Leu Pro His Val Arg His Met Ala Tyr Gln Leu Cys                405                 410                 415His Ala Leu Arg Phe Leu His Glu Asn Gln Leu Thr His Thr Asp Leu            420                 425                 430Lys Pro Glu Asn Ile Leu Phe Val Asn Ser Glu Phe Glu Thr Leu Tyr        435                 440                 445Asn Glu His Lys Ser Cys Glu Glu Lys Ser Val Lys Asn Thr Ser Ile    450                 455                 460Arg Val Ala Asp Phe Gly Ser Ala Thr Phe Asp His Glu His His Thr465                 470                 475                 480Thr Ile Val Ala Thr Arg His Tyr Arg Pro Pro Glu Val Ile Leu Glu                485                 490                 495Leu Gly Trp Ala Gln Pro Cys Asp Val Trp Ser Ile Gly Cys Ile Leu            500                 505                 510Phe Glu Tyr Tyr Arg Gly Phe Thr Leu Phe Gln Thr His Glu Asn Arg        515                 520                 525Glu His Leu Val Met Met Glu Lys Ile Leu Gly Pro Ile Pro Ser His    530                 535                 540Met Ile His Arg Thr Arg Lys Gln Lys Tyr Phe Tyr Lys Gly Gly Leu545                 550                 555                 560Val Trp Asp Glu Asn Ser Ser Asp Gly Arg Tyr Val Lys Glu Asn Cys                565                 570                 575Lys Pro Leu Lys Ser Tyr Met Leu Gln Asp Ser Leu Glu His Val Gln            580                 585                 590Leu Phe Asp Leu Met Arg Arg Met Leu Glu Phe Asp Pro Ala Gln Arg        595                 600                 605Ile Thr Leu Ala Glu Ala Leu Leu His Pro Phe Phe Ala Gly Leu Thr    610                 615                 620Pro Glu Glu Arg Ser Phe His Thr Ser Arg Asn Pro Ser Arg625                 630                 635</s400><s200><s210>14</s210><s211>1918</s211><s212>DNA</s212><s213>Artificial</s213><s220><s223>Human CLK3 cDNA isoform 1</s223></s220></s200><s400> 14aatgcccgtc ctctccgcgc gcaggaggga gttggcggac cacgcggggt cggggcgacg     60gagcgggccc agccccacgg ccaggtcggg gccccacctc tcggctctga gagcccagcc    120ggcccgggcc gcgcacctgt caggtcgggg gacctacgtg cgccgcgaca cggcgggagg    180cgggccgggc caggctcgtc ccctcggccc tcccggaact agtctcctag gccgcggcgc    240ccgccggagc ggagagggct ggtgccccgg agccttcgag tcgggggcta gagcggccag    300gcctccgagc cgggtcgagc cgaggctggc gacggctgcg tcacgcgagg gggcggggct    360gccacgggcg gaggtcgcag ccggaagcgg aagaggcgct cggagcgggg agtggggcct    420agctgcagcc ggagcctggg agacgatgca tcactgtaag cgataccgct cccctgaacc    480agacccgtac ctgagctacc gatggaagag gaggaggtcc tacagtcggg aacatgaagg    540gagactgcga tacccgtccc gaagggagcc tcccccacga agatctcggt ccagaagcca    600tgaccgcctg ccctaccaga ggaggtaccg ggagcgccgt gacagcgata cataccggtg    660tgaagagcgg agcccatcct ttggagagga ctactatgga ccttcacgtt ctcgtcatcg    720tcggcgatcg cgggagaggg ggccataccg gacccgcaag catgcccacc actgccacaa    780acgccgcacc aggtcttgta gcagcgcctc ctcgagaagc caacagagca gtaagcgcag    840cagccggagt gtggaagatg acaaggaggg tcacctggtg tgccggatcg gcgattggct    900ccaagagcga tatgagattg tggggaacct gggtgaaggc acctttggca aggtggtgga    960gtgcttggac catgccagag ggaagtctca ggttgccctg aagatcatcc gcaacgtggg   1020caagtaccgg gaggctgccc ggctagaaat caacgtgctc aaaaaaatca aggagaagga   1080caaagaaaac aagttcctgt gtgtcttgat gtctgactgg ttcaacttcc acggtcacat   1140gtgcatcgcc tttgagctcc tgggcaagaa cacctttgag ttcctgaagg agaataactt   1200ccagccttac cccctaccac atgtccggca catggcctac cagctctgcc acgcccttag   1260atttctgcat gagaatcagc tgacccatac agacttgaaa ccagagaaca tcctgtttgt   1320gaattctgag tttgaaaccc tctacaatga gcacaagagc tgtgaggaga agtcagtgaa   1380gaacaccagc atccgagtgg ctgactttgg cagtgccaca tttgaccatg agcaccacac   1440caccattgtg gccacccgtc actatcgccc gcctgaggtg atccttgagc tgggctgggc   1500acagccctgt gacgtctgga gcattggctg cattctcttt gagtactacc ggggcttcac   1560actcttccag acccacgaaa accgagagca cctggtgatg atggagaaga tcctagggcc   1620catcccatca cacatgatcc accgtaccag gaagcagaaa tatttctaca aagggggcct   1680agtttgggat gagaacagct ctgacggccg gtatgtgaag gagaactgca aacctctgaa   1740gagttacatg ctccaagact ccctggagca cgtgcagctg tttgacctga tgaggaggat   1800gttagaattt gaccctgccc agcgcatcac actggccgag gccctgctgc accccttctt   1860tgctggcctg acccctgagg agcggtcctt ccacaccagc cgcaacccaa gcagatga     1918</s400><s200><s210>15</s210><s211>490</s211><s212>PRT</s212><s213>Artificial</s213><s220><s223>Human CLK3 protein isoform 2</s223></s220></s200><s400> 15Met His His Cys Lys Arg Tyr Arg Ser Pro Glu Pro Asp Pro Tyr Leu1               5                   10                  15Ser Tyr Arg Trp Lys Arg Arg Arg Ser Tyr Ser Arg Glu His Glu Gly            20                  25                  30Arg Leu Arg Tyr Pro Ser Arg Arg Glu Pro Pro Pro Arg Arg Ser Arg        35                  40                  45Ser Arg Ser His Asp Arg Leu Pro Tyr Gln Arg Arg Tyr Arg Glu Arg    50                  55                  60Arg Asp Ser Asp Thr Tyr Arg Cys Glu Glu Arg Ser Pro Ser Phe Gly65                  70                  75                  80Glu Asp Tyr Tyr Gly Pro Ser Arg Ser Arg His Arg Arg Arg Ser Arg                85                  90                  95Glu Arg Gly Pro Tyr Arg Thr Arg Lys His Ala His His Cys His Lys            100                 105                 110Arg Arg Thr Arg Ser Cys Ser Ser Ala Ser Ser Arg Ser Gln Gln Ser        115                 120                 125Ser Lys Arg Ser Ser Arg Ser Val Glu Asp Asp Lys Glu Gly His Leu    130                 135                 140Val Cys Arg Ile Gly Asp Trp Leu Gln Glu Arg Tyr Glu Ile Val Gly145                 150                 155                 160Asn Leu Gly Glu Gly Thr Phe Gly Lys Val Val Glu Cys Leu Asp His                165                 170                 175Ala Arg Gly Lys Ser Gln Val Ala Leu Lys Ile Ile Arg Asn Val Gly            180                 185                 190Lys Tyr Arg Glu Ala Ala Arg Leu Glu Ile Asn Val Leu Lys Lys Ile        195                 200                 205Lys Glu Lys Asp Lys Glu Asn Lys Phe Leu Cys Val Leu Met Ser Asp    210                 215                 220Trp Phe Asn Phe His Gly His Met Cys Ile Ala Phe Glu Leu Leu Gly225                 230                 235                 240Lys Asn Thr Phe Glu Phe Leu Lys Glu Asn Asn Phe Gln Pro Tyr Pro                245                 250                 255Leu Pro His Val Arg His Met Ala Tyr Gln Leu Cys His Ala Leu Arg            260                 265                 270Phe Leu His Glu Asn Gln Leu Thr His Thr Asp Leu Lys Pro Glu Asn        275                 280                 285Ile Leu Phe Val Asn Ser Glu Phe Glu Thr Leu Tyr Asn Glu His Lys    290                 295                 300Ser Cys Glu Glu Lys Ser Val Lys Asn Thr Ser Ile Arg Val Ala Asp305                 310                 315                 320Phe Gly Ser Ala Thr Phe Asp His Glu His His Thr Thr Ile Val Ala                325                 330                 335Thr Arg His Tyr Arg Pro Pro Glu Val Ile Leu Glu Leu Gly Trp Ala            340                 345                 350Gln Pro Cys Asp Val Trp Ser Ile Gly Cys Ile Leu Phe Glu Tyr Tyr        355                 360                 365Arg Gly Phe Thr Leu Phe Gln Thr His Glu Asn Arg Glu His Leu Val    370                 375                 380Met Met Glu Lys Ile Leu Gly Pro Ile Pro Ser His Met Ile His Arg385                 390                 395                 400Thr Arg Lys Gln Lys Tyr Phe Tyr Lys Gly Gly Leu Val Trp Asp Glu                405                 410                 415Asn Ser Ser Asp Gly Arg Tyr Val Lys Glu Asn Cys Lys Pro Leu Lys            420                 425                 430Ser Tyr Met Leu Gln Asp Ser Leu Glu His Val Gln Leu Phe Asp Leu        435                 440                 445Met Arg Arg Met Leu Glu Phe Asp Pro Ala Gln Arg Ile Thr Leu Ala    450                 455                 460Glu Ala Leu Leu His Pro Phe Phe Ala Gly Leu Thr Pro Glu Glu Arg465                 470                 475                 480Ser Phe His Thr Ser Arg Asn Pro Ser Arg                485                 490</s400><s200><s210>16</s210><s211>1473</s211><s212>DNA</s212><s213>Artificial</s213><s220><s223>Human CLK3 cDNA isoform 2</s223></s220></s200><s400> 16atgcatcact gtaagcgata ccgctcccct gaaccagacc cgtacctgag ctaccgatgg     60aagaggagga ggtcctacag tcgggaacat gaagggagac tgcgataccc gtcccgaagg    120gagcctcccc cacgaagatc tcggtccaga agccatgacc gcctgcccta ccagaggagg    180taccgggagc gccgtgacag cgatacatac cggtgtgaag agcggagccc atcctttgga    240gaggactact atggaccttc acgttctcgt catcgtcggc gatcgcggga gagggggcca    300taccggaccc gcaagcatgc ccaccactgc cacaaacgcc gcaccaggtc ttgtagcagc    360gcctcctcga gaagccaaca gagcagtaag cgcagcagcc ggagtgtgga agatgacaag    420gagggtcacc tggtgtgccg gatcggcgat tggctccaag agcgatatga gattgtgggg    480aacctgggtg aaggcacctt tggcaaggtg gtggagtgct tggaccatgc cagagggaag    540tctcaggttg ccctgaagat catccgcaac gtgggcaagt accgggaggc tgcccggcta    600gaaatcaacg tgctcaaaaa aatcaaggag aaggacaaag aaaacaagtt cctgtgtgtc    660ttgatgtctg actggttcaa cttccacggt cacatgtgca tcgcctttga gctcctgggc    720aagaacacct ttgagttcct gaaggagaat aacttccagc cttaccccct accacatgtc    780cggcacatgg cctaccagct ctgccacgcc cttagatttc tgcatgagaa tcagctgacc    840catacagact tgaaaccaga gaacatcctg tttgtgaatt ctgagtttga aaccctctac    900aatgagcaca agagctgtga ggagaagtca gtgaagaaca ccagcatccg agtggctgac    960tttggcagtg ccacatttga ccatgagcac cacaccacca ttgtggccac ccgtcactat   1020cgcccgcctg aggtgatcct tgagctgggc tgggcacagc cctgtgacgt ctggagcatt   1080ggctgcattc tctttgagta ctaccggggc ttcacactct tccagaccca cgaaaaccga   1140gagcacctgg tgatgatgga gaagatccta gggcccatcc catcacacat gatccaccgt   1200accaggaagc agaaatattt ctacaaaggg ggcctagttt gggatgagaa cagctctgac   1260ggccggtatg tgaaggagaa ctgcaaacct ctgaagagtt acatgctcca agactccctg   1320gagcacgtgc agctgtttga cctgatgagg aggatgttag aatttgaccc tgcccagcgc   1380atcacactgg ccgaggccct gctgcacccc ttctttgctg gcctgacccc tgaggagcgg   1440tccttccaca ccagccgcaa cccaagcaga tga                                1473</s400><s200><s210>17</s210><s211>481</s211><s212>PRT</s212><s213>Artificial</s213><s220><s223>Human CLK4 protein</s223></s220></s200><s400> 17Met Arg His Ser Lys Arg Thr His Cys Pro Asp Trp Asp Ser Arg Glu1               5                   10                  15Ser Trp Gly His Glu Ser Tyr Arg Gly Ser His Lys Arg Lys Arg Arg            20                  25                  30Ser His Ser Ser Thr Gln Glu Asn Arg His Cys Lys Pro His His Gln        35                  40                  45Phe Lys Glu Ser Asp Cys His Tyr Leu Glu Ala Arg Ser Leu Asn Glu    50                  55                  60Arg Asp Tyr Arg Asp Arg Arg Tyr Val Asp Glu Tyr Arg Asn Asp Tyr65                  70                  75                  80Cys Glu Gly Tyr Val Pro Arg His Tyr His Arg Asp Ile Glu Ser Gly                85                  90                  95Tyr Arg Ile His Cys Ser Lys Ser Ser Val Arg Ser Arg Arg Ser Ser            100                 105                 110Pro Lys Arg Lys Arg Asn Arg His Cys Ser Ser His Gln Ser Arg Ser        115                 120                 125Lys Ser His Arg Arg Lys Arg Ser Arg Ser Ile Glu Asp Asp Glu Glu    130                 135                 140Gly His Leu Ile Cys Gln Ser Gly Asp Val Leu Arg Ala Arg Tyr Glu145                 150                 155                 160Ile Val Asp Thr Leu Gly Glu Gly Ala Phe Gly Lys Val Val Glu Cys                165                 170                 175Ile Asp His Gly Met Asp Gly Met His Val Ala Val Lys Ile Val Lys            180                 185                 190Asn Val Gly Arg Tyr Arg Glu Ala Ala Arg Ser Glu Ile Gln Val Leu        195                 200                 205Glu His Leu Asn Ser Thr Asp Pro Asn Ser Val Phe Arg Cys Val Gln    210                 215                 220Met Leu Glu Trp Phe Asp His His Gly His Val Cys Ile Val Phe Glu225                 230                 235                 240Leu Leu Gly Leu Ser Thr Tyr Asp Phe Ile Lys Glu Asn Ser Phe Leu                245                 250                 255Pro Phe Gln Ile Asp His Ile Arg Gln Met Ala Tyr Gln Ile Cys Gln            260                 265                 270Ser Ile Asn Phe Leu His His Asn Lys Leu Thr His Thr Asp Leu Lys        275                 280                 285Pro Glu Asn Ile Leu Phe Val Lys Ser Asp Tyr Val Val Lys Tyr Asn    290                 295                 300Ser Lys Met Lys Arg Asp Glu Arg Thr Leu Lys Asn Thr Asp Ile Lys305                 310                 315                 320Val Val Asp Phe Gly Ser Ala Thr Tyr Asp Asp Glu His His Ser Thr                325                 330                 335Leu Val Ser Thr Arg His Tyr Arg Ala Pro Glu Val Ile Leu Ala Leu            340                 345                 350Gly Trp Ser Gln Pro Cys Asp Val Trp Ser Ile Gly Cys Ile Leu Ile        355                 360                 365Glu Tyr Tyr Leu Gly Phe Thr Val Phe Gln Thr His Asp Ser Lys Glu    370                 375                 380His Leu Ala Met Met Glu Arg Ile Leu Gly Pro Ile Pro Gln His Met385                 390                 395                 400Ile Gln Lys Thr Arg Lys Arg Lys Tyr Phe His His Asn Gln Leu Asp                405                 410                 415Trp Asp Glu His Ser Ser Ala Gly Arg Tyr Val Arg Arg Arg Cys Lys            420                 425                 430Pro Leu Lys Glu Phe Met Leu Cys His Asp Glu Glu His Glu Lys Leu        435                 440                 445Phe Asp Leu Val Arg Arg Met Leu Glu Tyr Asp Pro Thr Gln Arg Ile    450                 455                 460Thr Leu Asp Glu Ala Leu Gln His Pro Phe Phe Asp Leu Leu Lys Lys465                 470                 475                 480Lys</s400><s200><s210>18</s210><s211>1446</s211><s212>DNA</s212><s213>Artificial</s213><s220><s223>Human CLK4</s223></s220></s200><s400> 18atgcggcatt ccaaaagaac tcactgtcct gattgggata gcagagaaag ctggggacat     60gaaagctatc gtggaagtca caagcggaag aggagatctc atagtagcac acaagagaac    120aggcattgta aaccacatca ccagtttaaa gaatctgatt gtcattattt agaagcaagg    180tccttgaatg agcgagatta tcgggaccgg agatacgttg acgaatacag gaatgactac    240tgtgaaggat atgttcctag acattatcac agagacattg aaagcgggta tcgaatccac    300tgcagtaaat cttcagtccg cagcaggaga agcagtccta aaaggaagcg caatagacac    360tgttcaagtc atcagtcacg ttcgaagagc caccgaagga aaagatccag gagtatagag    420gatgatgagg agggtcacct gatctgtcaa agtggagacg ttctaagagc aagatatgaa    480atcgtggaca ctttgggtga aggagccttt ggcaaagttg tagagtgcat tgatcatggc    540atggatggca tgcatgtagc agtgaaaatc gtaaaaaatg taggccgtta ccgtgaagca    600gctcgttcag aaatccaagt attagagcac ttaaatagta ctgatcccaa tagtgtcttc    660cgatgtgtcc agatgctaga atggtttgat catcatggtc atgtttgtat tgtgtttgaa    720ctactgggac ttagtactta cgatttcatt aaagaaaaca gctttctgcc atttcaaatt    780gaccacatca ggcagatggc gtatcagatc tgccagtcaa taaatttttt acatcataat    840aaattaaccc atacagatct gaagcctgaa aatattttgt ttgtgaagtc tgactatgta    900gtcaaatata attctaaaat gaaacgtgat gaacgcacac tgaaaaacac agatatcaaa    960gttgttgact ttggaagtgc aacgtatgat gatgaacatc acagtacttt ggtgtctacc   1020cggcactaca gagctcccga ggtcattttg gctttaggtt ggtctcagcc ttgtgatgtt   1080tggagcatag gttgcattct tattgaatat taccttggtt tcacagtctt tcagactcat   1140gatagtaaag agcacctggc aatgatggaa cgaatattag gacccatacc acaacacatg   1200attcagaaaa caagaaaacg caagtatttt caccataacc agctagattg ggatgaacac   1260agttctgctg gtagatatgt taggagacgc tgcaaaccgt tgaaggaatt tatgctttgt   1320catgatgaag aacatgagaa actgtttgac ctggttcgaa gaatgttaga atatgatcca   1380actcaaagaa ttaccttgga tgaagcattg cagcatcctt tctttgactt attaaaaaag   1440aaatga                                                              1446</s400><s200><s210>19</s210><s211>763</s211><s212>PRT</s212><s213>Artificial</s213><s220><s223>Human DYRK1A protein long isoform</s223></s220></s200><s400> 19Met His Thr Gly Gly Glu Thr Ser Ala Cys Lys Pro Ser Ser Val Arg1               5                   10                  15Leu Ala Pro Ser Phe Ser Phe His Ala Ala Gly Leu Gln Met Ala Gly            20                  25                  30Gln Met Pro His Ser His Gln Tyr Ser Asp Arg Arg Gln Pro Asn Ile        35                  40                  45Ser Asp Gln Gln Val Ser Ala Leu Ser Tyr Ser Asp Gln Ile Gln Gln    50                  55                  60Pro Leu Thr Asn Gln Val Met Pro Asp Ile Val Met Leu Gln Arg Arg65                  70                  75                  80Met Pro Gln Thr Phe Arg Asp Pro Ala Thr Ala Pro Leu Arg Lys Leu                85                  90                  95Ser Val Asp Leu Ile Lys Thr Tyr Lys His Ile Asn Glu Val Tyr Tyr            100                 105                 110Ala Lys Lys Lys Arg Arg His Gln Gln Gly Gln Gly Asp Asp Ser Ser        115                 120                 125His Lys Lys Glu Arg Lys Val Tyr Asn Asp Gly Tyr Asp Asp Asp Asn    130                 135                 140Tyr Asp Tyr Ile Val Lys Asn Gly Glu Lys Trp Met Asp Arg Tyr Glu145                 150                 155                 160Ile Asp Ser Leu Ile Gly Lys Gly Ser Phe Gly Gln Val Val Lys Ala                165                 170                 175Tyr Asp Arg Val Glu Gln Glu Trp Val Ala Ile Lys Ile Ile Lys Asn            180                 185                 190Lys Lys Ala Phe Leu Asn Gln Ala Gln Ile Glu Val Arg Leu Leu Glu        195                 200                 205Leu Met Asn Lys His Asp Thr Glu Met Lys Tyr Tyr Ile Val His Leu    210                 215                 220Lys Arg His Phe Met Phe Arg Asn His Leu Cys Leu Val Phe Glu Met225                 230                 235                 240Leu Ser Tyr Asn Leu Tyr Asp Leu Leu Arg Asn Thr Asn Phe Arg Gly                245                 250                 255Val Ser Leu Asn Leu Thr Arg Lys Phe Ala Gln Gln Met Cys Thr Ala            260                 265                 270Leu Leu Phe Leu Ala Thr Pro Glu Leu Ser Ile Ile His Cys Asp Leu        275                 280                 285Lys Pro Glu Asn Ile Leu Leu Cys Asn Pro Lys Arg Ser Ala Ile Lys    290                 295                 300Ile Val Asp Phe Gly Ser Ser Cys Gln Leu Gly Gln Arg Ile Tyr Gln305                 310                 315                 320Tyr Ile Gln Ser Arg Phe Tyr Arg Ser Pro Glu Val Leu Leu Gly Met                325                 330                 335Pro Tyr Asp Leu Ala Ile Asp Met Trp Ser Leu Gly Cys Ile Leu Val            340                 345                 350Glu Met His Thr Gly Glu Pro Leu Phe Ser Gly Ala Asn Glu Val Asp        355                 360                 365Gln Met Asn Lys Ile Val Glu Val Leu Gly Ile Pro Pro Ala His Ile    370                 375                 380Leu Asp Gln Ala Pro Lys Ala Arg Lys Phe Phe Glu Lys Leu Pro Asp385                 390                 395                 400Gly Thr Trp Asn Leu Lys Lys Thr Lys Asp Gly Lys Arg Glu Tyr Lys                405                 410                 415Pro Pro Gly Thr Arg Lys Leu His Asn Ile Leu Gly Val Glu Thr Gly            420                 425                 430Gly Pro Gly Gly Arg Arg Ala Gly Glu Ser Gly His Thr Val Ala Asp        435                 440                 445Tyr Leu Lys Phe Lys Asp Leu Ile Leu Arg Met Leu Asp Tyr Asp Pro    450                 455                 460Lys Thr Arg Ile Gln Pro Tyr Tyr Ala Leu Gln His Ser Phe Phe Lys465                 470                 475                 480Lys Thr Ala Asp Glu Gly Thr Asn Thr Ser Asn Ser Val Ser Thr Ser                485                 490                 495Pro Ala Met Glu Gln Ser Gln Ser Ser Gly Thr Thr Ser Ser Thr Ser            500                 505                 510Ser Ser Ser Gly Gly Ser Ser Gly Thr Ser Asn Ser Gly Arg Ala Arg        515                 520                 525Ser Asp Pro Thr His Gln His Arg His Ser Gly Gly His Phe Thr Ala    530                 535                 540Ala Val Gln Ala Met Asp Cys Glu Thr His Ser Pro Gln Val Arg Gln545                 550                 555                 560Gln Phe Pro Ala Pro Leu Gly Trp Ser Gly Thr Glu Ala Pro Thr Gln                565                 570                 575Val Thr Val Glu Thr His Pro Val Gln Glu Thr Thr Phe His Val Ala            580                 585                 590Pro Gln Gln Asn Ala Leu His His His His Gly Asn Ser Ser His His        595                 600                 605His His His His His His His His His His His Gly Gln Gln Ala Leu    610                 615                 620Gly Asn Arg Thr Arg Pro Arg Val Tyr Asn Ser Pro Thr Asn Ser Ser625                 630                 635                 640Ser Thr Gln Asp Ser Met Glu Val Gly His Ser His His Ser Met Thr                645                 650                 655Ser Leu Ser Ser Ser Thr Thr Ser Ser Ser Thr Ser Ser Ser Ser Thr            660                 665                 670Gly Asn Gln Gly Asn Gln Ala Tyr Gln Asn Arg Pro Val Ala Ala Asn        675                 680                 685Thr Leu Asp Phe Gly Gln Asn Gly Ala Met Asp Val Asn Leu Thr Val    690                 695                 700Tyr Ser Asn Pro Arg Gln Glu Thr Gly Ile Ala Gly His Pro Thr Tyr705                 710                 715                 720Gln Phe Ser Ala Asn Thr Gly Pro Ala His Tyr Met Thr Glu Gly His                725                 730                 735Leu Thr Met Arg Gln Gly Ala Asp Arg Glu Glu Ser Pro Met Thr Gly            740                 745                 750Val Cys Val Gln Gln Ser Pro Val Ala Ser Ser        755                 760</s400><s200><s210>20</s210><s211>2292</s211><s212>DNA</s212><s213>Artificial</s213><s220><s223>Human DYRK1A cDNA long isoform</s223></s220></s200><s400> 20atgcatacag gaggagagac ttcagcatgc aaaccttcat ctgttcggct tgcaccgtca     60ttttcattcc atgctgctgg ccttcagatg gctggacaga tgccccattc acatcagtac    120agtgaccgtc gccagccaaa cataagtgac caacaggttt ctgccttatc atattctgac    180cagattcagc aacctctaac taaccaggtg atgcctgata ttgtcatgtt acagaggcgg    240atgccccaaa ccttccgtga cccagcaact gctcccctga gaaaactttc tgttgacttg    300atcaaaacat acaagcatat taatgaggtt tactatgcaa aaaagaagcg aagacaccaa    360cagggccagg gagacgattc tagtcataag aaggaacgga aggtttacaa tgatggttat    420gatgatgata actatgatta tattgtaaaa aacggagaaa agtggatgga tcgttacgaa    480attgactcct tgataggcaa aggttccttt ggacaggttg taaaggcata tgatcgtgtg    540gagcaagaat gggttgccat taaaataata aagaacaaga aggcttttct gaatcaagca    600cagatagaag tgcgacttct tgagctcatg aacaaacatg acactgaaat gaaatactac    660atagtgcatt tgaaacgcca ctttatgttt cgaaaccatc tctgtttagt ttttgaaatg    720ctgtcctaca acctctatga cttgctgaga aacaccaatt tccgaggggt ctctttgaac    780ctaacacgaa agtttgcgca acagatgtgc actgcactgc ttttccttgc gactccagaa    840cttagtatca ttcactgtga tctaaaacct gaaaatatcc ttctttgtaa ccccaaacgc    900agtgcaatca agatagttga ctttggcagt tcttgtcagt tggggcagag gatataccag    960tatattcaga gtcgctttta tcggtctcca gaggtgctac tgggaatgcc ttatgacctt   1020gccattgata tgtggtccct cgggtgtatt ttggttgaaa tgcacactgg agaacctctg   1080ttcagtggtg ccaatgaggt agatcagatg aataaaatag tggaagttct gggtattcca   1140cctgctcata ttcttgacca agcaccaaaa gcaagaaagt tctttgagaa gttgccagat   1200ggcacttgga acttaaagaa gaccaaagat ggaaaacggg agtacaaacc accaggaacc   1260cgtaaacttc ataacattct tggagtggaa acaggaggac ctggtgggcg acgtgctggg   1320gagtcaggtc atacggtcgc tgactacttg aagttcaaag acctcatttt aaggatgctt   1380gattatgacc ccaaaactcg aattcaacct tattatgctc tgcagcacag tttcttcaag   1440aaaacagctg atgaaggtac aaatacaagt aatagtgtat ctacaagccc cgccatggag   1500cagtctcagt cttcgggcac cacctccagt acatcgtcaa gctcaggtgg ctcatcgggg   1560acaagcaaca gtgggagagc ccggtcggat ccgacgcacc agcatcggca cagtggtggg   1620cacttcacag ctgccgtgca ggccatggac tgcgagacac acagtcccca ggtgcgtcag   1680caatttcctg ctcctcttgg ttggtcaggc actgaagctc ctacacaggt cactgttgaa   1740actcatcctg ttcaagaaac aacctttcat gtagcccctc aacagaatgc attgcatcat   1800caccatggta acagttccca tcaccatcac caccaccacc accatcacca ccaccatgga   1860caacaagcct tgggtaaccg gaccaggcca agggtctaca attctccaac gaatagctcc   1920tctacccaag attctatgga ggttggccac agtcaccact ccatgacatc cctgtcttcc   1980tcaacgactt cttcctcgac atcttcctcc tctactggta accaaggcaa tcaggcctac   2040cagaatcgcc cagtggctgc taataccttg gactttggac agaatggagc tatggacgtt   2100aatttgaccg tctactccaa tccccgccaa gagactggca tagctggaca tccaacatac   2160caattttctg ctaatacagg tcctgcacat tacatgactg aaggacatct gacaatgagg   2220caaggggctg atagagaaga gtcccccatg acaggagttt gtgtgcaaca gagtcctgta   2280gctagctcgt ga                                                       2292</s400><s200><s210>21</s210><s211>754</s211><s212>PRT</s212><s213>Artificial</s213><s220><s223>Human DYRK1A protein isoform 1</s223></s220></s200><s400> 21Met His Thr Gly Gly Glu Thr Ser Ala Cys Lys Pro Ser Ser Val Arg1               5                   10                  15Leu Ala Pro Ser Phe Ser Phe His Ala Ala Gly Leu Gln Met Ala Gly            20                  25                  30Gln Met Pro His Ser His Gln Tyr Ser Asp Arg Arg Gln Pro Asn Ile        35                  40                  45Ser Asp Gln Gln Val Ser Ala Leu Ser Tyr Ser Asp Gln Ile Gln Gln    50                  55                  60Pro Leu Thr Asn Gln Arg Arg Met Pro Gln Thr Phe Arg Asp Pro Ala65                  70                  75                  80Thr Ala Pro Leu Arg Lys Leu Ser Val Asp Leu Ile Lys Thr Tyr Lys                85                  90                  95His Ile Asn Glu Val Tyr Tyr Ala Lys Lys Lys Arg Arg His Gln Gln            100                 105                 110Gly Gln Gly Asp Asp Ser Ser His Lys Lys Glu Arg Lys Val Tyr Asn        115                 120                 125Asp Gly Tyr Asp Asp Asp Asn Tyr Asp Tyr Ile Val Lys Asn Gly Glu    130                 135                 140Lys Trp Met Asp Arg Tyr Glu Ile Asp Ser Leu Ile Gly Lys Gly Ser145                 150                 155                 160Phe Gly Gln Val Val Lys Ala Tyr Asp Arg Val Glu Gln Glu Trp Val                165                 170                 175Ala Ile Lys Ile Ile Lys Asn Lys Lys Ala Phe Leu Asn Gln Ala Gln            180                 185                 190Ile Glu Val Arg Leu Leu Glu Leu Met Asn Lys His Asp Thr Glu Met        195                 200                 205Lys Tyr Tyr Ile Val His Leu Lys Arg His Phe Met Phe Arg Asn His    210                 215                 220Leu Cys Leu Val Phe Glu Met Leu Ser Tyr Asn Leu Tyr Asp Leu Leu225                 230                 235                 240Arg Asn Thr Asn Phe Arg Gly Val Ser Leu Asn Leu Thr Arg Lys Phe                245                 250                 255Ala Gln Gln Met Cys Thr Ala Leu Leu Phe Leu Ala Thr Pro Glu Leu            260                 265                 270Ser Ile Ile His Cys Asp Leu Lys Pro Glu Asn Ile Leu Leu Cys Asn        275                 280                 285Pro Lys Arg Ser Ala Ile Lys Ile Val Asp Phe Gly Ser Ser Cys Gln    290                 295                 300Leu Gly Gln Arg Ile Tyr Gln Tyr Ile Gln Ser Arg Phe Tyr Arg Ser305                 310                 315                 320Pro Glu Val Leu Leu Gly Met Pro Tyr Asp Leu Ala Ile Asp Met Trp                325                 330                 335Ser Leu Gly Cys Ile Leu Val Glu Met His Thr Gly Glu Pro Leu Phe            340                 345                 350Ser Gly Ala Asn Glu Val Asp Gln Met Asn Lys Ile Val Glu Val Leu        355                 360                 365Gly Ile Pro Pro Ala His Ile Leu Asp Gln Ala Pro Lys Ala Arg Lys    370                 375                 380Phe Phe Glu Lys Leu Pro Asp Gly Thr Trp Asn Leu Lys Lys Thr Lys385                 390                 395                 400Asp Gly Lys Arg Glu Tyr Lys Pro Pro Gly Thr Arg Lys Leu His Asn                405                 410                 415Ile Leu Gly Val Glu Thr Gly Gly Pro Gly Gly Arg Arg Ala Gly Glu            420                 425                 430Ser Gly His Thr Val Ala Asp Tyr Leu Lys Phe Lys Asp Leu Ile Leu        435                 440                 445Arg Met Leu Asp Tyr Asp Pro Lys Thr Arg Ile Gln Pro Tyr Tyr Ala    450                 455                 460Leu Gln His Ser Phe Phe Lys Lys Thr Ala Asp Glu Gly Thr Asn Thr465                 470                 475                 480Ser Asn Ser Val Ser Thr Ser Pro Ala Met Glu Gln Ser Gln Ser Ser                485                 490                 495Gly Thr Thr Ser Ser Thr Ser Ser Ser Ser Gly Gly Ser Ser Gly Thr            500                 505                 510Ser Asn Ser Gly Arg Ala Arg Ser Asp Pro Thr His Gln His Arg His        515                 520                 525Ser Gly Gly His Phe Thr Ala Ala Val Gln Ala Met Asp Cys Glu Thr    530                 535                 540His Ser Pro Gln Val Arg Gln Gln Phe Pro Ala Pro Leu Gly Trp Ser545                 550                 555                 560Gly Thr Glu Ala Pro Thr Gln Val Thr Val Glu Thr His Pro Val Gln                565                 570                 575Glu Thr Thr Phe His Val Ala Pro Gln Gln Asn Ala Leu His His His            580                 585                 590His Gly Asn Ser Ser His His His His His His His His His His His        595                 600                 605His His Gly Gln Gln Ala Leu Gly Asn Arg Thr Arg Pro Arg Val Tyr    610                 615                 620Asn Ser Pro Thr Asn Ser Ser Ser Thr Gln Asp Ser Met Glu Val Gly625                 630                 635                 640His Ser His His Ser Met Thr Ser Leu Ser Ser Ser Thr Thr Ser Ser                645                 650                 655Ser Thr Ser Ser Ser Ser Thr Gly Asn Gln Gly Asn Gln Ala Tyr Gln            660                 665                 670Asn Arg Pro Val Ala Ala Asn Thr Leu Asp Phe Gly Gln Asn Gly Ala        675                 680                 685Met Asp Val Asn Leu Thr Val Tyr Ser Asn Pro Arg Gln Glu Thr Gly    690                 695                 700Ile Ala Gly His Pro Thr Tyr Gln Phe Ser Ala Asn Thr Gly Pro Ala705                 710                 715                 720His Tyr Met Thr Glu Gly His Leu Thr Met Arg Gln Gly Ala Asp Arg                725                 730                 735Glu Glu Ser Pro Met Thr Gly Val Cys Val Gln Gln Ser Pro Val Ala            740                 745                 750Ser Ser</s400><s200><s210>22</s210><s211>2265</s211><s212>DNA</s212><s213>Artificial</s213><s220><s223>Human DYRK1A cDNA isoform 1</s223></s220></s200><s400> 22atgcatacag gaggagagac ttcagcatgc aaaccttcat ctgttcggct tgcaccgtca     60ttttcattcc atgctgctgg ccttcagatg gctggacaga tgccccattc acatcagtac    120agtgaccgtc gccagccaaa cataagtgac caacaggttt ctgccttatc atattctgac    180cagattcagc aacctctaac taaccagagg cggatgcccc aaaccttccg tgacccagca    240actgctcccc tgagaaaact ttctgttgac ttgatcaaaa catacaagca tattaatgag    300gtttactatg caaaaaagaa gcgaagacac caacagggcc agggagacga ttctagtcat    360aagaaggaac ggaaggttta caatgatggt tatgatgatg ataactatga ttatattgta    420aaaaacggag aaaagtggat ggatcgttac gaaattgact ccttgatagg caaaggttcc    480tttggacagg ttgtaaaggc atatgatcgt gtggagcaag aatgggttgc cattaaaata    540ataaagaaca agaaggcttt tctgaatcaa gcacagatag aagtgcgact tcttgagctc    600atgaacaaac atgacactga aatgaaatac tacatagtgc atttgaaacg ccactttatg    660tttcgaaacc atctctgttt agtttttgaa atgctgtcct acaacctcta tgacttgctg    720agaaacacca atttccgagg ggtctctttg aacctaacac gaaagtttgc gcaacagatg    780tgcactgcac tgcttttcct tgcgactcca gaacttagta tcattcactg tgatctaaaa    840cctgaaaata tccttctttg taaccccaaa cgcagtgcaa tcaagatagt tgactttggc    900agttcttgtc agttggggca gaggatatac cagtatattc agagtcgctt ttatcggtct    960ccagaggtgc tactgggaat gccttatgac cttgccattg atatgtggtc cctcgggtgt   1020attttggttg aaatgcacac tggagaacct ctgttcagtg gtgccaatga ggtagatcag   1080atgaataaaa tagtggaagt tctgggtatt ccacctgctc atattcttga ccaagcacca   1140aaagcaagaa agttctttga gaagttgcca gatggcactt ggaacttaaa gaagaccaaa   1200gatggaaaac gggagtacaa accaccagga acccgtaaac ttcataacat tcttggagtg   1260gaaacaggag gacctggtgg gcgacgtgct ggggagtcag gtcatacggt cgctgactac   1320ttgaagttca aagacctcat tttaaggatg cttgattatg accccaaaac tcgaattcaa   1380ccttattatg ctctgcagca cagtttcttc aagaaaacag ctgatgaagg tacaaataca   1440agtaatagtg tatctacaag ccccgccatg gagcagtctc agtcttcggg caccacctcc   1500agtacatcgt caagctcagg tggctcatcg gggacaagca acagtgggag agcccggtcg   1560gatccgacgc accagcatcg gcacagtggt gggcacttca cagctgccgt gcaggccatg   1620gactgcgaga cacacagtcc ccaggtgcgt cagcaatttc ctgctcctct tggttggtca   1680ggcactgaag ctcctacaca ggtcactgtt gaaactcatc ctgttcaaga aacaaccttt   1740catgtagccc ctcaacagaa tgcattgcat catcaccatg gtaacagttc ccatcaccat   1800caccaccacc accaccatca ccaccaccat ggacaacaag ccttgggtaa ccggaccagg   1860ccaagggtct acaattctcc aacgaatagc tcctctaccc aagattctat ggaggttggc   1920cacagtcacc actccatgac atccctgtct tcctcaacga cttcttcctc gacatcttcc   1980tcctctactg gtaaccaagg caatcaggcc taccagaatc gcccagtggc tgctaatacc   2040ttggactttg gacagaatgg agctatggac gttaatttga ccgtctactc caatccccgc   2100caagagactg gcatagctgg acatccaaca taccaatttt ctgctaatac aggtcctgca   2160cattacatga ctgaaggaca tctgacaatg aggcaagggg ctgatagaga agagtccccc   2220atgacaggag tttgtgtgca acagagtcct gtagctagct cgtga                   2265</s400><s200><s210>23</s210><s211>529</s211><s212>PRT</s212><s213>Artificial</s213><s220><s223>Human DYRK1A protein isoform 2</s223></s220></s200><s400> 23Met His Thr Gly Gly Glu Thr Ser Ala Cys Lys Pro Ser Ser Val Arg1               5                   10                  15Leu Ala Pro Ser Phe Ser Phe His Ala Ala Gly Leu Gln Met Ala Gly            20                  25                  30Gln Met Pro His Ser His Gln Tyr Ser Asp Arg Arg Gln Pro Asn Ile        35                  40                  45Ser Asp Gln Gln Val Ser Ala Leu Ser Tyr Ser Asp Gln Ile Gln Gln    50                  55                  60Pro Leu Thr Asn Gln Val Met Pro Asp Ile Val Met Leu Gln Arg Arg65                  70                  75                  80Met Pro Gln Thr Phe Arg Asp Pro Ala Thr Ala Pro Leu Arg Lys Leu                85                  90                  95Ser Val Asp Leu Ile Lys Thr Tyr Lys His Ile Asn Glu Val Tyr Tyr            100                 105                 110Ala Lys Lys Lys Arg Arg His Gln Gln Gly Gln Gly Asp Asp Ser Ser        115                 120                 125His Lys Lys Glu Arg Lys Val Tyr Asn Asp Gly Tyr Asp Asp Asp Asn    130                 135                 140Tyr Asp Tyr Ile Val Lys Asn Gly Glu Lys Trp Met Asp Arg Tyr Glu145                 150                 155                 160Ile Asp Ser Leu Ile Gly Lys Gly Ser Phe Gly Gln Val Val Lys Ala                165                 170                 175Tyr Asp Arg Val Glu Gln Glu Trp Val Ala Ile Lys Ile Ile Lys Asn            180                 185                 190Lys Lys Ala Phe Leu Asn Gln Ala Gln Ile Glu Val Arg Leu Leu Glu        195                 200                 205Leu Met Asn Lys His Asp Thr Glu Met Lys Tyr Tyr Ile Val His Leu    210                 215                 220Lys Arg His Phe Met Phe Arg Asn His Leu Cys Leu Val Phe Glu Met225                 230                 235                 240Leu Ser Tyr Asn Leu Tyr Asp Leu Leu Arg Asn Thr Asn Phe Arg Gly                245                 250                 255Val Ser Leu Asn Leu Thr Arg Lys Phe Ala Gln Gln Met Cys Thr Ala            260                 265                 270Leu Leu Phe Leu Ala Thr Pro Glu Leu Ser Ile Ile His Cys Asp Leu        275                 280                 285Lys Pro Glu Asn Ile Leu Leu Cys Asn Pro Lys Arg Ser Ala Ile Lys    290                 295                 300Ile Val Asp Phe Gly Ser Ser Cys Gln Leu Gly Gln Arg Ile Tyr Gln305                 310                 315                 320Tyr Ile Gln Ser Arg Phe Tyr Arg Ser Pro Glu Val Leu Leu Gly Met                325                 330                 335Pro Tyr Asp Leu Ala Ile Asp Met Trp Ser Leu Gly Cys Ile Leu Val            340                 345                 350Glu Met His Thr Gly Glu Pro Leu Phe Ser Gly Ala Asn Glu Val Asp        355                 360                 365Gln Met Asn Lys Ile Val Glu Val Leu Gly Ile Pro Pro Ala His Ile    370                 375                 380Leu Asp Gln Ala Pro Lys Ala Arg Lys Phe Phe Glu Lys Leu Pro Asp385                 390                 395                 400Gly Thr Trp Asn Leu Lys Lys Thr Lys Asp Gly Lys Arg Glu Tyr Lys                405                 410                 415Pro Pro Gly Thr Arg Lys Leu His Asn Ile Leu Gly Val Glu Thr Gly            420                 425                 430Gly Pro Gly Gly Arg Arg Ala Gly Glu Ser Gly His Thr Val Ala Asp        435                 440                 445Tyr Leu Lys Phe Lys Asp Leu Ile Leu Arg Met Leu Asp Tyr Asp Pro    450                 455                 460Lys Thr Arg Ile Gln Pro Tyr Tyr Ala Leu Gln His Ser Phe Phe Lys465                 470                 475                 480Lys Thr Ala Asp Glu Gly Thr Asn Thr Ser Asn Ser Val Ser Thr Ser                485                 490                 495Pro Ala Met Glu Gln Ser Gln Ser Ser Gly Thr Thr Ser Ser Thr Ser            500                 505                 510Ser Ser Ser Gly Ala Ser Ala Ile Ser Cys Ser Ser Trp Leu Val Arg        515                 520                 525His</s400><s200><s210>24</s210><s211>1590</s211><s212>DNA</s212><s213>Artificial</s213><s220><s223>Human DYRK1A cDNA isoform 2</s223></s220></s200><s400> 24atgcatacag gaggagagac ttcagcatgc aaaccttcat ctgttcggct tgcaccgtca     60ttttcattcc atgctgctgg ccttcagatg gctggacaga tgccccattc acatcagtac    120agtgaccgtc gccagccaaa cataagtgac caacaggttt ctgccttatc atattctgac    180cagattcagc aacctctaac taaccaggtg atgcctgata ttgtcatgtt acagaggcgg    240atgccccaaa ccttccgtga cccagcaact gctcccctga gaaaactttc tgttgacttg    300atcaaaacat acaagcatat taatgaggtt tactatgcaa aaaagaagcg aagacaccaa    360cagggccagg gagacgattc tagtcataag aaggaacgga aggtttacaa tgatggttat    420gatgatgata actatgatta tattgtaaaa aacggagaaa agtggatgga tcgttacgaa    480attgactcct tgataggcaa aggttccttt ggacaggttg taaaggcata tgatcgtgtg    540gagcaagaat gggttgccat taaaataata aagaacaaga aggcttttct gaatcaagca    600cagatagaag tgcgacttct tgagctcatg aacaaacatg acactgaaat gaaatactac    660atagtgcatt tgaaacgcca ctttatgttt cgaaaccatc tctgtttagt ttttgaaatg    720ctgtcctaca acctctatga cttgctgaga aacaccaatt tccgaggggt ctctttgaac    780ctaacacgaa agtttgcgca acagatgtgc actgcactgc ttttccttgc gactccagaa    840cttagtatca ttcactgtga tctaaaacct gaaaatatcc ttctttgtaa ccccaaacgc    900agtgcaatca agatagttga ctttggcagt tcttgtcagt tggggcagag gatataccag    960tatattcaga gtcgctttta tcggtctcca gaggtgctac tgggaatgcc ttatgacctt   1020gccattgata tgtggtccct cgggtgtatt ttggttgaaa tgcacactgg agaacctctg   1080ttcagtggtg ccaatgaggt agatcagatg aataaaatag tggaagttct gggtattcca   1140cctgctcata ttcttgacca agcaccaaaa gcaagaaagt tctttgagaa gttgccagat   1200ggcacttgga acttaaagaa gaccaaagat ggaaaacggg agtacaaacc accaggaacc   1260cgtaaacttc ataacattct tggagtggaa acaggaggac ctggtgggcg acgtgctggg   1320gagtcaggtc atacggtcgc tgactacttg aagttcaaag acctcatttt aaggatgctt   1380gattatgacc ccaaaactcg aattcaacct tattatgctc tgcagcacag tttcttcaag   1440aaaacagctg atgaaggtac aaatacaagt aatagtgtat ctacaagccc cgccatggag   1500cagtctcagt cttcgggcac cacctccagt acatcgtcaa gctcaggtgc gtcagcaatt   1560tcctgctcct cttggttggt caggcactga                                    1590</s400><s200><s210>25</s210><s211>525</s211><s212>PRT</s212><s213>Artificial</s213><s220><s223>Human DYRK1A protein isoform 3</s223></s220></s200><s400> 25Met His Thr Gly Gly Glu Thr Ser Ala Cys Lys Pro Ser Ser Val Arg1               5                   10                  15Leu Ala Pro Ser Phe Ser Phe His Ala Ala Gly Leu Gln Met Ala Gly            20                  25                  30Gln Met Pro His Ser His Gln Tyr Ser Asp Arg Arg Gln Pro Asn Ile        35                  40                  45Ser Asp Gln Gln Val Ser Ala Leu Ser Tyr Ser Asp Gln Ile Gln Gln    50                  55                  60Pro Leu Thr Asn Gln Val Met Pro Asp Ile Val Met Leu Gln Arg Arg65                  70                  75                  80Met Pro Gln Thr Phe Arg Asp Pro Ala Thr Ala Pro Leu Arg Lys Leu                85                  90                  95Ser Val Asp Leu Ile Lys Thr Tyr Lys His Ile Asn Glu Val Tyr Tyr            100                 105                 110Ala Lys Lys Lys Arg Arg His Gln Gln Gly Gln Gly Asp Asp Ser Ser        115                 120                 125His Lys Lys Glu Arg Lys Val Tyr Asn Asp Gly Tyr Asp Asp Asp Asn    130                 135                 140Tyr Asp Tyr Ile Val Lys Asn Gly Glu Lys Trp Met Asp Arg Tyr Glu145                 150                 155                 160Ile Asp Ser Leu Ile Gly Lys Gly Ser Phe Gly Gln Val Val Lys Ala                165                 170                 175Tyr Asp Arg Val Glu Gln Glu Trp Val Ala Ile Lys Ile Ile Lys Asn            180                 185                 190Lys Lys Ala Phe Leu Asn Gln Ala Gln Ile Glu Val Arg Leu Leu Glu        195                 200                 205Leu Met Asn Lys His Asp Thr Glu Met Lys Tyr Tyr Ile Val His Leu    210                 215                 220Lys Arg His Phe Met Phe Arg Asn His Leu Cys Leu Val Phe Glu Met225                 230                 235                 240Leu Ser Tyr Asn Leu Tyr Asp Leu Leu Arg Asn Thr Asn Phe Arg Gly                245                 250                 255Val Ser Leu Asn Leu Thr Arg Lys Phe Ala Gln Gln Met Cys Thr Ala            260                 265                 270Leu Leu Phe Leu Ala Thr Pro Glu Leu Ser Ile Ile His Cys Asp Leu        275                 280                 285Lys Pro Glu Asn Ile Leu Leu Cys Asn Pro Lys Arg Ser Ala Ile Lys    290                 295                 300Ile Val Asp Phe Gly Ser Ser Cys Gln Leu Gly Gln Arg Ile Tyr Gln305                 310                 315                 320Tyr Ile Gln Ser Arg Phe Tyr Arg Ser Pro Glu Val Leu Leu Gly Met                325                 330                 335Pro Tyr Asp Leu Ala Ile Asp Met Trp Ser Leu Gly Cys Ile Leu Val            340                 345                 350Glu Met His Thr Gly Glu Pro Leu Phe Ser Gly Ala Asn Glu Val Asp        355                 360                 365Gln Met Asn Lys Ile Val Glu Val Leu Gly Ile Pro Pro Ala His Ile    370                 375                 380Leu Asp Gln Ala Pro Lys Ala Arg Lys Phe Phe Glu Lys Leu Pro Asp385                 390                 395                 400Gly Thr Trp Asn Leu Lys Lys Thr Lys Asp Gly Lys Arg Glu Tyr Lys                405                 410                 415Pro Pro Gly Thr Arg Lys Leu His Asn Ile Leu Gly Val Glu Thr Gly            420                 425                 430Gly Pro Gly Gly Arg Arg Ala Gly Glu Ser Gly His Thr Val Ala Asp        435                 440                 445Tyr Leu Lys Phe Lys Asp Leu Ile Leu Arg Met Leu Asp Tyr Asp Pro    450                 455                 460Lys Thr Arg Ile Gln Pro Tyr Tyr Ala Leu Gln His Ser Phe Phe Lys465                 470                 475                 480Lys Thr Ala Asp Glu Gly Thr Asn Thr Ser Asn Ser Val Ser Thr Ser                485                 490                 495Pro Ala Met Glu Gln Ser Gln Ser Ser Gly Thr Thr Ser Ser Thr Ser            500                 505                 510Ser Ser Ser Gly Gly Ala Ala Leu Asp Ala Arg Cys Leu        515                 520                 525</s400><s200><s210>26</s210><s211>1578</s211><s212>DNA</s212><s213>Artificial</s213><s220><s223>Human DYRK1A cDNA isoform 3</s223></s220></s200><s400> 26atgcatacag gaggagagac ttcagcatgc aaaccttcat ctgttcggct tgcaccgtca     60ttttcattcc atgctgctgg ccttcagatg gctggacaga tgccccattc acatcagtac    120agtgaccgtc gccagccaaa cataagtgac caacaggttt ctgccttatc atattctgac    180cagattcagc aacctctaac taaccaggtg atgcctgata ttgtcatgtt acagaggcgg    240atgccccaaa ccttccgtga cccagcaact gctcccctga gaaaactttc tgttgacttg    300atcaaaacat acaagcatat taatgaggtt tactatgcaa aaaagaagcg aagacaccaa    360cagggccagg gagacgattc tagtcataag aaggaacgga aggtttacaa tgatggttat    420gatgatgata actatgatta tattgtaaaa aacggagaaa agtggatgga tcgttacgaa    480attgactcct tgataggcaa aggttccttt ggacaggttg taaaggcata tgatcgtgtg    540gagcaagaat gggttgccat taaaataata aagaacaaga aggcttttct gaatcaagca    600cagatagaag tgcgacttct tgagctcatg aacaaacatg acactgaaat gaaatactac    660atagtgcatt tgaaacgcca ctttatgttt cgaaaccatc tctgtttagt ttttgaaatg    720ctgtcctaca acctctatga cttgctgaga aacaccaatt tccgaggggt ctctttgaac    780ctaacacgaa agtttgcgca acagatgtgc actgcactgc ttttccttgc gactccagaa    840cttagtatca ttcactgtga tctaaaacct gaaaatatcc ttctttgtaa ccccaaacgc    900agtgcaatca agatagttga ctttggcagt tcttgtcagt tggggcagag gatataccag    960tatattcaga gtcgctttta tcggtctcca gaggtgctac tgggaatgcc ttatgacctt   1020gccattgata tgtggtccct cgggtgtatt ttggttgaaa tgcacactgg agaacctctg   1080ttcagtggtg ccaatgaggt agatcagatg aataaaatag tggaagttct gggtattcca   1140cctgctcata ttcttgacca agcaccaaaa gcaagaaagt tctttgagaa gttgccagat   1200ggcacttgga acttaaagaa gaccaaagat ggaaaacggg agtacaaacc accaggaacc   1260cgtaaacttc ataacattct tggagtggaa acaggaggac ctggtgggcg acgtgctggg   1320gagtcaggtc atacggtcgc tgactacttg aagttcaaag acctcatttt aaggatgctt   1380gattatgacc ccaaaactcg aattcaacct tattatgctc tgcagcacag tttcttcaag   1440aaaacagctg atgaaggtac aaatacaagt aatagtgtat ctacaagccc cgccatggag   1500cagtctcagt cttcgggcac cacctccagt acatcgtcaa gctcaggtgg agcagcactg   1560gatgccaggt gcctttag                                                 1578</s400><s200><s210>27</s210><s211>584</s211><s212>PRT</s212><s213>Artificial</s213><s220><s223>Human DYRK1A protein isoform 4</s223></s220></s200><s400> 27Met His Thr Gly Gly Glu Thr Ser Ala Cys Lys Pro Ser Ser Val Arg1               5                   10                  15Leu Ala Pro Ser Phe Ser Phe His Ala Ala Gly Leu Gln Met Ala Gly            20                  25                  30Gln Met Pro His Ser His Gln Tyr Ser Asp Arg Arg Gln Pro Asn Ile        35                  40                  45Ser Asp Gln Gln Val Ser Ala Leu Ser Tyr Ser Asp Gln Ile Gln Gln    50                  55                  60Pro Leu Thr Asn Gln Val Met Pro Asp Ile Val Met Leu Gln Arg Arg65                  70                  75                  80Met Pro Gln Thr Phe Arg Asp Pro Ala Thr Ala Pro Leu Arg Lys Leu                85                  90                  95Ser Val Asp Leu Ile Lys Thr Tyr Lys His Ile Asn Glu Val Tyr Tyr            100                 105                 110Ala Lys Lys Lys Arg Arg His Gln Gln Gly Gln Gly Asp Asp Ser Ser        115                 120                 125His Lys Lys Glu Arg Lys Val Tyr Asn Asp Gly Tyr Asp Asp Asp Asn    130                 135                 140Tyr Asp Tyr Ile Val Lys Asn Gly Glu Lys Trp Met Asp Arg Tyr Glu145                 150                 155                 160Ile Asp Ser Leu Ile Gly Lys Gly Ser Phe Gly Gln Val Val Lys Ala                165                 170                 175Tyr Asp Arg Val Glu Gln Glu Trp Val Ala Ile Lys Ile Ile Lys Asn            180                 185                 190Lys Lys Ala Phe Leu Asn Gln Ala Gln Ile Glu Val Arg Leu Leu Glu        195                 200                 205Leu Met Asn Lys His Asp Thr Glu Met Lys Tyr Tyr Ile Val His Leu    210                 215                 220Lys Arg His Phe Met Phe Arg Asn His Leu Cys Leu Val Phe Glu Met225                 230                 235                 240Leu Ser Tyr Asn Leu Tyr Asp Leu Leu Arg Asn Thr Asn Phe Arg Gly                245                 250                 255Val Ser Leu Asn Leu Thr Arg Lys Phe Ala Gln Gln Met Cys Thr Ala            260                 265                 270Leu Leu Phe Leu Ala Thr Pro Glu Leu Ser Ile Ile His Cys Asp Leu        275                 280                 285Lys Pro Glu Asn Ile Leu Leu Cys Asn Pro Lys Arg Ser Ala Ile Lys    290                 295                 300Ile Val Asp Phe Gly Ser Ser Cys Gln Leu Gly Gln Arg Ile Tyr Gln305                 310                 315                 320Tyr Ile Gln Ser Arg Phe Tyr Arg Ser Pro Glu Val Leu Leu Gly Met                325                 330                 335Pro Tyr Asp Leu Ala Ile Asp Met Trp Ser Leu Gly Cys Ile Leu Val            340                 345                 350Glu Met His Thr Gly Glu Pro Leu Phe Ser Gly Ala Asn Glu Val Asp        355                 360                 365Gln Met Asn Lys Ile Val Glu Val Leu Gly Ile Pro Pro Ala His Ile    370                 375                 380Leu Asp Gln Ala Pro Lys Ala Arg Lys Phe Phe Glu Lys Leu Pro Asp385                 390                 395                 400Gly Thr Trp Asn Leu Lys Lys Thr Lys Asp Gly Lys Arg Glu Tyr Lys                405                 410                 415Pro Pro Gly Thr Arg Lys Leu His Asn Ile Leu Gly Val Glu Thr Gly            420                 425                 430Gly Pro Gly Gly Arg Arg Ala Gly Glu Ser Gly His Thr Val Ala Asp        435                 440                 445Tyr Leu Lys Phe Lys Asp Leu Ile Leu Arg Met Leu Asp Tyr Asp Pro    450                 455                 460Lys Thr Arg Ile Gln Pro Tyr Tyr Ala Leu Gln His Ser Phe Phe Lys465                 470                 475                 480Lys Thr Ala Asp Glu Gly Thr Asn Thr Ser Asn Ser Val Ser Thr Ser                485                 490                 495Pro Ala Met Glu Gln Ser Gln Ser Ser Gly Thr Thr Ser Ser Thr Ser            500                 505                 510Ser Ser Ser Gly Gly Ser Ser Gly Thr Ser Asn Ser Gly Arg Ala Arg        515                 520                 525Ser Asp Pro Thr His Gln His Arg His Ser Gly Gly His Phe Thr Ala    530                 535                 540Ala Val Gln Ala Met Asp Cys Glu Thr His Ser Pro Gln Val Ser Ser545                 550                 555                 560His Val Val His Leu Leu Val Ser Pro Ala Ile Leu Arg Trp Ser Ser                565                 570                 575Thr Gly Cys Gln Val Pro Leu Glu            580</s400><s200><s210>28</s210><s211>1755</s211><s212>DNA</s212><s213>Artificial</s213><s220><s223>Human DYRK1A cDNA isoform 4</s223></s220></s200><s400> 28atgcatacag gaggagagac ttcagcatgc aaaccttcat ctgttcggct tgcaccgtca     60ttttcattcc atgctgctgg ccttcagatg gctggacaga tgccccattc acatcagtac    120agtgaccgtc gccagccaaa cataagtgac caacaggttt ctgccttatc atattctgac    180cagattcagc aacctctaac taaccaggtg atgcctgata ttgtcatgtt acagaggcgg    240atgccccaaa ccttccgtga cccagcaact gctcccctga gaaaactttc tgttgacttg    300atcaaaacat acaagcatat taatgaggtt tactatgcaa aaaagaagcg aagacaccaa    360cagggccagg gagacgattc tagtcataag aaggaacgga aggtttacaa tgatggttat    420gatgatgata actatgatta tattgtaaaa aacggagaaa agtggatgga tcgttacgaa    480attgactcct tgataggcaa aggttccttt ggacaggttg taaaggcata tgatcgtgtg    540gagcaagaat gggttgccat taaaataata aagaacaaga aggcttttct gaatcaagca    600cagatagaag tgcgacttct tgagctcatg aacaaacatg acactgaaat gaaatactac    660atagtgcatt tgaaacgcca ctttatgttt cgaaaccatc tctgtttagt ttttgaaatg    720ctgtcctaca acctctatga cttgctgaga aacaccaatt tccgaggggt ctctttgaac    780ctaacacgaa agtttgcgca acagatgtgc actgcactgc ttttccttgc gactccagaa    840cttagtatca ttcactgtga tctaaaacct gaaaatatcc ttctttgtaa ccccaaacgc    900agtgcaatca agatagttga ctttggcagt tcttgtcagt tggggcagag gatataccag    960tatattcaga gtcgctttta tcggtctcca gaggtgctac tgggaatgcc ttatgacctt   1020gccattgata tgtggtccct cgggtgtatt ttggttgaaa tgcacactgg agaacctctg   1080ttcagtggtg ccaatgaggt agatcagatg aataaaatag tggaagttct gggtattcca   1140cctgctcata ttcttgacca agcaccaaaa gcaagaaagt tctttgagaa gttgccagat   1200ggcacttgga acttaaagaa gaccaaagat ggaaaacggg agtacaaacc accaggaacc   1260cgtaaacttc ataacattct tggagtggaa acaggaggac ctggtgggcg acgtgctggg   1320gagtcaggtc atacggtcgc tgactacttg aagttcaaag acctcatttt aaggatgctt   1380gattatgacc ccaaaactcg aattcaacct tattatgctc tgcagcacag tttcttcaag   1440aaaacagctg atgaaggtac aaatacaagt aatagtgtat ctacaagccc cgccatggag   1500cagtctcagt cttcgggcac cacctccagt acatcgtcaa gctcaggtgg ctcatcgggg   1560acaagcaaca gtgggagagc ccggtcggat ccgacgcacc agcatcggca cagtggtggg   1620cacttcacag ctgccgtgca ggccatggac tgcgagacac acagtcccca ggtgagctcg   1680cacgtggttc atttgcttgt gtcacctgcc attctcaggt ggagcagcac tggatgccag   1740gtgcctttag aatga                                                    1755</s400><s200><s210>29</s210><s211>629</s211><s212>PRT</s212><s213>Artificial</s213><s220><s223>Human DYRK1B protein isoform 1</s223></s220></s200><s400> 29Met Ala Val Pro Pro Gly His Gly Pro Phe Ser Gly Phe Pro Gly Pro1               5                   10                  15Gln Glu His Thr Gln Val Leu Pro Asp Val Arg Leu Leu Pro Arg Arg            20                  25                  30Leu Pro Leu Ala Phe Arg Asp Ala Thr Ser Ala Pro Leu Arg Lys Leu        35                  40                  45Ser Val Asp Leu Ile Lys Thr Tyr Lys His Ile Asn Glu Val Tyr Tyr    50                  55                  60Ala Lys Lys Lys Arg Arg Ala Gln Gln Ala Pro Pro Gln Asp Ser Ser65                  70                  75                  80Asn Lys Lys Glu Lys Lys Val Leu Asn His Gly Tyr Asp Asp Asp Asn                85                  90                  95His Asp Tyr Ile Val Arg Ser Gly Glu Arg Trp Leu Glu Arg Tyr Glu            100                 105                 110Ile Asp Ser Leu Ile Gly Lys Gly Ser Phe Gly Gln Val Val Lys Ala        115                 120                 125Tyr Asp His Gln Thr Gln Glu Leu Val Ala Ile Lys Ile Ile Lys Asn    130                 135                 140Lys Lys Ala Phe Leu Asn Gln Ala Gln Ile Glu Leu Arg Leu Leu Glu145                 150                 155                 160Leu Met Asn Gln His Asp Thr Glu Met Lys Tyr Tyr Ile Val His Leu                165                 170                 175Lys Arg His Phe Met Phe Arg Asn His Leu Cys Leu Val Phe Glu Leu            180                 185                 190Leu Ser Tyr Asn Leu Tyr Asp Leu Leu Arg Asn Thr His Phe Arg Gly        195                 200                 205Val Ser Leu Asn Leu Thr Arg Lys Leu Ala Gln Gln Leu Cys Thr Ala    210                 215                 220Leu Leu Phe Leu Ala Thr Pro Glu Leu Ser Ile Ile His Cys Asp Leu225                 230                 235                 240Lys Pro Glu Asn Ile Leu Leu Cys Asn Pro Lys Arg Ser Ala Ile Lys                245                 250                 255Ile Val Asp Phe Gly Ser Ser Cys Gln Leu Gly Gln Arg Ile Tyr Gln            260                 265                 270Tyr Ile Gln Ser Arg Phe Tyr Arg Ser Pro Glu Val Leu Leu Gly Thr        275                 280                 285Pro Tyr Asp Leu Ala Ile Asp Met Trp Ser Leu Gly Cys Ile Leu Val    290                 295                 300Glu Met His Thr Gly Glu Pro Leu Phe Ser Gly Ser Asn Glu Val Asp305                 310                 315                 320Gln Met Asn Arg Ile Val Glu Val Leu Gly Ile Pro Pro Ala Ala Met                325                 330                 335Leu Asp Gln Ala Pro Lys Ala Arg Lys Tyr Phe Glu Arg Leu Pro Gly            340                 345                 350Gly Gly Trp Thr Leu Arg Arg Thr Lys Glu Leu Arg Lys Asp Tyr Gln        355                 360                 365Gly Pro Gly Thr Arg Arg Leu Gln Glu Val Leu Gly Val Gln Thr Gly    370                 375                 380Gly Pro Gly Gly Arg Arg Ala Gly Glu Pro Gly His Ser Pro Ala Asp385                 390                 395                 400Tyr Leu Arg Phe Gln Asp Leu Val Leu Arg Met Leu Glu Tyr Glu Pro                405                 410                 415Ala Ala Arg Ile Ser Pro Leu Gly Ala Leu Gln His Gly Phe Phe Arg            420                 425                 430Arg Thr Ala Asp Glu Ala Thr Asn Thr Gly Pro Ala Gly Ser Ser Ala        435                 440                 445Ser Thr Ser Pro Ala Pro Leu Asp Thr Cys Pro Ser Ser Ser Thr Ala    450                 455                 460Ser Ser Ile Ser Ser Ser Gly Gly Ser Ser Gly Ser Ser Ser Asp Asn465                 470                 475                 480Arg Thr Tyr Arg Tyr Ser Asn Arg Tyr Cys Gly Gly Pro Gly Pro Pro                485                 490                 495Ile Thr Asp Cys Glu Met Asn Ser Pro Gln Val Pro Pro Ser Gln Pro            500                 505                 510Leu Arg Pro Trp Ala Gly Gly Asp Val Pro His Lys Thr His Gln Ala        515                 520                 525Pro Ala Ser Ala Ser Ser Leu Pro Gly Thr Gly Ala Gln Leu Pro Pro    530                 535                 540Gln Pro Arg Tyr Leu Gly Arg Pro Pro Ser Pro Thr Ser Pro Pro Pro545                 550                 555                 560Pro Glu Leu Met Asp Val Ser Leu Val Gly Gly Pro Ala Asp Cys Ser                565                 570                 575Pro Pro His Pro Ala Pro Ala Pro Gln His Pro Ala Ala Ser Ala Leu            580                 585                 590Arg Thr Arg Met Thr Gly Gly Arg Pro Pro Leu Pro Pro Pro Asp Asp        595                 600                 605Pro Ala Thr Leu Gly Pro His Leu Gly Leu Arg Gly Val Pro Gln Ser    610                 615                 620Thr Ala Ala Ser Ser625</s400><s200><s210>30</s210><s211>1890</s211><s212>DNA</s212><s213>Artificial</s213><s220><s223>Human DYRK1B cDNA isoform 1</s223></s220></s200><s400> 30atggccgtcc caccgggcca tggtcccttc tctggcttcc cagggcccca ggagcacacg     60caggtattgc ctgatgtgcg gctactgcct cggaggctgc ccctggcctt ccgggatgca    120acctcagccc cgctgcgtaa gctctctgtg gacctcatca agacctacaa gcacatcaat    180gaggtatact atgcgaagaa gaagcggcgg gcccagcagg cgccacccca ggattcgagc    240aacaagaagg agaagaaggt cctgaaccat ggttatgatg acgacaacca tgactacatc    300gtgcgcagtg gcgagcgctg gctggagcgc tacgaaattg actcgctcat tggcaaaggc    360tcctttggcc aggtggtgaa agcctatgat catcagaccc aggagcttgt ggccatcaag    420atcatcaaga acaaaaaggc tttcctgaac caggcccaga ttgagctgcg gctgctggag    480ctgatgaacc agcatgacac ggagatgaag tactatatag tacacctgaa gcggcacttc    540atgttccgga accacctgtg cctggtattt gagctgctgt cctacaacct gtacgacctc    600ctgcgcaaca cccacttccg cggcgtctcg ctgaacctga cccggaagct ggcgcagcag    660ctctgcacgg cactgctctt tctggccacg cctgagctca gcatcattca ctgcgacctc    720aagcccgaaa acatcttgct gtgcaacccc aagcgcagcg ccatcaagat tgtggacttc    780ggcagctcct gccagcttgg ccagaggatc taccagtata tccagagccg cttctaccgc    840tcacctgagg tgctcctggg cacaccctac gacctggcca ttgacatgtg gtccctgggc    900tgcatccttg tggagatgca caccggagag cccctcttca gtggctccaa tgaggtcgac    960cagatgaacc gcattgtgga ggtgctgggc atcccaccgg ccgccatgct ggaccaggcg   1020cccaaggctc gcaagtactt tgaacggctg cctgggggtg gctggaccct acgaaggacg   1080aaagaactca ggaaggatta ccagggcccc gggacacggc ggctgcagga ggtgctgggc   1140gtgcagacgg gcgggcccgg gggccggcgg gcgggggagc cgggccacag ccccgccgac   1200tacctccgct tccaggacct ggtgctgcgc atgctggagt atgagcccgc cgcccgcatc   1260agccccctgg gggctctgca gcacggcttc ttccgccgca cggccgacga ggccaccaac   1320acgggcccgg caggcagcag tgcctccacc tcgcccgcgc ccctcgacac ctgcccctct   1380tccagcaccg ccagctccat ctccagttct ggaggctcca gtggctcctc cagtgacaac   1440cggacctacc gctacagcaa ccgatattgt gggggccctg ggccccctat cacagactgt   1500gagatgaaca gcccccaggt cccaccctcc cagccgctgc ggccctgggc agggggtgat   1560gtgccccaca agacacatca agcccctgcc tctgcctcgt cactgcctgg gaccggggcc   1620cagttacccc cccagccccg ataccttggt cgtcccccat caccaacctc accaccaccc   1680ccggagctga tggatgtgag cctggtgggc ggccctgctg actgctcccc acctcaccca   1740gcgcctgccc cccagcaccc ggctgcctca gccctccgga ctcggatgac tggaggtcgt   1800ccacccctcc cgcctcctga tgaccctgcc actctggggc ctcacctggg cctccgtggt   1860gtaccccaga gcacagcagc cagctcgtga                                    1890</s400><s200><s210>31</s210><s211>589</s211><s212>PRT</s212><s213>Artificial</s213><s220><s223>Human DYRK1B protein isoform 2</s223></s220></s200><s400> 31Met Ala Val Pro Pro Gly His Gly Pro Phe Ser Gly Phe Pro Gly Pro1               5                   10                  15Gln Glu His Thr Gln Val Leu Pro Asp Val Arg Leu Leu Pro Arg Arg            20                  25                  30Leu Pro Leu Ala Phe Arg Asp Ala Thr Ser Ala Pro Leu Arg Lys Leu        35                  40                  45Ser Val Asp Leu Ile Lys Thr Tyr Lys His Ile Asn Glu Val Tyr Tyr    50                  55                  60Ala Lys Lys Lys Arg Arg Ala Gln Gln Ala Pro Pro Gln Asp Ser Ser65                  70                  75                  80Asn Lys Lys Glu Lys Lys Val Leu Asn His Gly Tyr Asp Asp Asp Asn                85                  90                  95His Asp Tyr Ile Val Arg Ser Gly Glu Arg Trp Leu Glu Arg Tyr Glu            100                 105                 110Ile Asp Ser Leu Ile Gly Lys Gly Ser Phe Gly Gln Val Val Lys Ala        115                 120                 125Tyr Asp His Gln Thr Gln Glu Leu Val Ala Ile Lys Ile Ile Lys Asn    130                 135                 140Lys Lys Ala Phe Leu Asn Gln Ala Gln Ile Glu Leu Arg Leu Leu Glu145                 150                 155                 160Leu Met Asn Gln His Asp Thr Glu Met Lys Tyr Tyr Ile Val His Leu                165                 170                 175Lys Arg His Phe Met Phe Arg Asn His Leu Cys Leu Val Phe Glu Leu            180                 185                 190Leu Ser Tyr Asn Leu Tyr Asp Leu Leu Arg Asn Thr His Phe Arg Gly        195                 200                 205Val Ser Leu Asn Leu Thr Arg Lys Leu Ala Gln Gln Leu Cys Thr Ala    210                 215                 220Leu Leu Phe Leu Ala Thr Pro Glu Leu Ser Ile Ile His Cys Asp Leu225                 230                 235                 240Lys Pro Glu Asn Ile Leu Leu Cys Asn Pro Lys Arg Ser Ala Ile Lys                245                 250                 255Ile Val Asp Phe Gly Ser Ser Cys Gln Leu Gly Gln Arg Ile Tyr Gln            260                 265                 270Tyr Ile Gln Ser Arg Phe Tyr Arg Ser Pro Glu Val Leu Leu Gly Thr        275                 280                 285Pro Tyr Asp Leu Ala Ile Asp Met Trp Ser Leu Gly Cys Ile Leu Val    290                 295                 300Glu Met His Thr Gly Glu Pro Leu Phe Ser Gly Ser Asn Glu Val Asp305                 310                 315                 320Gln Met Asn Arg Ile Val Glu Val Leu Gly Ile Pro Pro Ala Ala Met                325                 330                 335Leu Asp Gln Ala Pro Lys Ala Arg Lys Tyr Phe Glu Arg Leu Pro Gly            340                 345                 350Gly Gly Trp Thr Leu Arg Arg Thr Lys Glu Leu Arg Lys Asp Leu Val        355                 360                 365Leu Arg Met Leu Glu Tyr Glu Pro Ala Ala Arg Ile Ser Pro Leu Gly    370                 375                 380Ala Leu Gln His Gly Phe Phe Arg Arg Thr Ala Asp Glu Ala Thr Asn385                 390                 395                 400Thr Gly Pro Ala Gly Ser Ser Ala Ser Thr Ser Pro Ala Pro Leu Asp                405                 410                 415Thr Cys Pro Ser Ser Ser Thr Ala Ser Ser Ile Ser Ser Ser Gly Gly            420                 425                 430Ser Ser Gly Ser Ser Ser Asp Asn Arg Thr Tyr Arg Tyr Ser Asn Arg        435                 440                 445Tyr Cys Gly Gly Pro Gly Pro Pro Ile Thr Asp Cys Glu Met Asn Ser    450                 455                 460Pro Gln Val Pro Pro Ser Gln Pro Leu Arg Pro Trp Ala Gly Gly Asp465                 470                 475                 480Val Pro His Lys Thr His Gln Ala Pro Ala Ser Ala Ser Ser Leu Pro                485                 490                 495Gly Thr Gly Ala Gln Leu Pro Pro Gln Pro Arg Tyr Leu Gly Arg Pro            500                 505                 510Pro Ser Pro Thr Ser Pro Pro Pro Pro Glu Leu Met Asp Val Ser Leu        515                 520                 525Val Gly Gly Pro Ala Asp Cys Ser Pro Pro His Pro Ala Pro Ala Pro    530                 535                 540Gln His Pro Ala Ala Ser Ala Leu Arg Thr Arg Met Thr Gly Gly Arg545                 550                 555                 560Pro Pro Leu Pro Pro Pro Asp Asp Pro Ala Thr Leu Gly Pro His Leu                565                 570                 575Gly Leu Arg Gly Val Pro Gln Ser Thr Ala Ala Ser Ser            580                 585</s400><s200><s210>32</s210><s211>1770</s211><s212>DNA</s212><s213>Artificial</s213><s220><s223>Human DYRK1B cDNA isoform 2</s223></s220></s200><s400> 32atggccgtcc caccgggcca tggtcccttc tctggcttcc cagggcccca ggagcacacg     60caggtattgc ctgatgtgcg gctactgcct cggaggctgc ccctggcctt ccgggatgca    120acctcagccc cgctgcgtaa gctctctgtg gacctcatca agacctacaa gcacatcaat    180gaggtatact atgcgaagaa gaagcggcgg gcccagcagg cgccacccca ggattcgagc    240aacaagaagg agaagaaggt cctgaaccat ggttatgatg acgacaacca tgactacatc    300gtgcgcagtg gcgagcgctg gctggagcgc tacgaaattg actcgctcat tggcaaaggc    360tcctttggcc aggtggtgaa agcctatgat catcagaccc aggagcttgt ggccatcaag    420atcatcaaga acaaaaaggc tttcctgaac caggcccaga ttgagctgcg gctgctggag    480ctgatgaacc agcatgacac ggagatgaag tactatatag tacacctgaa gcggcacttc    540atgttccgga accacctgtg cctggtattt gagctgctgt cctacaacct gtacgacctc    600ctgcgcaaca cccacttccg cggcgtctcg ctgaacctga cccggaagct ggcgcagcag    660ctctgcacgg cactgctctt tctggccacg cctgagctca gcatcattca ctgcgacctc    720aagcccgaaa acatcttgct gtgcaacccc aagcgcagcg ccatcaagat tgtggacttc    780ggcagctcct gccagcttgg ccagaggatc taccagtata tccagagccg cttctaccgc    840tcacctgagg tgctcctggg cacaccctac gacctggcca ttgacatgtg gtccctgggc    900tgcatccttg tggagatgca caccggagag cccctcttca gtggctccaa tgaggtcgac    960cagatgaacc gcattgtgga ggtgctgggc atcccaccgg ccgccatgct ggaccaggcg   1020cccaaggctc gcaagtactt tgaacggctg cctgggggtg gctggaccct acgaaggacg   1080aaagaactca ggaaggacct ggtgctgcgc atgctggagt atgagcccgc cgcccgcatc   1140agccccctgg gggctctgca gcacggcttc ttccgccgca cggccgacga ggccaccaac   1200acgggcccgg caggcagcag tgcctccacc tcgcccgcgc ccctcgacac ctgcccctct   1260tccagcaccg ccagctccat ctccagttct ggaggctcca gtggctcctc cagtgacaac   1320cggacctacc gctacagcaa ccgatattgt gggggccctg ggccccctat cacagactgt   1380gagatgaaca gcccccaggt cccaccctcc cagccgctgc ggccctgggc agggggtgat   1440gtgccccaca agacacatca agcccctgcc tctgcctcgt cactgcctgg gaccggggcc   1500cagttacccc cccagccccg ataccttggt cgtcccccat caccaacctc accaccaccc   1560ccggagctga tggatgtgag cctggtgggc ggccctgctg actgctcccc acctcaccca   1620gcgcctgccc cccagcaccc ggctgcctca gccctccgga ctcggatgac tggaggtcgt   1680ccacccctcc cgcctcctga tgaccctgcc actctggggc ctcacctggg cctccgtggt   1740gtaccccaga gcacagcagc cagctcgtga                                    1770</s400><s200><s210>33</s210><s211>601</s211><s212>PRT</s212><s213>Artificial</s213><s220><s223>Human DYRK1B protein isoform 3</s223></s220></s200><s400> 33Met Ala Val Pro Pro Gly His Gly Pro Phe Ser Gly Phe Pro Gly Pro1               5                   10                  15Gln Glu His Thr Gln Val Leu Pro Asp Val Arg Leu Leu Pro Arg Arg            20                  25                  30Leu Pro Leu Ala Phe Arg Asp Ala Thr Ser Ala Pro Leu Arg Lys Leu        35                  40                  45Ser Val Asp Leu Ile Lys Thr Tyr Lys His Ile Asn Glu Val Tyr Tyr    50                  55                  60Ala Lys Lys Lys Arg Arg Ala Gln Gln Ala Pro Pro Gln Asp Ser Ser65                  70                  75                  80Asn Lys Lys Glu Lys Lys Val Leu Asn His Gly Tyr Asp Asp Asp Asn                85                  90                  95His Asp Tyr Ile Val Arg Ser Gly Glu Arg Trp Leu Glu Arg Tyr Glu            100                 105                 110Ile Asp Ser Leu Ile Gly Lys Gly Ser Phe Gly Gln Val Val Lys Ala        115                 120                 125Tyr Asp His Gln Thr Gln Glu Leu Val Ala Ile Lys Ile Ile Lys Asn    130                 135                 140Lys Lys Ala Phe Leu Asn Gln Ala Gln Ile Glu Leu Arg Leu Leu Glu145                 150                 155                 160Leu Met Asn Gln His Asp Thr Glu Met Lys Tyr Tyr Ile Val His Leu                165                 170                 175Lys Arg His Phe Met Phe Arg Asn His Leu Cys Leu Val Phe Glu Leu            180                 185                 190Leu Ser Tyr Asn Leu Tyr Asp Leu Leu Arg Asn Thr His Phe Arg Gly        195                 200                 205Val Ser Leu Asn Leu Thr Arg Lys Leu Ala Gln Gln Leu Cys Thr Ala    210                 215                 220Leu Leu Phe Leu Ala Thr Pro Glu Leu Ser Ile Ile His Cys Asp Leu225                 230                 235                 240Lys Pro Glu Asn Ile Leu Leu Cys Asn Pro Lys Arg Ser Ala Ile Lys                245                 250                 255Ile Val Asp Phe Gly Ser Ser Cys Gln Leu Gly Gln Arg Ile Tyr Gln            260                 265                 270Tyr Ile Gln Ser Arg Phe Tyr Arg Ser Pro Glu Val Leu Leu Gly Thr        275                 280                 285Pro Tyr Asp Leu Ala Ile Asp Met Trp Ser Leu Gly Cys Ile Leu Val    290                 295                 300Glu Met His Thr Gly Glu Pro Leu Phe Ser Gly Ser Asn Glu Val Asp305                 310                 315                 320Gln Met Asn Arg Ile Val Glu Val Leu Gly Ile Pro Pro Ala Ala Met                325                 330                 335Leu Asp Gln Ala Pro Lys Ala Arg Lys Tyr Phe Glu Arg Leu Pro Gly            340                 345                 350Gly Gly Trp Thr Leu Arg Arg Thr Lys Glu Leu Arg Lys Asp Tyr Gln        355                 360                 365Gly Pro Gly Thr Arg Arg Leu Gln Glu Asp Leu Val Leu Arg Met Leu    370                 375                 380Glu Tyr Glu Pro Ala Ala Arg Ile Ser Pro Leu Gly Ala Leu Gln His385                 390                 395                 400Gly Phe Phe Arg Arg Thr Ala Asp Glu Ala Thr Asn Thr Gly Pro Ala                405                 410                 415Gly Ser Ser Ala Ser Thr Ser Pro Ala Pro Leu Asp Thr Cys Pro Ser            420                 425                 430Ser Ser Thr Ala Ser Ser Ile Ser Ser Ser Gly Gly Ser Ser Gly Ser        435                 440                 445Ser Ser Asp Asn Arg Thr Tyr Arg Tyr Ser Asn Arg Tyr Cys Gly Gly    450                 455                 460Pro Gly Pro Pro Ile Thr Asp Cys Glu Met Asn Ser Pro Gln Val Pro465                 470                 475                 480Pro Ser Gln Pro Leu Arg Pro Trp Ala Gly Gly Asp Val Pro His Lys                485                 490                 495Thr His Gln Ala Pro Ala Ser Ala Ser Ser Leu Pro Gly Thr Gly Ala            500                 505                 510Gln Leu Pro Pro Gln Pro Arg Tyr Leu Gly Arg Pro Pro Ser Pro Thr        515                 520                 525Ser Pro Pro Pro Pro Glu Leu Met Asp Val Ser Leu Val Gly Gly Pro    530                 535                 540Ala Asp Cys Ser Pro Pro His Pro Ala Pro Ala Pro Gln His Pro Ala545                 550                 555                 560Ala Ser Ala Leu Arg Thr Arg Met Thr Gly Gly Arg Pro Pro Leu Pro                565                 570                 575Pro Pro Asp Asp Pro Ala Thr Leu Gly Pro His Leu Gly Leu Arg Gly            580                 585                 590Val Pro Gln Ser Thr Ala Ala Ser Ser        595                 600</s400><s200><s210>34</s210><s211>1806</s211><s212>DNA</s212><s213>Artificial</s213><s220><s223>Human DYRK1B cDNA isoform 3</s223></s220></s200><s400> 34atggccgtcc caccgggcca tggtcccttc tctggcttcc cagggcccca ggagcacacg     60caggtattgc ctgatgtgcg gctactgcct cggaggctgc ccctggcctt ccgggatgca    120acctcagccc cgctgcgtaa gctctctgtg gacctcatca agacctacaa gcacatcaat    180gaggtatact atgcgaagaa gaagcggcgg gcccagcagg cgccacccca ggattcgagc    240aacaagaagg agaagaaggt cctgaaccat ggttatgatg acgacaacca tgactacatc    300gtgcgcagtg gcgagcgctg gctggagcgc tacgaaattg actcgctcat tggcaaaggc    360tcctttggcc aggtggtgaa agcctatgat catcagaccc aggagcttgt ggccatcaag    420atcatcaaga acaaaaaggc tttcctgaac caggcccaga ttgagctgcg gctgctggag    480ctgatgaacc agcatgacac ggagatgaag tactatatag tacacctgaa gcggcacttc    540atgttccgga accacctgtg cctggtattt gagctgctgt cctacaacct gtacgacctc    600ctgcgcaaca cccacttccg cggcgtctcg ctgaacctga cccggaagct ggcgcagcag    660ctctgcacgg cactgctctt tctggccacg cctgagctca gcatcattca ctgcgacctc    720aagcccgaaa acatcttgct gtgcaacccc aagcgcagcg ccatcaagat tgtggacttc    780ggcagctcct gccagcttgg ccagaggatc taccagtata tccagagccg cttctaccgc    840tcacctgagg tgctcctggg cacaccctac gacctggcca ttgacatgtg gtccctgggc    900tgcatccttg tggagatgca caccggagag cccctcttca gtggctccaa tgaggtcgac    960cagatgaacc gcattgtgga ggtgctgggc atcccaccgg ccgccatgct ggaccaggcg   1020cccaaggctc gcaagtactt tgaacggctg cctgggggtg gctggaccct acgaaggacg   1080aaagaactca ggaaggatta ccagggcccc gggacacggc ggctgcagga ggacctggtg   1140ctgcgcatgc tggagtatga gcccgccgcc cgcatcagcc ccctgggggc tctgcagcac   1200ggcttcttcc gccgcacggc cgacgaggcc accaacacgg gcccggcagg cagcagtgcc   1260tccacctcgc ccgcgcccct cgacacctgc ccctcttcca gcaccgccag ctccatctcc   1320agttctggag gctccagtgg ctcctccagt gacaaccgga cctaccgcta cagcaaccga   1380tattgtgggg gccctgggcc ccctatcaca gactgtgaga tgaacagccc ccaggtccca   1440ccctcccagc cgctgcggcc ctgggcaggg ggtgatgtgc cccacaagac acatcaagcc   1500cctgcctctg cctcgtcact gcctgggacc ggggcccagt taccccccca gccccgatac   1560cttggtcgtc ccccatcacc aacctcacca ccacccccgg agctgatgga tgtgagcctg   1620gtgggcggcc ctgctgactg ctccccacct cacccagcgc ctgcccccca gcacccggct   1680gcctcagccc tccggactcg gatgactgga ggtcgtccac ccctcccgcc tcctgatgac   1740cctgccactc tggggcctca cctgggcctc cgtggtgtac cccagagcac agcagccagc   1800tcgtga                                                              1806</s400><s200><s210>35</s210><s211>601</s211><s212>PRT</s212><s213>Artificial</s213><s220><s223>Human DYRK2 protein isoform 1</s223></s220></s200><s400> 35Met Leu Thr Arg Lys Pro Ser Ala Ala Ala Pro Ala Ala Tyr Pro Thr1               5                   10                  15Gly Arg Gly Gly Asp Ser Ala Val Arg Gln Leu Gln Ala Ser Pro Gly            20                  25                  30Leu Gly Ala Gly Ala Thr Arg Ser Gly Val Gly Thr Gly Pro Pro Ser        35                  40                  45Pro Ile Ala Leu Pro Pro Leu Arg Ala Ser Asn Ala Ala Ala Ala Ala    50                  55                  60His Thr Ile Gly Gly Ser Lys His Thr Met Asn Asp His Leu His Val65                  70                  75                  80Gly Ser His Ala His Gly Gln Ile Gln Val Gln Gln Leu Phe Glu Asp                85                  90                  95Asn Ser Asn Lys Arg Thr Val Leu Thr Thr Gln Pro Asn Gly Leu Thr            100                 105                 110Thr Val Gly Lys Thr Gly Leu Pro Val Val Pro Glu Arg Gln Leu Asp        115                 120                 125Ser Ile His Arg Arg Gln Gly Ser Ser Thr Ser Leu Lys Ser Met Glu    130                 135                 140Gly Met Gly Lys Val Lys Ala Thr Pro Met Thr Pro Glu Gln Ala Met145                 150                 155                 160Lys Gln Tyr Met Gln Lys Leu Thr Ala Phe Glu His His Glu Ile Phe                165                 170                 175Ser Tyr Pro Glu Ile Tyr Phe Leu Gly Leu Asn Ala Lys Lys Arg Gln            180                 185                 190Gly Met Thr Gly Gly Pro Asn Asn Gly Gly Tyr Asp Asp Asp Gln Gly        195                 200                 205Ser Tyr Val Gln Val Pro His Asp His Val Ala Tyr Arg Tyr Glu Val    210                 215                 220Leu Lys Val Ile Gly Lys Gly Ser Phe Gly Gln Val Val Lys Ala Tyr225                 230                 235                 240Asp His Lys Val His Gln His Val Ala Leu Lys Met Val Arg Asn Glu                245                 250                 255Lys Arg Phe His Arg Gln Ala Ala Glu Glu Ile Arg Ile Leu Glu His            260                 265                 270Leu Arg Lys Gln Asp Lys Asp Asn Thr Met Asn Val Ile His Met Leu        275                 280                 285Glu Asn Phe Thr Phe Arg Asn His Ile Cys Met Thr Phe Glu Leu Leu    290                 295                 300Ser Met Asn Leu Tyr Glu Leu Ile Lys Lys Asn Lys Phe Gln Gly Phe305                 310                 315                 320Ser Leu Pro Leu Val Arg Lys Phe Ala His Ser Ile Leu Gln Cys Leu                325                 330                 335Asp Ala Leu His Lys Asn Arg Ile Ile His Cys Asp Leu Lys Pro Glu            340                 345                 350Asn Ile Leu Leu Lys Gln Gln Gly Arg Ser Gly Ile Lys Val Ile Asp        355                 360                 365Phe Gly Ser Ser Cys Tyr Glu His Gln Arg Val Tyr Thr Tyr Ile Gln    370                 375                 380Ser Arg Phe Tyr Arg Ala Pro Glu Val Ile Leu Gly Ala Arg Tyr Gly385                 390                 395                 400Met Pro Ile Asp Met Trp Ser Leu Gly Cys Ile Leu Ala Glu Leu Leu                405                 410                 415Thr Gly Tyr Pro Leu Leu Pro Gly Glu Asp Glu Gly Asp Gln Leu Ala            420                 425                 430Cys Met Ile Glu Leu Leu Gly Met Pro Ser Gln Lys Leu Leu Asp Ala        435                 440                 445Ser Lys Arg Ala Lys Asn Phe Val Ser Ser Lys Gly Tyr Pro Arg Tyr    450                 455                 460Cys Thr Val Thr Thr Leu Ser Asp Gly Ser Val Val Leu Asn Gly Gly465                 470                 475                 480Arg Ser Arg Arg Gly Lys Leu Arg Gly Pro Pro Glu Ser Arg Glu Trp                485                 490                 495Gly Asn Ala Leu Lys Gly Cys Asp Asp Pro Leu Phe Leu Asp Phe Leu            500                 505                 510Lys Gln Cys Leu Glu Trp Asp Pro Ala Val Arg Met Thr Pro Gly Gln        515                 520                 525Ala Leu Arg His Pro Trp Leu Arg Arg Arg Leu Pro Lys Pro Pro Thr    530                 535                 540Gly Glu Lys Thr Ser Val Lys Arg Ile Thr Glu Ser Thr Gly Ala Ile545                 550                 555                 560Thr Ser Ile Ser Lys Leu Pro Pro Pro Ser Ser Ser Ala Ser Lys Leu                565                 570                 575Arg Thr Asn Leu Ala Gln Met Thr Asp Ala Asn Gly Asn Ile Gln Gln            580                 585                 590Arg Thr Val Leu Pro Lys Leu Val Ser        595                 600</s400><s200><s210>36</s210><s211>1806</s211><s212>DNA</s212><s213>Artificial</s213><s220><s223>Human DYRK2 cDNA isoform</s223></s220></s200><s400> 36atgttaacca ggaaaccttc ggccgccgct cccgccgcct acccgaccgg ccgaggtggg     60gacagcgccg ttcgtcagct tcaggcttcc ccggggctcg gtgcaggggc cacccggagc    120ggagtgggga ctggcccgcc ctcccccatc gccctgccgc ctctccgggc cagcaacgct    180gccgccgcag cccacacgat tggcggcagt aagcacacaa tgaatgatca cctgcatgtc    240ggcagccacg ctcacggaca gatccaggtt caacagttgt ttgaggataa cagtaacaag    300cggacagtgc tcacgacaca accaaatggg cttacaacag tgggcaaaac gggcttgcca    360gtggtgccag agcggcagct ggacagcatt catagacggc aggggagctc cacctctcta    420aagtccatgg aaggcatggg gaaggtgaaa gccaccccca tgacacctga acaagcaatg    480aagcaataca tgcaaaaact cacagccttc gaacaccatg agattttcag ctaccctgaa    540atatatttct tgggtctaaa tgctaagaag cgccagggca tgacaggtgg gcccaacaat    600ggtggctatg atgatgacca gggatcatat gtgcaggtgc cccacgatca cgtggcttac    660aggtatgagg tcctcaaggt cattgggaag gggagctttg ggcaggtggt caaggcctac    720gatcacaaag tccaccagca cgtggcccta aagatggtgc ggaatgagaa gcgcttccac    780cggcaagcag cggaggagat ccgaatcctg gaacacctgc ggaagcagga caaggataac    840acaatgaatg tcatccatat gctggagaat ttcaccttcc gcaaccacat ctgcatgacg    900tttgagctgc tgagcatgaa cctctatgag ctcatcaaga agaataaatt ccagggcttc    960agtctgcctt tggttcgcaa gtttgcccac tcgattctgc agtgcttgga tgctttgcac   1020aaaaacagaa taattcactg tgaccttaag cccgagaaca ttttgttaaa gcagcagggt   1080agaagcggta ttaaagtaat tgattttggc tccagttgtt acgagcatca gcgtgtctac   1140acgtacatcc agtcgcgttt ttaccgggct ccagaagtga tccttggggc caggtatggc   1200atgcccattg atatgtggag cctgggctgc attttagcag agctcctgac gggttacccc   1260ctcttgcctg gggaagatga aggggaccag ctggcctgta tgattgaact gttgggcatg   1320ccctcacaga aactgctgga tgcatccaaa cgagccaaaa attttgtgag ctccaagggt   1380tatccccgtt actgcactgt cacgactctc tcagatggct ctgtggtcct aaacggaggc   1440cgttcccgga gggggaaact gaggggccca ccggagagca gagagtgggg gaacgcgctg   1500aaggggtgtg atgatcccct tttccttgac ttcttaaaac agtgtttaga gtgggatcct   1560gcagtgcgca tgaccccagg ccaggctttg cggcacccct ggctgaggag gcggttgcca   1620aagcctccca ccggggagaa aacgtcagtg aaaaggataa ctgagagcac cggtgctatc   1680acatctatat ccaagttacc tccaccttct agctcagctt ccaaactgag gactaatttg   1740gcgcagatga cagatgccaa tgggaatatt cagcagagga cagtgttgcc aaaacttgtt   1800agctga                                                              1806</s400><s200><s210>37</s210><s211>528</s211><s212>PRT</s212><s213>Artificial</s213><s220><s223>Human DYRK2 protein isoform 2</s223></s220></s200><s400> 37Met Asn Asp His Leu His Val Gly Ser His Ala His Gly Gln Ile Gln1               5                   10                  15Val Gln Gln Leu Phe Glu Asp Asn Ser Asn Lys Arg Thr Val Leu Thr            20                  25                  30Thr Gln Pro Asn Gly Leu Thr Thr Val Gly Lys Thr Gly Leu Pro Val        35                  40                  45Val Pro Glu Arg Gln Leu Asp Ser Ile His Arg Arg Gln Gly Ser Ser    50                  55                  60Thr Ser Leu Lys Ser Met Glu Gly Met Gly Lys Val Lys Ala Thr Pro65                  70                  75                  80Met Thr Pro Glu Gln Ala Met Lys Gln Tyr Met Gln Lys Leu Thr Ala                85                  90                  95Phe Glu His His Glu Ile Phe Ser Tyr Pro Glu Ile Tyr Phe Leu Gly            100                 105                 110Leu Asn Ala Lys Lys Arg Gln Gly Met Thr Gly Gly Pro Asn Asn Gly        115                 120                 125Gly Tyr Asp Asp Asp Gln Gly Ser Tyr Val Gln Val Pro His Asp His    130                 135                 140Val Ala Tyr Arg Tyr Glu Val Leu Lys Val Ile Gly Lys Gly Ser Phe145                 150                 155                 160Gly Gln Val Val Lys Ala Tyr Asp His Lys Val His Gln His Val Ala                165                 170                 175Leu Lys Met Val Arg Asn Glu Lys Arg Phe His Arg Gln Ala Ala Glu            180                 185                 190Glu Ile Arg Ile Leu Glu His Leu Arg Lys Gln Asp Lys Asp Asn Thr        195                 200                 205Met Asn Val Ile His Met Leu Glu Asn Phe Thr Phe Arg Asn His Ile    210                 215                 220Cys Met Thr Phe Glu Leu Leu Ser Met Asn Leu Tyr Glu Leu Ile Lys225                 230                 235                 240Lys Asn Lys Phe Gln Gly Phe Ser Leu Pro Leu Val Arg Lys Phe Ala                245                 250                 255His Ser Ile Leu Gln Cys Leu Asp Ala Leu His Lys Asn Arg Ile Ile            260                 265                 270His Cys Asp Leu Lys Pro Glu Asn Ile Leu Leu Lys Gln Gln Gly Arg        275                 280                 285Ser Gly Ile Lys Val Ile Asp Phe Gly Ser Ser Cys Tyr Glu His Gln    290                 295                 300Arg Val Tyr Thr Tyr Ile Gln Ser Arg Phe Tyr Arg Ala Pro Glu Val305                 310                 315                 320Ile Leu Gly Ala Arg Tyr Gly Met Pro Ile Asp Met Trp Ser Leu Gly                325                 330                 335Cys Ile Leu Ala Glu Leu Leu Thr Gly Tyr Pro Leu Leu Pro Gly Glu            340                 345                 350Asp Glu Gly Asp Gln Leu Ala Cys Met Ile Glu Leu Leu Gly Met Pro        355                 360                 365Ser Gln Lys Leu Leu Asp Ala Ser Lys Arg Ala Lys Asn Phe Val Ser    370                 375                 380Ser Lys Gly Tyr Pro Arg Tyr Cys Thr Val Thr Thr Leu Ser Asp Gly385                 390                 395                 400Ser Val Val Leu Asn Gly Gly Arg Ser Arg Arg Gly Lys Leu Arg Gly                405                 410                 415Pro Pro Glu Ser Arg Glu Trp Gly Asn Ala Leu Lys Gly Cys Asp Asp            420                 425                 430Pro Leu Phe Leu Asp Phe Leu Lys Gln Cys Leu Glu Trp Asp Pro Ala        435                 440                 445Val Arg Met Thr Pro Gly Gln Ala Leu Arg His Pro Trp Leu Arg Arg    450                 455                 460Arg Leu Pro Lys Pro Pro Thr Gly Glu Lys Thr Ser Val Lys Arg Ile465                 470                 475                 480Thr Glu Ser Thr Gly Ala Ile Thr Ser Ile Ser Lys Leu Pro Pro Pro                485                 490                 495Ser Ser Ser Ala Ser Lys Leu Arg Thr Asn Leu Ala Gln Met Thr Asp            500                 505                 510Ala Asn Gly Asn Ile Gln Gln Arg Thr Val Leu Pro Lys Leu Val Ser        515                 520                 525</s400><s200><s210>38</s210><s211>1586</s211><s212>DNA</s212><s213>Artificial</s213><s220><s223>Human DYRK2 cDNA isoform 2</s223></s220></s200><s400> 38atgaatgatc acctgcatgt cggcagccac gctcacggac agatccaggt tcaacagttg     60tttgaggata acagtaacaa gcggacagtg ctcacgacac aaccaaatgg gcttacaaca    120gtgggcaaaa cgggcttgcc agtggtgcca gagcggcagc tggacagcat tcatagacgg    180caggggagct ccacctctct aaagtccatg gaaggcatgg ggaaggtgaa agccaccccc    240atgacacctg aacaagcaat gaagcaatac atgcaaaaac tcacagcctt cgaacaccat    300gagattttca gctaccctga aatatatttc ttgggtctaa atgctaagaa gcgccagggc    360atgacaggtg ggcccaacaa tggtggctat gatgatgacc agggatcata tgtgcaggtg    420ccccacgatc acgtggctta caggtatgag gtcctcaagg tcattgggaa ggggagcttt    480gggcaggtgg tcaaggccta cgatcacaaa gtccaccagc acgtggccct aaagatggtg    540cggaatgaga agcgcttcca ccggcaagca gcggaggaga tccgaatcct ggaacacctg    600cggaagcagg acaaggataa cacaatgaat gtcatccata tgctggagat ttcaccttcc    660gcaaccacat ctgcatgacg tttgagctgc tgagcatgaa cctctatgag ctcatcaaga    720agaataaatt ccagggcttc agtctgcctt tggttcgcaa gtttgcccac tcgattctgc    780agtgcttgga tgctttgcac aaaaacagaa taattcactg tgaccttaag cccgagaaca    840ttttgttaaa gcagcagggt agaagcggta ttaaagtaat tgattttggc tccagttgtt    900acgagcatca gcgtgtctac acgtacatcc agtcgcgttt ttaccgggct ccagaagtga    960tccttggggc caggtatggc atgcccattg atatgtggag cctgggctgc attttagcag   1020agctcctgac gggttacccc ctcttgcctg gggaagatga aggggaccag ctggcctgta   1080tgattgaact gttgggcatg ccctcacaga aactgctgga tgcatccaaa cgagccaaaa   1140attttgtgag ctccaagggt tatccccgtt actgcactgt cacgactctc tcagatggct   1200ctgtggtcct aaacggaggc cgttcccgga gggggaaact gaggggccca ccggagagca   1260gagagtgggg gaacgcgctg aaggggtgtg atgatcccct tttccttgac ttcttaaaac   1320agtgtttaga gtgggatcct gcagtgcgca tgaccccagg ccaggctttg cggcacccct   1380ggctgaggag gcggttgcca aagcctccca ccggggagaa aacgtcagtg aaaaggataa   1440ctgagagcac cggtgctatc acatctatat ccaagttacc tccaccttct agctcagctt   1500ccaaactgag gactaatttg gcgcagatga cagatgccaa tgggaatatt cagcagagga   1560cagtgttgcc aaaacttgtt agctga                                        1586</s400><s200><s210>39</s210><s211>588</s211><s212>PRT</s212><s213>Artificial</s213><s220><s223>Human DYRK3 protein isoform 1</s223></s220></s200><s400> 39Met Gly Gly Thr Ala Arg Gly Pro Gly Arg Lys Asp Ala Gly Pro Pro1               5                   10                  15Gly Ala Gly Leu Pro Pro Gln Gln Arg Arg Leu Gly Asp Gly Val Tyr            20                  25                  30Asp Thr Phe Met Met Ile Asp Glu Thr Lys Cys Pro Pro Cys Ser Asn        35                  40                  45Val Leu Cys Asn Pro Ser Glu Pro Pro Pro Pro Arg Arg Leu Asn Met    50                  55                  60Thr Thr Glu Gln Phe Thr Gly Asp His Thr Gln His Phe Leu Asp Gly65                  70                  75                  80Gly Glu Met Lys Val Glu Gln Leu Phe Gln Glu Phe Gly Asn Arg Lys                85                  90                  95Ser Asn Thr Ile Gln Ser Asp Gly Ile Ser Asp Ser Glu Lys Cys Ser            100                 105                 110Pro Thr Val Ser Gln Gly Lys Ser Ser Asp Cys Leu Asn Thr Val Lys        115                 120                 125Ser Asn Ser Ser Ser Lys Ala Pro Lys Val Val Pro Leu Thr Pro Glu    130                 135                 140Gln Ala Leu Lys Gln Tyr Lys His His Leu Thr Ala Tyr Glu Lys Leu145                 150                 155                 160Glu Ile Ile Asn Tyr Pro Glu Ile Tyr Phe Val Gly Pro Asn Ala Lys                165                 170                 175Lys Arg His Gly Val Ile Gly Gly Pro Asn Asn Gly Gly Tyr Asp Asp            180                 185                 190Ala Asp Gly Ala Tyr Ile His Val Pro Arg Asp His Leu Ala Tyr Arg        195                 200                 205Tyr Glu Val Leu Lys Ile Ile Gly Lys Gly Ser Phe Gly Gln Val Ala    210                 215                 220Arg Val Tyr Asp His Lys Leu Arg Gln Tyr Val Ala Leu Lys Met Val225                 230                 235                 240Arg Asn Glu Lys Arg Phe His Arg Gln Ala Ala Glu Glu Ile Arg Ile                245                 250                 255Leu Glu His Leu Lys Lys Gln Asp Lys Thr Gly Ser Met Asn Val Ile            260                 265                 270His Met Leu Glu Ser Phe Thr Phe Arg Asn His Val Cys Met Ala Phe        275                 280                 285Glu Leu Leu Ser Ile Asp Leu Tyr Glu Leu Ile Lys Lys Asn Lys Phe    290                 295                 300Gln Gly Phe Ser Val Gln Leu Val Arg Lys Phe Ala Gln Ser Ile Leu305                 310                 315                 320Gln Ser Leu Asp Ala Leu His Lys Asn Lys Ile Ile His Cys Asp Leu                325                 330                 335Lys Pro Glu Asn Ile Leu Leu Lys His His Gly Arg Ser Ser Thr Lys            340                 345                 350Val Ile Asp Phe Gly Ser Ser Cys Phe Glu Tyr Gln Lys Leu Tyr Thr        355                 360                 365Tyr Ile Gln Ser Arg Phe Tyr Arg Ala Pro Glu Ile Ile Leu Gly Ser    370                 375                 380Arg Tyr Ser Thr Pro Ile Asp Ile Trp Ser Phe Gly Cys Ile Leu Ala385                 390                 395                 400Glu Leu Leu Thr Gly Gln Pro Leu Phe Pro Gly Glu Asp Glu Gly Asp                405                 410                 415Gln Leu Ala Cys Met Met Glu Leu Leu Gly Met Pro Pro Pro Lys Leu            420                 425                 430Leu Glu Gln Ser Lys Arg Ala Lys Tyr Phe Ile Asn Ser Lys Gly Ile        435                 440                 445Pro Arg Tyr Cys Ser Val Thr Thr Gln Ala Asp Gly Arg Val Val Leu    450                 455                 460Val Gly Gly Arg Ser Arg Arg Gly Lys Lys Arg Gly Pro Pro Gly Ser465                 470                 475                 480Lys Asp Trp Gly Thr Ala Leu Lys Gly Cys Asp Asp Tyr Leu Phe Ile                485                 490                 495Glu Phe Leu Lys Arg Cys Leu His Trp Asp Pro Ser Ala Arg Leu Thr            500                 505                 510Pro Ala Gln Ala Leu Arg His Pro Trp Ile Ser Lys Ser Val Pro Arg        515                 520                 525Pro Leu Thr Thr Ile Asp Lys Val Ser Gly Lys Arg Val Val Asn Pro    530                 535                 540Ala Ser Ala Phe Gln Gly Leu Gly Ser Lys Leu Pro Pro Val Val Gly545                 550                 555                 560Ile Ala Asn Lys Leu Lys Ala Asn Leu Met Ser Glu Thr Asn Gly Ser                565                 570                 575Ile Pro Leu Cys Ser Val Leu Pro Lys Leu Ile Ser            580                 585</s400><s200><s210>40</s210><s211>1767</s211><s212>DNA</s212><s213>Artificial</s213><s220><s223>Human DYRK3 cDNA isoform 1</s223></s220></s200><s400> 40atgggaggca cagctcgtgg gcctgggcgg aaggatgcgg ggccgcctgg ggccgggctc     60ccgccccagc agcggaggtt gggggatggt gtctatgaca ccttcatgat gatagatgaa    120accaaatgtc ccccctgttc aaatgtactc tgcaatcctt ctgaaccacc tccacccaga    180agactaaata tgaccactga gcagtttaca ggagatcata ctcagcactt tttggatgga    240ggtgagatga aggtagaaca gctgtttcaa gaatttggca acagaaaatc caatactatt    300cagtcagatg gcatcagtga ctctgaaaaa tgctctccta ctgtttctca gggtaaaagt    360tcagattgct tgaatacagt aaaatccaac agttcatcca aggcacccaa agtggtgcct    420ctgactccag aacaagccct gaagcaatat aaacaccacc tcactgccta tgagaaactg    480gaaataatta attatccaga aatttacttt gtaggtccaa atgccaagaa aagacatgga    540gttattggtg gtcccaataa tggagggtat gatgatgcag atggggccta tattcatgta    600cctcgagacc atctagctta tcgatatgag gtgctgaaaa ttattggcaa ggggagtttt    660gggcaggtgg ccagggtcta tgatcacaaa cttcgacagt acgtggccct aaaaatggtg    720cgcaatgaga agcgctttca tcgtcaagca gctgaggaga tccggatttt ggagcatctt    780aagaaacagg ataaaactgg tagtatgaac gttatccaca tgctggaaag tttcacattc    840cggaaccatg tttgcatggc ctttgaattg ctgagcatag acctttatga gctgattaaa    900aaaaataagt ttcagggttt tagcgtccag ttggtacgca agtttgccca gtccatcttg    960caatctttgg atgccctcca caaaaataag attattcact gcgatctgaa gccagaaaac   1020attctcctga aacaccacgg gcgcagttca accaaggtca ttgactttgg gtccagctgt   1080ttcgagtacc agaagctcta cacatatatc cagtctcggt tctacagagc tccagaaatc   1140atcttaggaa gccgctacag cacaccaatt gacatatgga gttttggctg catccttgca   1200gaacttttaa caggacagcc tctcttccct ggagaggatg aaggagacca gttggcctgc   1260atgatggagc ttctagggat gccaccacca aaacttctgg agcaatccaa acgtgccaag   1320tactttatta attccaaggg cataccccgc tactgctctg tgactaccca ggcagatggg   1380agggttgtgc ttgtgggggg tcgctcacgt aggggtaaaa agcggggtcc cccaggcagc   1440aaagactggg ggacagcact gaaagggtgt gatgactact tgtttataga gttcttgaaa   1500aggtgtcttc actgggaccc ctctgcccgc ttgaccccag ctcaagcatt aagacaccct   1560tggattagca agtctgtccc cagacctctc accaccatag acaaggtgtc agggaaacgg   1620gtagttaatc ctgcaagtgc tttccaggga ttgggttcta agctgcctcc agttgttgga   1680atagccaata agcttaaagc taacttaatg tcagaaacca atggtagtat acccctatgc   1740agtgtattgc caaaactgat tagctag                                       1767</s400><s200><s210>41</s210><s211>568</s211><s212>PRT</s212><s213>Artificial</s213><s220><s223>Human DYRK3 protein isoform 2</s223></s220></s200><s400> 41Met Lys Trp Lys Glu Lys Leu Gly Asp Gly Val Tyr Asp Thr Phe Met1               5                   10                  15Met Ile Asp Glu Thr Lys Cys Pro Pro Cys Ser Asn Val Leu Cys Asn            20                  25                  30Pro Ser Glu Pro Pro Pro Pro Arg Arg Leu Asn Met Thr Thr Glu Gln        35                  40                  45Phe Thr Gly Asp His Thr Gln His Phe Leu Asp Gly Gly Glu Met Lys    50                  55                  60Val Glu Gln Leu Phe Gln Glu Phe Gly Asn Arg Lys Ser Asn Thr Ile65                  70                  75                  80Gln Ser Asp Gly Ile Ser Asp Ser Glu Lys Cys Ser Pro Thr Val Ser                85                  90                  95Gln Gly Lys Ser Ser Asp Cys Leu Asn Thr Val Lys Ser Asn Ser Ser            100                 105                 110Ser Lys Ala Pro Lys Val Val Pro Leu Thr Pro Glu Gln Ala Leu Lys        115                 120                 125Gln Tyr Lys His His Leu Thr Ala Tyr Glu Lys Leu Glu Ile Ile Asn    130                 135                 140Tyr Pro Glu Ile Tyr Phe Val Gly Pro Asn Ala Lys Lys Arg His Gly145                 150                 155                 160Val Ile Gly Gly Pro Asn Asn Gly Gly Tyr Asp Asp Ala Asp Gly Ala                165                 170                 175Tyr Ile His Val Pro Arg Asp His Leu Ala Tyr Arg Tyr Glu Val Leu            180                 185                 190Lys Ile Ile Gly Lys Gly Ser Phe Gly Gln Val Ala Arg Val Tyr Asp        195                 200                 205His Lys Leu Arg Gln Tyr Val Ala Leu Lys Met Val Arg Asn Glu Lys    210                 215                 220Arg Phe His Arg Gln Ala Ala Glu Glu Ile Arg Ile Leu Glu His Leu225                 230                 235                 240Lys Lys Gln Asp Lys Thr Gly Ser Met Asn Val Ile His Met Leu Glu                245                 250                 255Ser Phe Thr Phe Arg Asn His Val Cys Met Ala Phe Glu Leu Leu Ser            260                 265                 270Ile Asp Leu Tyr Glu Leu Ile Lys Lys Asn Lys Phe Gln Gly Phe Ser        275                 280                 285Val Gln Leu Val Arg Lys Phe Ala Gln Ser Ile Leu Gln Ser Leu Asp    290                 295                 300Ala Leu His Lys Asn Lys Ile Ile His Cys Asp Leu Lys Pro Glu Asn305                 310                 315                 320Ile Leu Leu Lys His His Gly Arg Ser Ser Thr Lys Val Ile Asp Phe                325                 330                 335Gly Ser Ser Cys Phe Glu Tyr Gln Lys Leu Tyr Thr Tyr Ile Gln Ser            340                 345                 350Arg Phe Tyr Arg Ala Pro Glu Ile Ile Leu Gly Ser Arg Tyr Ser Thr        355                 360                 365Pro Ile Asp Ile Trp Ser Phe Gly Cys Ile Leu Ala Glu Leu Leu Thr    370                 375                 380Gly Gln Pro Leu Phe Pro Gly Glu Asp Glu Gly Asp Gln Leu Ala Cys385                 390                 395                 400Met Met Glu Leu Leu Gly Met Pro Pro Pro Lys Leu Leu Glu Gln Ser                405                 410                 415Lys Arg Ala Lys Tyr Phe Ile Asn Ser Lys Gly Ile Pro Arg Tyr Cys            420                 425                 430Ser Val Thr Thr Gln Ala Asp Gly Arg Val Val Leu Val Gly Gly Arg        435                 440                 445Ser Arg Arg Gly Lys Lys Arg Gly Pro Pro Gly Ser Lys Asp Trp Gly    450                 455                 460Thr Ala Leu Lys Gly Cys Asp Asp Tyr Leu Phe Ile Glu Phe Leu Lys465                 470                 475                 480Arg Cys Leu His Trp Asp Pro Ser Ala Arg Leu Thr Pro Ala Gln Ala                485                 490                 495Leu Arg His Pro Trp Ile Ser Lys Ser Val Pro Arg Pro Leu Thr Thr            500                 505                 510Ile Asp Lys Val Ser Gly Lys Arg Val Val Asn Pro Ala Ser Ala Phe        515                 520                 525Gln Gly Leu Gly Ser Lys Leu Pro Pro Val Val Gly Ile Ala Asn Lys    530                 535                 540Leu Lys Ala Asn Leu Met Ser Glu Thr Asn Gly Ser Ile Pro Leu Cys545                 550                 555                 560Ser Val Leu Pro Lys Leu Ile Ser                565</s400><s200><s210>42</s210><s211>1707</s211><s212>DNA</s212><s213>Artificial</s213><s220><s223>Human DYRK3 cDNA isoform 2</s223></s220></s200><s400> 42atgaagtgga aagagaagtt gggggatggt gtctatgaca ccttcatgat gatagatgaa     60accaaatgtc ccccctgttc aaatgtactc tgcaatcctt ctgaaccacc tccacccaga    120agactaaata tgaccactga gcagtttaca ggagatcata ctcagcactt tttggatgga    180ggtgagatga aggtagaaca gctgtttcaa gaatttggca acagaaaatc caatactatt    240cagtcagatg gcatcagtga ctctgaaaaa tgctctccta ctgtttctca gggtaaaagt    300tcagattgct tgaatacagt aaaatccaac agttcatcca aggcacccaa agtggtgcct    360ctgactccag aacaagccct gaagcaatat aaacaccacc tcactgccta tgagaaactg    420gaaataatta attatccaga aatttacttt gtaggtccaa atgccaagaa aagacatgga    480gttattggtg gtcccaataa tggagggtat gatgatgcag atggggccta tattcatgta    540cctcgagacc atctagctta tcgatatgag gtgctgaaaa ttattggcaa ggggagtttt    600gggcaggtgg ccagggtcta tgatcacaaa cttcgacagt acgtggccct aaaaatggtg    660cgcaatgaga agcgctttca tcgtcaagca gctgaggaga tccggatttt ggagcatctt    720aagaaacagg ataaaactgg tagtatgaac gttatccaca tgctggaaag tttcacattc    780cggaaccatg tttgcatggc ctttgaattg ctgagcatag acctttatga gctgattaaa    840aaaaataagt ttcagggttt tagcgtccag ttggtacgca agtttgccca gtccatcttg    900caatctttgg atgccctcca caaaaataag attattcact gcgatctgaa gccagaaaac    960attctcctga aacaccacgg gcgcagttca accaaggtca ttgactttgg gtccagctgt   1020ttcgagtacc agaagctcta cacatatatc cagtctcggt tctacagagc tccagaaatc   1080atcttaggaa gccgctacag cacaccaatt gacatatgga gttttggctg catccttgca   1140gaacttttaa caggacagcc tctcttccct ggagaggatg aaggagacca gttggcctgc   1200atgatggagc ttctagggat gccaccacca aaacttctgg agcaatccaa acgtgccaag   1260tactttatta attccaaggg cataccccgc tactgctctg tgactaccca ggcagatggg   1320agggttgtgc ttgtgggggg tcgctcacgt aggggtaaaa agcggggtcc cccaggcagc   1380aaagactggg ggacagcact gaaagggtgt gatgactact tgtttataga gttcttgaaa   1440aggtgtcttc actgggaccc ctctgcccgc ttgaccccag ctcaagcatt aagacaccct   1500tggattagca agtctgtccc cagacctctc accaccatag acaaggtgtc agggaaacgg   1560gtagttaatc ctgcaagtgc tttccaggga ttgggttcta agctgcctcc agttgttgga   1620atagccaata agcttaaagc taacttaatg tcagaaacca atggtagtat acccctatgc   1680agtgtattgc caaaactgat tagctag                                       1707</s400><s200><s210>43</s210><s211>520</s211><s212>PRT</s212><s213>Artificial</s213><s220><s223>Human DYRK4 protein isoform 1</s223></s220></s200><s400> 43Met Pro Ala Ser Glu Leu Lys Ala Ser Glu Ile Pro Phe His Pro Ser1               5                   10                  15Ile Lys Thr Gln Asp Pro Lys Ala Glu Glu Lys Ser Pro Lys Lys Gln            20                  25                  30Lys Val Thr Leu Thr Ala Ala Glu Ala Leu Lys Leu Phe Lys Asn Gln        35                  40                  45Leu Ser Pro Tyr Glu Gln Ser Glu Ile Leu Gly Tyr Ala Glu Leu Trp    50                  55                  60Phe Leu Gly Leu Glu Ala Lys Lys Leu Asp Thr Ala Pro Glu Lys Phe65                  70                  75                  80Ser Lys Thr Ser Phe Asp Asp Glu His Gly Phe Tyr Leu Lys Val Leu                85                  90                  95His Asp His Ile Ala Tyr Arg Tyr Glu Val Leu Glu Thr Ile Gly Lys            100                 105                 110Gly Ser Phe Gly Gln Val Ala Lys Cys Leu Asp His Lys Asn Asn Glu        115                 120                 125Leu Val Ala Leu Lys Ile Ile Arg Asn Lys Lys Arg Phe His Gln Gln    130                 135                 140Ala Leu Met Glu Leu Lys Ile Leu Glu Ala Leu Arg Lys Lys Asp Lys145                 150                 155                 160Asp Asn Thr Tyr Asn Val Val His Met Lys Asp Phe Phe Tyr Phe Arg                165                 170                 175Asn His Phe Cys Ile Thr Phe Glu Leu Leu Gly Ile Asn Leu Tyr Glu            180                 185                 190Leu Met Lys Asn Asn Asn Phe Gln Gly Phe Ser Leu Ser Ile Val Arg        195                 200                 205Arg Phe Thr Leu Ser Val Leu Lys Cys Leu Gln Met Leu Ser Val Glu    210                 215                 220Lys Ile Ile His Cys Asp Leu Lys Pro Glu Asn Ile Val Leu Tyr Gln225                 230                 235                 240Lys Gly Gln Ala Ser Val Lys Val Ile Asp Phe Gly Ser Ser Cys Tyr                245                 250                 255Glu His Gln Lys Val Tyr Thr Tyr Ile Gln Ser Arg Phe Tyr Arg Ser            260                 265                 270Pro Glu Val Ile Leu Gly His Pro Tyr Asp Val Ala Ile Asp Met Trp        275                 280                 285Ser Leu Gly Cys Ile Thr Ala Glu Leu Tyr Thr Gly Tyr Pro Leu Phe    290                 295                 300Pro Gly Glu Asn Glu Val Glu Gln Leu Ala Cys Ile Met Glu Val Leu305                 310                 315                 320Gly Leu Pro Pro Ala Gly Phe Ile Gln Thr Ala Ser Arg Arg Gln Thr                325                 330                 335Phe Phe Asp Ser Lys Gly Phe Pro Lys Asn Ile Thr Asn Asn Arg Gly            340                 345                 350Lys Lys Arg Tyr Pro Asp Ser Lys Asp Leu Thr Met Val Leu Lys Thr        355                 360                 365Tyr Asp Thr Ser Phe Leu Asp Phe Leu Arg Arg Cys Leu Val Trp Glu    370                 375                 380Pro Ser Leu Arg Met Thr Pro Asp Gln Ala Leu Lys His Ala Trp Ile385                 390                 395                 400His Gln Ser Arg Asn Leu Lys Pro Gln Pro Arg Pro Gln Thr Leu Arg                405                 410                 415Lys Ser Asn Ser Phe Phe Pro Ser Glu Thr Arg Lys Asp Lys Val Gln            420                 425                 430Gly Cys His His Ser Ser Arg Lys Ala Asp Glu Ile Thr Lys Glu Thr        435                 440                 445Thr Glu Lys Thr Lys Asp Ser Pro Thr Lys His Val Gln His Ser Gly    450                 455                 460Asp Gln Gln Asp Cys Leu Gln His Gly Ala Asp Thr Val Gln Leu Pro465                 470                 475                 480Gln Leu Val Asp Ala Pro Lys Lys Ser Glu Ala Ala Val Gly Ala Glu                485                 490                 495Val Ser Met Thr Ser Pro Gly Gln Ser Lys Asn Phe Ser Leu Lys Asn            500                 505                 510Thr Asn Val Leu Pro Pro Ile Val        515                 520</s400><s200><s210>44</s210><s211>1563</s211><s212>DNA</s212><s213>Artificial</s213><s220><s223>Human DYRK4 cDNA isoform 1</s223></s220></s200><s400> 44atgccggcct cagagctcaa ggcttcagaa atacctttcc accctagcat taaaacccag     60gatcccaagg cagaggagaa gtcaccaaag aagcaaaagg tgactctgac agcggcagag    120gccctaaagc tttttaagaa ccagctgtct ccatatgaac aaagtgaaat cctgggctac    180gcggagctgt ggttcctggg tcttgaagcc aagaagctcg acacggctcc tgagaaattt    240agcaagacga gttttgatga tgagcatggc ttctatctga aggtcctgca tgatcacatt    300gcctaccgct atgaagttct ggagacaatc gggaaggggt cctttggaca ggtggccaag    360tgcttggatc acaaaaacaa tgagctggtg gccctgaaaa tcatcaggaa caagaagagg    420tttcaccagc aggccctgat ggagctgaag atcctggaag ctctcagaaa gaaggacaaa    480gacaacacct acaatgtggt gcatatgaag gactttttct actttcgcaa tcacttctgc    540atcacctttg agctcctggg aatcaacttg tatgagttga tgaagaataa caactttcaa    600ggcttcagtc tgtccatagt tcggcgcttc actctctctg ttttgaagtg cttgcagatg    660ctttcggtag agaaaatcat tcactgtgat ctcaagcccg aaaatatagt gctataccaa    720aagggccaag cctctgttaa agtcattgac tttggatcaa gctgttatga acaccagaaa    780gtatacacgt acatccaaag ccggttctac cgatccccag aagtgatcct gggccacccc    840tacgacgtgg ccattgacat gtggagcctg ggctgcatca cggcggagtt gtacacgggc    900taccccctgt tccccgggga gaatgaggtg gagcagctgg cctgcatcat ggaggtgctg    960ggtctgccgc cagccggctt cattcagaca gcctccagga gacagacatt ctttgattcc   1020aaaggttttc ctaaaaatat aaccaacaac agggggaaaa aaagataccc agattccaag   1080gacctcacga tggtgctgaa aacctatgac accagcttcc tggactttct cagaaggtgt   1140ttggtatggg aaccttctct tcgcatgacc ccggaccagg ccctcaagca tgcttggatt   1200catcagtctc ggaacctcaa gccacagccc aggccccaga ccctgaggaa atccaattcc   1260tttttcccct ctgagacaag gaaggacaag gttcaaggct gtcatcactc gagcagaaaa   1320gcagatgaga tcaccaaaga gactacagag aaaacaaaag atagccccac gaagcatgtt   1380cagcattcag gtgatcagca ggactgtctc cagcacggag ctgacactgt tcagctgcct   1440caactggtag acgctcccaa gaagtcagag gcagctgtcg gggcggaggt gtccatgacc   1500tccccaggac agagcaaaaa cttctccctc aagaacacaa acgttttacc ccctattgta   1560tga                                                                 1563</s400><s200><s210>45</s210><s211>519</s211><s212>PRT</s212><s213>Artificial</s213><s220><s223>Human DYRK4 protein isoform 2</s223></s220></s200><s400> 45Met Pro Ala Ser Glu Leu Lys Ala Ser Glu Ile Pro Phe His Pro Ser1               5                   10                  15Ile Lys Thr Gln Asp Pro Lys Ala Glu Glu Lys Ser Pro Lys Lys Gln            20                  25                  30Lys Val Thr Leu Thr Ala Ala Glu Ala Leu Lys Leu Phe Lys Asn Gln        35                  40                  45Leu Ser Pro Tyr Glu Gln Ser Glu Ile Leu Gly Tyr Ala Glu Leu Trp    50                  55                  60Phe Leu Gly Leu Glu Ala Lys Lys Leu Asp Thr Ala Pro Glu Lys Phe65                  70                  75                  80Ser Lys Thr Ser Phe Asp Asp Glu His Gly Phe Tyr Leu Lys Val Leu                85                  90                  95His Asp His Ile Ala Tyr Arg Tyr Glu Val Leu Glu Thr Ile Gly Lys            100                 105                 110Gly Ser Phe Gly Gln Val Ala Lys Cys Leu Asp His Lys Asn Asn Glu        115                 120                 125Leu Val Ala Leu Lys Ile Ile Arg Asn Lys Lys Arg Phe His Gln Gln    130                 135                 140Ala Leu Met Glu Leu Lys Ile Leu Glu Ala Leu Arg Lys Lys Asp Lys145                 150                 155                 160Asp Asn Thr Tyr Asn Val Val His Met Lys Asp Phe Phe Tyr Phe Arg                165                 170                 175Asn His Phe Cys Ile Thr Phe Glu Leu Leu Gly Ile Asn Leu Tyr Glu            180                 185                 190Leu Met Lys Asn Asn Asn Phe Gln Gly Phe Ser Leu Ser Ile Val Arg        195                 200                 205Arg Phe Thr Leu Ser Val Leu Lys Cys Leu Gln Met Leu Ser Val Glu    210                 215                 220Lys Ile Ile His Cys Asp Leu Lys Pro Glu Asn Ile Val Leu Tyr Gln225                 230                 235                 240Lys Gly Gln Ala Ser Val Lys Val Ile Asp Phe Gly Ser Ser Cys Tyr                245                 250                 255Glu His Gln Lys Val Tyr Thr Tyr Ile Gln Ser Arg Phe Tyr Arg Ser            260                 265                 270Pro Glu Val Ile Leu Gly His Pro Tyr Asp Val Ala Ile Asp Met Trp        275                 280                 285Ser Leu Gly Cys Ile Thr Ala Glu Leu Tyr Thr Gly Tyr Pro Leu Phe    290                 295                 300Pro Gly Glu Asn Glu Val Glu Gln Leu Ala Cys Ile Met Glu Val Leu305                 310                 315                 320Gly Leu Pro Pro Ala Gly Phe Ile Gln Thr Ala Ser Arg Arg Gln Thr                325                 330                 335Phe Phe Asp Ser Lys Gly Phe Pro Lys Asn Ile Thr Asn Asn Arg Gly            340                 345                 350Lys Lys Arg Tyr Pro Asp Ser Lys Asp Leu Thr Met Val Leu Lys Thr        355                 360                 365Tyr Asp Thr Ser Phe Leu Asp Phe Leu Arg Arg Cys Leu Val Trp Glu    370                 375                 380Pro Ser Leu Arg Met Thr Pro Asp Gln Ala Leu Lys His Ala Trp Ile385                 390                 395                 400His Gln Ser Arg Asn Leu Lys Pro Gln Pro Arg Pro Gln Thr Leu Arg                405                 410                 415Lys Ser Asn Ser Phe Phe Pro Ser Glu Thr Arg Lys Asp Lys Val Gln            420                 425                 430Gly Cys His His Ser Ser Arg Lys Asp Glu Ile Thr Lys Glu Thr Thr        435                 440                 445Glu Lys Thr Lys Asp Ser Pro Thr Lys His Val Gln His Ser Gly Asp    450                 455                 460Gln Gln Asp Cys Leu Gln His Gly Ala Asp Thr Val Gln Leu Pro Gln465                 470                 475                 480Leu Val Asp Ala Pro Lys Lys Ser Glu Ala Ala Val Gly Ala Glu Val                485                 490                 495Ser Met Thr Ser Pro Gly Gln Ser Lys Asn Phe Ser Leu Lys Asn Thr            500                 505                 510Asn Val Leu Pro Pro Ile Val        515</s400><s200><s210>46</s210><s211>1560</s211><s212>DNA</s212><s213>Artificial</s213><s220><s223>Human DYRK4 cDNA isoform 2</s223></s220></s200><s400> 46atgccggcct cagagctcaa ggcttcagaa atacctttcc accctagcat taaaacccag     60gatcccaagg cagaggagaa gtcaccaaag aagcaaaagg tgactctgac agcggcagag    120gccctaaagc tttttaagaa ccagctgtct ccatatgaac aaagtgaaat cctgggctac    180gcggagctgt ggttcctggg tcttgaagcc aagaagctcg acacggctcc tgagaaattt    240agcaagacga gttttgatga tgagcatggc ttctatctga aggtcctgca tgatcacatt    300gcctaccgct atgaagttct ggagacaatc gggaaggggt cctttggaca ggtggccaag    360tgcttggatc acaaaaacaa tgagctggtg gccctgaaaa tcatcaggaa caagaagagg    420tttcaccagc aggccctgat ggagctgaag atcctggaag ctctcagaaa gaaggacaaa    480gacaacacct acaatgtggt gcatatgaag gactttttct actttcgcaa tcacttctgc    540atcacctttg agctcctggg aatcaacttg tatgagttga tgaagaataa caactttcaa    600ggcttcagtc tgtccatagt tcggcgcttc actctctctg ttttgaagtg cttgcagatg    660ctttcggtag agaaaatcat tcactgtgat ctcaagcccg aaaatatagt gctataccaa    720aagggccaag cctctgttaa agtcattgac tttggatcaa gctgttatga acaccagaaa    780gtatacacgt acatccaaag ccggttctac cgatccccag aagtgatcct gggccacccc    840tacgacgtgg ccattgacat gtggagcctg ggctgcatca cggcggagtt gtacacgggc    900taccccctgt tccccgggga gaatgaggtg gagcagctgg cctgcatcat ggaggtgctg    960ggtctgccgc cagccggctt cattcagaca gcctccagga gacagacatt ctttgattcc   1020aaaggttttc ctaaaaatat aaccaacaac agggggaaaa aaagataccc agattccaag   1080gacctcacga tggtgctgaa aacctatgac accagcttcc tggactttct cagaaggtgt   1140ttggtatggg aaccttctct tcgcatgacc ccggaccagg ccctcaagca tgcttggatt   1200catcagtctc ggaacctcaa gccacagccc aggccccaga ccctgaggaa atccaattcc   1260tttttcccct ctgagacaag gaaggacaag gttcaaggct gtcatcactc gagcagaaaa   1320gatgagatca ccaaagagac tacagagaaa acaaaagata gccccacgaa gcatgttcag   1380cattcaggtg atcagcagga ctgtctccag cacggagctg acactgttca gctgcctcaa   1440ctggtagacg ctcccaagaa gtcagaggca gctgtcgggg cggaggtgtc catgacctcc   1500ccaggacaga gcaaaaactt ctccctcaag aacacaaacg ttttaccccc tattgtatga   1560</s400><s200><s210>47</s210><s211>635</s211><s212>PRT</s212><s213>Artificial</s213><s220><s223>Human DYRK4 protein isoform 3</s223></s220></s200><s400> 47Met Gln Leu Leu Pro Pro Pro Ile Arg Thr Gly Thr Lys Thr Gln Met1               5                   10                  15Asp Ala Lys Lys Pro Arg Lys Cys Asp Leu Thr Pro Phe Leu Val Leu            20                  25                  30Lys Ala Arg Lys Lys Gln Lys Phe Thr Ser Ala Lys Val Gly Ser Lys        35                  40                  45Leu Ser Val Gln Ile Gln Lys Pro Pro Ser Asn Ile Lys Asn Ser Arg    50                  55                  60Met Thr Gln Val Phe His Lys Asn Thr Ser Val Thr Ser Leu Pro Phe65                  70                  75                  80Val Asp Thr Lys Gly Lys Lys Asn Thr Val Ser Phe Pro His Ile Ser                85                  90                  95Lys Lys Val Leu Leu Lys Ser Ser Leu Leu Tyr Gln Glu Asn Gln Ala            100                 105                 110His Asn Gln Met Pro Ala Ser Glu Leu Lys Ala Ser Glu Ile Pro Phe        115                 120                 125His Pro Ser Ile Lys Thr Gln Asp Pro Lys Ala Glu Glu Lys Ser Pro    130                 135                 140Lys Lys Gln Lys Val Thr Leu Thr Ala Ala Glu Ala Leu Lys Leu Phe145                 150                 155                 160Lys Asn Gln Leu Ser Pro Tyr Glu Gln Ser Glu Ile Leu Gly Tyr Ala                165                 170                 175Glu Leu Trp Phe Leu Gly Leu Glu Ala Lys Lys Leu Asp Thr Ala Pro            180                 185                 190Glu Lys Phe Ser Lys Thr Ser Phe Asp Asp Glu His Gly Phe Tyr Leu        195                 200                 205Lys Val Leu His Asp His Ile Ala Tyr Arg Tyr Glu Val Leu Glu Thr    210                 215                 220Ile Gly Lys Gly Ser Phe Gly Gln Val Ala Lys Cys Leu Asp His Lys225                 230                 235                 240Asn Asn Glu Leu Val Ala Leu Lys Ile Ile Arg Asn Lys Lys Arg Phe                245                 250                 255His Gln Gln Ala Leu Met Glu Leu Lys Ile Leu Glu Ala Leu Arg Lys            260                 265                 270Lys Asp Lys Asp Asn Thr Tyr Asn Val Val His Met Lys Asp Phe Phe        275                 280                 285Tyr Phe Arg Asn His Phe Cys Ile Thr Phe Glu Leu Leu Gly Ile Asn    290                 295                 300Leu Tyr Glu Leu Met Lys Asn Asn Asn Phe Gln Gly Phe Ser Leu Ser305                 310                 315                 320Ile Val Arg Arg Phe Thr Leu Ser Val Leu Lys Cys Leu Gln Met Leu                325                 330                 335Ser Val Glu Lys Ile Ile His Cys Asp Leu Lys Pro Glu Asn Ile Val            340                 345                 350Leu Tyr Gln Lys Gly Gln Ala Ser Val Lys Val Ile Asp Phe Gly Ser        355                 360                 365Ser Cys Tyr Glu His Gln Lys Val Tyr Thr Tyr Ile Gln Ser Arg Phe    370                 375                 380Tyr Arg Ser Pro Glu Val Ile Leu Gly His Pro Tyr Asp Val Ala Ile385                 390                 395                 400Asp Met Trp Ser Leu Gly Cys Ile Thr Ala Glu Leu Tyr Thr Gly Tyr                405                 410                 415Pro Leu Phe Pro Gly Glu Asn Glu Val Glu Gln Leu Ala Cys Ile Met            420                 425                 430Glu Val Leu Gly Leu Pro Pro Ala Gly Phe Ile Gln Thr Ala Ser Arg        435                 440                 445Arg Gln Thr Phe Phe Asp Ser Lys Gly Phe Pro Lys Asn Ile Thr Asn    450                 455                 460Asn Arg Gly Lys Lys Arg Tyr Pro Asp Ser Lys Asp Leu Thr Met Val465                 470                 475                 480Leu Lys Thr Tyr Asp Thr Ser Phe Leu Asp Phe Leu Arg Arg Cys Leu                485                 490                 495Val Trp Glu Pro Ser Leu Arg Met Thr Pro Asp Gln Ala Leu Lys His            500                 505                 510Ala Trp Ile His Gln Ser Arg Asn Leu Lys Pro Gln Pro Arg Pro Gln        515                 520                 525Thr Leu Arg Lys Ser Asn Ser Phe Phe Pro Ser Glu Thr Arg Lys Asp    530                 535                 540Lys Val Gln Gly Cys His His Ser Ser Arg Lys Ala Asp Glu Ile Thr545                 550                 555                 560Lys Glu Thr Thr Glu Lys Thr Lys Asp Ser Pro Thr Lys His Val Gln                565                 570                 575His Ser Gly Asp Gln Gln Asp Cys Leu Gln His Gly Ala Asp Thr Val            580                 585                 590Gln Leu Pro Gln Leu Val Asp Ala Pro Lys Lys Ser Glu Ala Ala Val        595                 600                 605Gly Ala Glu Val Ser Met Thr Ser Pro Gly Gln Ser Lys Asn Phe Ser    610                 615                 620Leu Lys Asn Thr Asn Val Leu Pro Pro Ile Val625                 630                 635</s400><s200><s210>48</s210><s211>644</s211><s212>PRT</s212><s213>Artificial</s213><s220><s223>Human DYRK4 protein isoform 4</s223></s220></s200><s400> 48Met Gln Leu Leu Pro Pro Pro Ile Arg Thr Gly Thr Lys Thr Gln Met1               5                   10                  15Asp Ala Lys Lys Pro Arg Lys Cys Asp Leu Thr Pro Phe Leu Val Leu            20                  25                  30Lys Ala Arg Lys Lys Gln Lys Phe Thr Ser Ala Lys Gly Pro Thr Leu        35                  40                  45Ser Glu Ile Tyr Met Val Gly Ser Lys Leu Ser Val Gln Ile Gln Lys    50                  55                  60Pro Pro Ser Asn Ile Lys Asn Ser Arg Met Thr Gln Val Phe His Lys65                  70                  75                  80Asn Thr Ser Val Thr Ser Leu Pro Phe Val Asp Thr Lys Gly Lys Lys                85                  90                  95Asn Thr Val Ser Phe Pro His Ile Ser Lys Lys Val Leu Leu Lys Ser            100                 105                 110Ser Leu Leu Tyr Gln Glu Asn Gln Ala His Asn Gln Met Pro Ala Ser        115                 120                 125Glu Leu Lys Ala Ser Glu Ile Pro Phe His Pro Ser Ile Lys Thr Gln    130                 135                 140Asp Pro Lys Ala Glu Glu Lys Ser Pro Lys Lys Gln Lys Val Thr Leu145                 150                 155                 160Thr Ala Ala Glu Ala Leu Lys Leu Phe Lys Asn Gln Leu Ser Pro Tyr                165                 170                 175Glu Gln Ser Glu Ile Leu Gly Tyr Ala Glu Leu Trp Phe Leu Gly Leu            180                 185                 190Glu Ala Lys Lys Leu Asp Thr Ala Pro Glu Lys Phe Ser Lys Thr Ser        195                 200                 205Phe Asp Asp Glu His Gly Phe Tyr Leu Lys Val Leu His Asp His Ile    210                 215                 220Ala Tyr Arg Tyr Glu Val Leu Glu Thr Ile Gly Lys Gly Ser Phe Gly225                 230                 235                 240Gln Val Ala Lys Cys Leu Asp His Lys Asn Asn Glu Leu Val Ala Leu                245                 250                 255Lys Ile Ile Arg Asn Lys Lys Arg Phe His Gln Gln Ala Leu Met Glu            260                 265                 270Leu Lys Ile Leu Glu Ala Leu Arg Lys Lys Asp Lys Asp Asn Thr Tyr        275                 280                 285Asn Val Val His Met Lys Asp Phe Phe Tyr Phe Arg Asn His Phe Cys    290                 295                 300Ile Thr Phe Glu Leu Leu Gly Ile Asn Leu Tyr Glu Leu Met Lys Asn305                 310                 315                 320Asn Asn Phe Gln Gly Phe Ser Leu Ser Ile Val Arg Arg Phe Thr Leu                325                 330                 335Ser Val Leu Lys Cys Leu Gln Met Leu Ser Val Glu Lys Ile Ile His            340                 345                 350Cys Asp Leu Lys Pro Glu Asn Ile Val Leu Tyr Gln Lys Gly Gln Ala        355                 360                 365Ser Val Lys Val Ile Asp Phe Gly Ser Ser Cys Tyr Glu His Gln Lys    370                 375                 380Val Tyr Thr Tyr Ile Gln Ser Arg Phe Tyr Arg Ser Pro Glu Val Ile385                 390                 395                 400Leu Gly His Pro Tyr Asp Val Ala Ile Asp Met Trp Ser Leu Gly Cys                405                 410                 415Ile Thr Ala Glu Leu Tyr Thr Gly Tyr Pro Leu Phe Pro Gly Glu Asn            420                 425                 430Glu Val Glu Gln Leu Ala Cys Ile Met Glu Val Leu Gly Leu Pro Pro        435                 440                 445Ala Gly Phe Ile Gln Thr Ala Ser Arg Arg Gln Thr Phe Phe Asp Ser    450                 455                 460Lys Gly Phe Pro Lys Asn Ile Thr Asn Asn Arg Gly Lys Lys Arg Tyr465                 470                 475                 480Pro Asp Ser Lys Asp Leu Thr Met Val Leu Lys Thr Tyr Asp Thr Ser                485                 490                 495Phe Leu Asp Phe Leu Arg Arg Cys Leu Val Trp Glu Pro Ser Leu Arg            500                 505                 510Met Thr Pro Asp Gln Ala Leu Lys His Ala Trp Ile His Gln Ser Arg        515                 520                 525Asn Leu Lys Pro Gln Pro Arg Pro Gln Thr Leu Arg Lys Ser Asn Ser    530                 535                 540Phe Phe Pro Ser Glu Thr Arg Lys Asp Lys Val Gln Gly Cys His His545                 550                 555                 560Ser Ser Arg Lys Ala Asp Glu Ile Thr Lys Glu Thr Thr Glu Lys Thr                565                 570                 575Lys Asp Ser Pro Thr Lys His Val Gln His Ser Gly Asp Gln Gln Asp            580                 585                 590Cys Leu Gln His Gly Ala Asp Thr Val Gln Leu Pro Gln Leu Val Asp        595                 600                 605Ala Pro Lys Lys Ser Glu Ala Ala Val Gly Ala Glu Val Ser Met Thr    610                 615                 620Ser Pro Gly Gln Ser Lys Asn Phe Ser Leu Lys Asn Thr Asn Val Leu625                 630                 635                 640Pro Pro Ile Val</s400><s200><s210>49</s210><s211>517</s211><s212>PRT</s212><s213>Artificial</s213><s220><s223>Human DYRK4 protein isoform 5</s223></s220></s200><s400> 49Met Pro Ala Ser Glu Leu Lys Ala Ser Glu Ile Pro Phe His Pro Ser1               5                   10                  15Ile Lys Thr Gln Asp Pro Lys Ala Glu Glu Lys Ser Pro Lys Lys Gln            20                  25                  30Lys Val Thr Leu Thr Ala Ala Glu Ala Leu Lys Leu Phe Lys Asn Gln        35                  40                  45Leu Ser Pro Tyr Glu Gln Ser Glu Ile Leu Gly Tyr Ala Glu Leu Trp    50                  55                  60Phe Leu Gly Leu Glu Ala Lys Lys Leu Asp Thr Ala Pro Glu Lys Phe65                  70                  75                  80Ser Lys Thr Ser Phe Asp Asp Glu His Gly Phe Tyr Leu Lys Val Leu                85                  90                  95His Asp His Ile Ala Tyr Arg Tyr Glu Val Leu Glu Thr Ile Gly Lys            100                 105                 110Gly Ser Phe Gly Gln Val Ala Lys Cys Leu Asp His Lys Asn Asn Glu        115                 120                 125Leu Val Ala Leu Lys Ile Ile Arg Asn Lys Lys Arg Phe His Gln Gln    130                 135                 140Ala Leu Met Glu Leu Lys Ile Leu Glu Ala Leu Arg Lys Lys Asp Lys145                 150                 155                 160Asp Asn Thr Tyr Asn Val Val His Met Lys Asp Phe Phe Tyr Phe Arg                165                 170                 175Asn His Phe Cys Ile Thr Phe Glu Leu Leu Gly Ile Asn Leu Tyr Glu            180                 185                 190Leu Met Lys Asn Asn Asn Phe Gln Gly Phe Ser Leu Ser Ile Val Arg        195                 200                 205Arg Phe Thr Leu Ser Val Leu Lys Cys Leu Gln Met Leu Ser Val Glu    210                 215                 220Lys Ile Ile His Cys Asp Leu Lys Pro Glu Asn Ile Val Leu Tyr Gln225                 230                 235                 240Lys Gly Gln Ala Ser Val Lys Val Ile Asp Phe Gly Ser Ser Cys Tyr                245                 250                 255Glu His Gln Lys Val Tyr Thr Tyr Ile Gln Ser Arg Phe Tyr Arg Ser            260                 265                 270Pro Glu Val Ile Leu Gly His Pro Tyr Asp Val Ala Ile Asp Met Trp        275                 280                 285Ser Leu Gly Cys Ile Thr Ala Glu Leu Tyr Thr Gly Tyr Pro Leu Phe    290                 295                 300Pro Gly Glu Asn Glu Val Glu Gln Leu Ala Cys Ile Met Glu Val Leu305                 310                 315                 320Gly Leu Pro Pro Ala Gly Phe Ile Gln Thr Ala Ser Arg Arg Gln Thr                325                 330                 335Phe Phe Asp Ser Lys Gly Phe Pro Lys Asn Ile Thr Asn Asn Arg Gly            340                 345                 350Lys Lys Arg Tyr Pro Asp Ser Lys Asp Leu Thr Met Val Leu Lys Thr        355                 360                 365Tyr Asp Thr Ser Phe Leu Asp Phe Leu Arg Arg Trp Glu Pro Ser Leu    370                 375                 380Arg Met Thr Pro Asp Gln Ala Leu Lys His Ala Trp Ile His Gln Ser385                 390                 395                 400Arg Asn Leu Lys Pro Gln Pro Arg Pro Gln Thr Leu Arg Lys Ser Asn                405                 410                 415Ser Phe Phe Pro Ser Glu Thr Arg Lys Asp Lys Val Gln Gly Cys His            420                 425                 430His Ser Ser Arg Lys Ala Asp Glu Ile Thr Lys Glu Thr Thr Glu Lys        435                 440                 445Thr Lys Asp Ser Pro Thr Lys His Val Gln His Ser Gly Asp Gln Gln    450                 455                 460Asp Cys Leu Gln His Gly Ala Asp Thr Val Gln Leu Pro Gln Leu Val465                 470                 475                 480Asp Ala Pro Lys Lys Ser Glu Ala Ala Val Gly Ala Glu Val Ser Met                485                 490                 495Thr Ser Pro Gly Gln Ser Lys Asn Phe Ser Leu Lys Asn Thr Asn Val            500                 505                 510Leu Pro Pro Ile Val        515</s400></sequence-list-new-rules></sequence-cwu><?xml version="1.0" encoding="UTF-8"?><!DOCTYPE us-patent-application SYSTEM "us-patent-application-v46-2022-02-17.dtd" [ ]><us-patent-application lang="EN" dtd-version="v4.6 2022-02-17" file="US20230000843A1-20230105.XML" status="PRODUCTION" id="us-patent-application" country="US" date-produced="20221220" date-publ="20230105"><us-bibliographic-data-application lang="EN" country="US"><publication-reference><document-id><country>US</country><doc-number>20230000843</doc-number><kind>A1</kind><date>20230105</date></document-id></publication-reference><application-reference appl-type="utility"><document-id><country>US</country><doc-number>17764922</doc-number><date>20200930</date></document-id></application-reference><us-application-series-code>17</us-application-series-code><priority-claims><priority-claim sequence="01" kind="national"><country>AU</country><doc-number>2019903681</doc-number><date>20190930</date></priority-claim></priority-claims><classifications-ipcr><classification-ipcr><ipc-version-indicator><date>20060101</date></ipc-version-indicator><classification-level>A</classification-level><section>A</section><class>61</class><subclass>K</subclass><main-group>31</main-group><subgroup>439</subgroup><symbol-position>F</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source></classification-ipcr><classification-ipcr><ipc-version-indicator><date>20060101</date></ipc-version-indicator><classification-level>A</classification-level><section>A</section><class>61</class><subclass>K</subclass><main-group>31</main-group><subgroup>444</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source></classification-ipcr><classification-ipcr><ipc-version-indicator><date>20060101</date></ipc-version-indicator><classification-level>A</classification-level><section>A</section><class>61</class><subclass>K</subclass><main-group>31</main-group><subgroup>506</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source></classification-ipcr><classification-ipcr><ipc-version-indicator><date>20060101</date></ipc-version-indicator><classification-level>A</classification-level><section>A</section><class>61</class><subclass>K</subclass><main-group>31</main-group><subgroup>497</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source></classification-ipcr><classification-ipcr><ipc-version-indicator><date>20060101</date></ipc-version-indicator><classification-level>A</classification-level><section>A</section><class>61</class><subclass>P</subclass><main-group>25</main-group><subgroup>28</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source></classification-ipcr></classifications-ipcr><classifications-cpc><main-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>A</section><class>61</class><subclass>K</subclass><main-group>31</main-group><subgroup>439</subgroup><symbol-position>F</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc></main-cpc><further-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>A</section><class>61</class><subclass>K</subclass><main-group>31</main-group><subgroup>444</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>A</section><class>61</class><subclass>K</subclass><main-group>31</main-group><subgroup>506</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>A</section><class>61</class><subclass>K</subclass><main-group>31</main-group><subgroup>497</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc><classification-cpc><cpc-version-indicator><date>20180101</date></cpc-version-indicator><section>A</section><class>61</class><subclass>P</subclass><main-group>25</main-group><subgroup>28</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc></further-cpc></classifications-cpc><invention-title id="d2e61">MEDICINAL COGNITIVE TREATMENTS</invention-title><us-parties><us-applicants><us-applicant sequence="00" app-type="applicant" designation="us-only" applicant-authority-category="assignee"><addressbook><orgname>ACTINOGEN MEDICAL LIMITED</orgname><address><city>Sydney, New South Wales</city><country>AU</country></address></addressbook><residence><country>AU</country></residence></us-applicant></us-applicants><inventors><inventor sequence="00" designation="us-only"><addressbook><last-name>MILLER</last-name><first-name>Tamara Diane</first-name><address><city>Sydney, New South Wales</city><country>AU</country></address></addressbook></inventor><inventor sequence="01" designation="us-only"><addressbook><last-name>KETELBEY</last-name><first-name>John William</first-name><address><city>Sydney, New South Wales</city><country>AU</country></address></addressbook></inventor></inventors></us-parties><pct-or-regional-filing-data><document-id><country>WO</country><doc-number>PCT/AU2020/051043</doc-number><date>20200930</date></document-id><us-371c12-date><date>20220329</date></us-371c12-date></pct-or-regional-filing-data></us-bibliographic-data-application><abstract id="abstract"><p id="p-0001" num="0000">The present disclosure generally relates to a method of improving cognition and/or treating cognitive decline in a cognitively healthy subject comprising administering to the cognitively healthy subject a therapeutically effective amount of a compound of Formula I, or a pharmaceutically acceptable salt, solvate or prodrug thereof, as described herein.</p></abstract><drawings id="DRAWINGS"><figure id="Fig-EMI-D00000" num="00000"><img id="EMI-D00000" he="136.65mm" wi="125.98mm" file="US20230000843A1-20230105-D00000.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00001" num="00001"><img id="EMI-D00001" he="219.03mm" wi="148.51mm" file="US20230000843A1-20230105-D00001.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00002" num="00002"><img id="EMI-D00002" he="221.57mm" wi="150.96mm" file="US20230000843A1-20230105-D00002.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00003" num="00003"><img id="EMI-D00003" he="219.63mm" wi="148.59mm" file="US20230000843A1-20230105-D00003.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00004" num="00004"><img id="EMI-D00004" he="148.17mm" wi="127.93mm" file="US20230000843A1-20230105-D00004.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00005" num="00005"><img id="EMI-D00005" he="220.98mm" wi="148.76mm" file="US20230000843A1-20230105-D00005.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00006" num="00006"><img id="EMI-D00006" he="220.90mm" wi="150.03mm" file="US20230000843A1-20230105-D00006.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00007" num="00007"><img id="EMI-D00007" he="220.81mm" wi="148.17mm" file="US20230000843A1-20230105-D00007.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00008" num="00008"><img id="EMI-D00008" he="147.91mm" wi="128.02mm" file="US20230000843A1-20230105-D00008.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00009" num="00009"><img id="EMI-D00009" he="218.86mm" wi="148.93mm" file="US20230000843A1-20230105-D00009.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00010" num="00010"><img id="EMI-D00010" he="220.98mm" wi="148.17mm" file="US20230000843A1-20230105-D00010.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00011" num="00011"><img id="EMI-D00011" he="220.47mm" wi="148.25mm" file="US20230000843A1-20230105-D00011.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00012" num="00012"><img id="EMI-D00012" he="147.40mm" wi="127.93mm" file="US20230000843A1-20230105-D00012.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00013" num="00013"><img id="EMI-D00013" he="220.22mm" wi="150.45mm" file="US20230000843A1-20230105-D00013.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00014" num="00014"><img id="EMI-D00014" he="220.30mm" wi="150.54mm" file="US20230000843A1-20230105-D00014.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00015" num="00015"><img id="EMI-D00015" he="217.93mm" wi="148.59mm" file="US20230000843A1-20230105-D00015.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00016" num="00016"><img id="EMI-D00016" he="156.29mm" wi="128.02mm" file="US20230000843A1-20230105-D00016.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00017" num="00017"><img id="EMI-D00017" he="222.42mm" wi="144.10mm" file="US20230000843A1-20230105-D00017.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00018" num="00018"><img id="EMI-D00018" he="221.40mm" wi="149.27mm" file="US20230000843A1-20230105-D00018.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00019" num="00019"><img id="EMI-D00019" he="221.06mm" wi="148.59mm" file="US20230000843A1-20230105-D00019.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00020" num="00020"><img id="EMI-D00020" he="147.49mm" wi="128.02mm" file="US20230000843A1-20230105-D00020.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00021" num="00021"><img id="EMI-D00021" he="220.05mm" wi="148.42mm" file="US20230000843A1-20230105-D00021.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00022" num="00022"><img id="EMI-D00022" he="219.29mm" wi="148.76mm" file="US20230000843A1-20230105-D00022.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00023" num="00023"><img id="EMI-D00023" he="212.68mm" wi="148.93mm" file="US20230000843A1-20230105-D00023.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00024" num="00024"><img id="EMI-D00024" he="155.87mm" wi="128.19mm" file="US20230000843A1-20230105-D00024.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00025" num="00025"><img id="EMI-D00025" he="185.84mm" wi="155.87mm" file="US20230000843A1-20230105-D00025.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure></drawings><description id="description"><?summary-of-invention description="Summary of Invention" end="lead"?><heading id="h-0001" level="1">FIELD</heading><p id="p-0002" num="0001">The present disclosure generally relates to the field of pharmaceutical treatments for improving cognition and/or treating decline in cognition in cognitively healthy subjects. The present disclosure also relates to a method of treating and/or preventing cognitive decline in cognitively healthy subjects. The present disclosure also relates to a method of improving cognitive performance in cognitively healthy subjects.</p><heading id="h-0002" level="1">BACKGROUND</heading><p id="p-0003" num="0002">Change in cognitive performance as a normal process of aging has been documented in scientific literature. Some cognitive abilities, such as vocabulary, are resistant to brain aging and may even improve with age. Other cognitive abilities, such as conceptual reasoning, memory, and processing speed, can gradually decline with age. Such changes in cognitive abilities associated with aging are commonly referred to as &#x201c;age-related cognitive decline&#x201d;.</p><p id="p-0004" num="0003">With an increasingly aging population, age-related cognitive decline is emerging as a prevalent health and social issue. Indeed, cognitive decline is among the most feared aspects of growing old. It is also the most costly, in terms of the financial, personal and societal burdens.</p><p id="p-0005" num="0004">It is well accepted in the scientific community that cognitive ability can be divided into specific cognitive domains, being processing speed, attention, memory, language, visuospatial abilities/construction, and executive functioning/reasoning.</p><p id="p-0006" num="0005">Processing speed refers to the speed with which cognitive activities are performed as well as the speed of motor responses, and this fluid ability begins to decline in the third decade of life and continues throughout the lifespan. Attention refers to the ability to concentrate and focus on specific stimuli, with more noticeable age-related declines seen in more complex attention tasks, such as selective and divided attention. Memory includes both declarative (explicit) memory and non-declarative (implicit) memory, though it is the declarative memory in which age-related decline is more commonly witnessed. Language is a complex cognitive domain composed of both crystallised and fluid cognitive abilities, and while general vocabulary remains relatively unchanged with age, visual confrontation naming, or the ability to see a common object and name it, declines dramatically from about 70 years of age. Visual construction skills, which involves the ability to put together individual parts to make a coherent whole, also typically declines over time. In contrast, visuospatial abilities, which includes the ability to recognise familiar objects such as household items or faces, typically remains relatively intact with age. Lastly, executive functioning/reasoning refers to capacities that allow a person to successfully engage in independent, appropriate, purposive, and self-serving behaviour, and research has shown that concept formation, abstraction, and mental flexibility decline with age, particularly after 70 years of age.</p><p id="p-0007" num="0006">The reasons behind age-related cognitive decline remain to be fully elucidated. From a physiological perspective, it is understood that grey matter volume begins to decrease after 20 years of age, with the majority of atrophy occurring in the prefrontal cortex. Even more significant decreases in volume occur in the white matter as well as its functioning. Declines in neurotransmitter levels may also contribute to age-related cognitive decline.</p><p id="p-0008" num="0007">These physiological reasons, however, do not explain the variability in age-related cognitive decline amongst individuals. To this extent, it is estimated that approximately 60% of age-related cognitive decline may be attributed to genetics, though it is also believed that medical illness, psychological factors, and sensory deficits (e.g., vision and hearing impairment) can also accelerate age-related cognitive decline.</p><p id="p-0009" num="0008">Irrespective of the pathophysiology, although age-related cognitive decline may not impair a person's ability to perform daily activities, it is undisputed that normal, age-related cognitive decline in a healthy, aging individual can result in subtle declines in complex functional abilities. A good example of this, is the ability to drive, which poses as a safety issue for not only the aging population, but those that may be inadvertently affected.</p><p id="p-0010" num="0009">It is believed that participation in certain activities, building cognitive reserve, and engaging in cognitive retraining may all be approaches to delay age-related cognitive decline. Tentative associations between exercise, diet, alcohol, sleep and social activity have also been linked to age-related cognitive decline. However, these mechanisms influence age-related cognitive decline in a variable manner amongst different individuals.</p><p id="p-0011" num="0010">Accordingly, there remains a need for alternative and effective treatments for improving cognition in cognitively healthy subjects and/or treating and/or preventing cognitive decline in cognitively healthy subjects, particularly in aging, cognitively healthy individuals.</p><heading id="h-0003" level="1">SUMMARY</heading><p id="p-0012" num="0011">The subject matter of the present disclosure is predicated in part on the surprising discovery that an azabicyclothiophenyl compound of Formula I as described herein can improve cognition and/or treat cognitive decline in cognitively healthy subjects.</p><p id="p-0013" num="0012">Accordingly, in a first aspect, there is provided a method of preventing and/or treating cognitive decline in a cognitively healthy subject, comprising administering to the cognitively healthy subject a therapeutically effective amount of a compound of Formula I, or a pharmaceutically acceptable salt, solvate or prodrug thereof:</p><p id="p-0014" num="0000"><chemistry id="CHEM-US-00001" num="00001"><img id="EMI-C00001" he="27.35mm" wi="68.24mm" file="US20230000843A1-20230105-C00001.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0015" num="0000">wherein R<sup>1 </sup>and R<sup>2 </sup>are each independently selected from the group consisting of hydrogen, halogen, C<sub>1-6</sub>alkyl, &#x2014;O&#x2014;C<sub>1-6</sub>alkyl, C<sub>1-6</sub>haloalkyl, &#x2014;O&#x2014;C<sub>1-6</sub>haloalkyl, C<sub>2-6</sub>alkenyl, C<sub>2-6</sub>alkynyl, 3-10-membered carbocyclyl, 3-10-membered heterocyclyl, &#x2014;CN, &#x2014;CF<sub>3</sub>, &#x2014;OR<sup>3</sup>, &#x2014;SR<sup>3</sup>, &#x2014;NR<sup>3</sup>R<sup>4</sup>, &#x2014;COR<sup>3</sup>, &#x2014;CO<sub>2</sub>R<sup>3</sup>, &#x2014;CONR<sup>3</sup>R<sup>4</sup>, &#x2014;NR<sup>3</sup>COR<sup>4</sup>, &#x2014;SO<sub>2</sub>R<sup>3</sup>, &#x2014;SO<sub>2</sub>NR<sup>3</sup>R<sup>4</sup>, and &#x2014;NR<sup>3</sup>SO<sub>2</sub>R<sup>4</sup>; wherein R<sup>3 </sup>and R<sup>4 </sup>are independently selected from the group consisting of hydrogen, C<sub>1-6</sub>alkyl, 3-7-membered carbocyclyl and 3-7-membered heterocyclyl; wherein each 3-10-membered carbocyclyl, 3-10-membered heterocyclyl, 3-7-membered carbocyclyl, and 3-7-membered heterocyclyl, is unsubstituted or substituted with one or more substituents selected from the group consisting of hydrogen, halogen, C<sub>1-6</sub>alkyl, &#x2014;O&#x2014;C<sub>1-6</sub>alkyl, C<sub>1-6</sub>haloalkyl, &#x2014;O&#x2014;C<sub>1-6</sub>haloalkyl, C<sub>2-6</sub>alkenyl, C<sub>2-6</sub>alkynyl, &#x2014;CN, &#x2014;CF<sub>3</sub>, &#x2014;OR<sup>5</sup>, &#x2014;SR<sup>5</sup>, &#x2014;NR<sup>5</sup>R<sup>6</sup>, &#x2014;COR<sup>5</sup>, &#x2014;CO<sub>2</sub>R<sup>5</sup>, &#x2014;CONR<sup>5</sup>R<sup>6</sup>, &#x2014;NR<sup>5</sup>COR<sup>6</sup>, &#x2014;SO<sub>2</sub>R<sup>5</sup>, &#x2014;SO<sub>2</sub>NR<sup>5</sup>R<sup>6</sup>, and &#x2014;NR<sup>5</sup>SO<sub>2</sub>R<sup>6</sup>; and wherein each R<sup>5 </sup>and R<sup>6 </sup>are independently selected from the group consisting of hydrogen and C<sub>1-6</sub>alkyl.</p><p id="p-0016" num="0013">In a further aspect, there is provided a method of preventing and/or treating cognitive decline in a cognitively healthy subject, comprising administering to the cognitively healthy subject a therapeutically effective amount of a compound of Formula I, or a pharmaceutically acceptable salt, solvate or prodrug thereof:</p><p id="p-0017" num="0000"><chemistry id="CHEM-US-00002" num="00002"><img id="EMI-C00002" he="27.35mm" wi="68.83mm" file="US20230000843A1-20230105-C00002.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0018" num="0000">wherein R<sup>1 </sup>and R<sup>2 </sup>are each independently selected from the group consisting of hydrogen, halogen, C<sub>1-6</sub>alkyl, &#x2014;O&#x2014;C<sub>1-6</sub>alkyl, C<sub>1-6</sub>haloalkyl, &#x2014;O&#x2014;C<sub>1-6</sub>haloalkyl, C<sub>2-6</sub>alkenyl, C<sub>2-6</sub>alkynyl, 3-10-membered carbocyclyl, 3-10-membered heterocyclyl, &#x2014;CN, &#x2014;CF<sub>3</sub>, &#x2014;OR<sup>3</sup>, &#x2014;SR<sup>3</sup>, &#x2014;NR<sup>3</sup>R<sup>4</sup>, &#x2014;COR<sup>3</sup>, &#x2014;CO<sub>2</sub>R<sup>3</sup>, &#x2014;CONR<sup>3</sup>R<sup>4</sup>, &#x2014;NR<sup>3</sup>COR<sup>4</sup>, &#x2014;SO<sub>2</sub>R<sup>3</sup>, &#x2014;SO<sub>2</sub>NR<sup>3</sup>R<sup>4</sup>, and &#x2014;NR<sup>3</sup>SO<sub>2</sub>R<sup>4</sup>; wherein R<sup>3 </sup>and R<sup>4 </sup>are independently selected from the group consisting of hydrogen, C<sub>1-6</sub>alkyl, 3-7-membered carbocyclyl and 3-7-membered heterocyclyl; wherein each 3-10-membered carbocyclyl, 3-10-membered heterocyclyl, 3-7-membered carbocyclyl, and 3-7-membered heterocyclyl, is unsubstituted or substituted with one or more substituents selected from the group consisting of hydrogen, halogen, C<sub>1-6</sub>alkyl, &#x2014;O&#x2014;C<sub>1-6</sub>alkyl, C<sub>1-6</sub>haloalkyl, &#x2014;O&#x2014;C<sub>1-6</sub>haloalkyl, C<sub>2-6</sub>alkenyl, C<sub>2-6</sub>alkynyl, &#x2014;CN, &#x2014;CF<sub>3</sub>, &#x2014;OR<sup>5</sup>, &#x2014;SR<sup>5</sup>, &#x2014;NR<sup>5</sup>R<sup>6</sup>, &#x2014;COR<sup>5</sup>, &#x2014;CO<sub>2</sub>R<sup>5</sup>, &#x2014;CONR<sup>5</sup>R<sup>6</sup>, &#x2014;NR<sup>5</sup>COR<sup>6</sup>, &#x2014;SO<sub>2</sub>R<sup>5</sup>, &#x2014;SO<sub>2</sub>NR<sup>5</sup>R<sup>6</sup>, and &#x2014;NR<sup>5</sup>SO<sub>2</sub>R<sup>6</sup>; and wherein each R<sup>5 </sup>and R<sup>6 </sup>are independently selected from the group consisting of hydrogen and C<sub>1-6</sub>alkyl.</p><p id="p-0019" num="0014">In some embodiments, wherein R<sup>1 </sup>and R<sup>2 </sup>are each independently selected from the group consisting of hydrogen, halogen, 3-10-membered carbocyclyl, 3-10-membered heterocyclyl, &#x2014;OH, &#x2014;CN, and &#x2014;NH<sub>2</sub>; and wherein if present, each 3-10-membered carbocyclyl and 3-10-membered heterocyclyl may be further substituted with one or more substituents selected from the group consisting of hydrogen, halogen, &#x2014;OH, &#x2014;CN, &#x2014;CF<sub>3</sub>, &#x2014;NH<sub>2</sub>, and C<sub>1-6</sub>alkyl.</p><p id="p-0020" num="0015">In some embodiments, R<sup>1 </sup>and R<sup>2 </sup>are each independently selected from the group consisting of hydrogen, halogen, 6-membered carbocyclyl, 6-membered heterocyclyl, &#x2014;OH, &#x2014;CN, and &#x2014;NH<sub>2</sub>; and wherein if present, each 6-membered carbocyclyl and 6-membered heterocyclyl may be further substituted with one or more substituents selected from the group consisting of hydrogen, halogen, &#x2014;OH, &#x2014;CN, &#x2014;CF<sub>3</sub>, &#x2014;NH<sub>2</sub>, and C<sub>1-6</sub>alkyl.</p><p id="p-0021" num="0016">In some embodiments, R<sup>1 </sup>is selected from the group consisting of hydrogen, halogen, &#x2014;OH, &#x2014;CN, &#x2014;CF<sub>3</sub>, &#x2014;NH<sub>2</sub>, and C<sub>1-6</sub>alkyl, and R<sup>2 </sup>is selected from the group consisting of:</p><p id="p-0022" num="0000"><chemistry id="CHEM-US-00003" num="00003"><img id="EMI-C00003" he="67.65mm" wi="63.75mm" file="US20230000843A1-20230105-C00003.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0023" num="0017">In some embodiments, the compound of Formula I is selected from the group consisting of:</p><p id="p-0024" num="0000"><chemistry id="CHEM-US-00004" num="00004"><img id="EMI-C00004" he="238.93mm" wi="54.19mm" file="US20230000843A1-20230105-C00004.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry><chemistry id="CHEM-US-00005" num="00005"><img id="EMI-C00005" he="92.37mm" wi="63.50mm" file="US20230000843A1-20230105-C00005.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0025" num="0018">In some embodiments, the compound of Formula I is:</p><p id="p-0026" num="0000"><chemistry id="CHEM-US-00006" num="00006"><img id="EMI-C00006" he="32.77mm" wi="55.12mm" file="US20230000843A1-20230105-C00006.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0027" num="0019">In some embodiments, the compound of Formula Ia is:</p><p id="p-0028" num="0000"><chemistry id="CHEM-US-00007" num="00007"><img id="EMI-C00007" he="32.77mm" wi="55.12mm" file="US20230000843A1-20230105-C00007.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0029" num="0020">In some embodiments, the cognitively healthy subject is not suffering from another, diagnosed medical condition that is associated with the central nervous system (CNS).</p><p id="p-0030" num="0021">In some embodiments, the cognitively healthy subject has an increased risk of cognitive decline.</p><p id="p-0031" num="0022">In some embodiments, the increased risk of cognitive decline is provided by a risk factor selected from the group consisting of an increased risk of stroke, the presence of genetic markers associated with cognitive decline, a family history of cognitive decline, environmental factors associated with cognitive decline, societal factors associated with cognitive decline, external factors associated with cognitive decline, and side effects associated with therapeutic treatment.</p><p id="p-0032" num="0023">In some embodiments, the administration of a compound of Formula I, or a pharmaceutically acceptable salt, solvate or prodrug thereof, provides improved cognitive ability of the treated subject relative to a non-treated subject.</p><p id="p-0033" num="0024">In some embodiments, the improved cognitive ability of the treated subject is determinable by cognitive testing.</p><p id="p-0034" num="0025">In some embodiments, the administration of a compound of Formula I, or a pharmaceutically acceptable salt, solvate or prodrug thereof, provides an improvement of psychomotor function of the treated subject relative to a non-treated subject.</p><p id="p-0035" num="0026">In some embodiments, the improvement of psychomotor function is at least partial restoration of motor function.</p><p id="p-0036" num="0027">In some embodiments, the improvement in psychomotor function is provided by an improvement in simple reaction time.</p><p id="p-0037" num="0028">In some embodiments, the administration of a compound of Formula I, or a pharmaceutically acceptable salt, solvate or prodrug thereof, provides an improvement of visual attention of the treated subject relative to a non-treated subject.</p><p id="p-0038" num="0029">In some embodiments, the improvement in visual attention is provided by an improvement in choice retention time.</p><p id="p-0039" num="0030">In some embodiments, the administration of a compound of Formula I, or a pharmaceutically acceptable salt, solvate or prodrug thereof, provides an improvement of learning and memory of the treated subject relative to a non-treated subject.</p><p id="p-0040" num="0031">In some embodiments, the improvement in learning and memory is provided by an improvement in visual recognition learning.</p><p id="p-0041" num="0032">In some embodiments, the administration of a compound of Formula I, or a pharmaceutically acceptable salt, solvate or prodrug thereof, provides an improvement of working memory of the treated subject relative to a non-treated subject.</p><p id="p-0042" num="0033">In some embodiments, the administration of a compound of Formula I, or a pharmaceutically acceptable salt, solvate or prodrug thereof, provides an improvement of visual associate memory of the treated subject relative to a non-treated subject.</p><p id="p-0043" num="0034">In some embodiments, the cognitively healthy subject has age-related cognitive decline.</p><p id="p-0044" num="0035">In some embodiments, the cognitively healthy subject is of at least 1, at least 5, at least 10, at least 20, at least 30, at least 40, at least 50, at least 60, at least 70, at least 80, at least 90, or at least 100 years of age.</p><p id="p-0045" num="0036">In some embodiments, the cognitively healthy subject has a low IQ.</p><p id="p-0046" num="0037">In some embodiments, the cognitively healthy subject is between about 1 and about 20 years of age.</p><p id="p-0047" num="0038">In some embodiments, the cognitively healthy subject is male.</p><p id="p-0048" num="0039">In some embodiments, the compound of Formula I, or a pharmaceutically acceptable salt, solvate or prodrug thereof, is administered in amount so as to deliver a total daily dosage of from about 10 to about 40 mg of Formula I.</p><p id="p-0049" num="0040">In some embodiments, the compound of Formula I, or a pharmaceutically acceptable salt, solvate or prodrug thereof, is administered as a single once-daily dosage or a twice-daily dosage.</p><p id="p-0050" num="0041">In some embodiments, the compound of Formula I, or a pharmaceutically acceptable salt, solvate or prodrug thereof, is administered as a twice-daily dosage of 10 mg per dosage.</p><p id="p-0051" num="0042">In some embodiments, the compound of Formula I, or a pharmaceutically acceptable salt, solvate or prodrug thereof, is administered orally.</p><p id="p-0052" num="0043">In some embodiments, the compound of Formula I, or a pharmaceutically acceptable salt, solvate or prodrug thereof, is administered with food.</p><p id="p-0053" num="0044">In a further aspect, there is provided use of a compound of Formula I, or a pharmaceutically acceptable salt, solvate or prodrug thereof:</p><p id="p-0054" num="0000"><chemistry id="CHEM-US-00008" num="00008"><img id="EMI-C00008" he="27.60mm" wi="63.08mm" file="US20230000843A1-20230105-C00008.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0055" num="0000">wherein R<sup>1 </sup>and R<sup>2 </sup>are each independently selected from the group consisting of hydrogen, halogen, C<sub>1-6</sub>alkyl, &#x2014;O&#x2014;C<sub>1-6</sub>alkyl, C<sub>1-6</sub>haloalkyl, &#x2014;O&#x2014;C<sub>1-6</sub>haloalkyl, C<sub>2-6</sub>alkenyl, C<sub>2-6</sub>alkynyl, 3-10-membered carbocyclyl, 3-10-membered heterocyclyl, &#x2014;CN, &#x2014;CF<sub>3</sub>, &#x2014;OR<sup>3</sup>, &#x2014;SR<sup>3</sup>, &#x2014;NR<sup>3</sup>R<sup>4</sup>, &#x2014;COR<sup>3</sup>, &#x2014;CO<sub>2</sub>R<sup>3</sup>, &#x2014;CONR<sup>3</sup>R<sup>4</sup>, &#x2014;NR<sup>3</sup>COR<sup>4</sup>, &#x2014;SO<sub>2</sub>R<sup>3</sup>, &#x2014;SO<sub>2</sub>NR<sup>3</sup>R<sup>4</sup>, and &#x2014;NR<sup>3</sup>SO<sub>2</sub>R<sup>4</sup>; wherein R<sup>3 </sup>and R<sup>4 </sup>are independently selected from the group consisting of hydrogen, C<sub>1-6</sub>alkyl, 3-7-membered carbocyclyl and 3-7-membered heterocyclyl; wherein each 3-10-membered carbocyclyl, 3-10-membered heterocyclyl, 3-7-membered carbocyclyl, and 3-7-membered heterocyclyl, is unsubstituted or substituted with one or more substituents selected from the group consisting of hydrogen, halogen, C<sub>1-6</sub>alkyl, &#x2014;O&#x2014;C<sub>1-6</sub>alkyl, C<sub>1-6</sub>haloalkyl, &#x2014;O&#x2014;C<sub>1-6</sub>haloalkyl, C<sub>2-6</sub>alkenyl, C<sub>2-6</sub>alkynyl, &#x2014;CN, &#x2014;CF<sub>3</sub>, &#x2014;OR<sup>5</sup>, &#x2014;SR<sup>5</sup>, &#x2014;NR<sup>5</sup>R<sup>6</sup>, &#x2014;COR<sup>5</sup>, &#x2014;CO<sub>2</sub>R<sup>5</sup>, &#x2014;CONR<sup>5</sup>R<sup>6</sup>, &#x2014;NR<sup>5</sup>COR<sup>6</sup>, &#x2014;SO<sub>2</sub>R<sup>5</sup>, &#x2014;SO<sub>2</sub>NR<sup>5</sup>R<sup>6</sup>, and &#x2014;NR<sup>5</sup>SO<sub>2</sub>R<sup>6</sup>; and wherein each R<sup>5 </sup>and R<sup>6 </sup>are independently selected from the group consisting of hydrogen and C<sub>1-6</sub>alkyl; in the manufacture of a medicament for the prevention and/or treatment of cognitive decline in a cognitively healthy subject.</p><p id="p-0056" num="0045">In some embodiments, the compound of Formula I, or a pharmaceutically acceptable salt, solvate or prodrug thereof, is a compound of Formula Ia:</p><p id="p-0057" num="0000"><chemistry id="CHEM-US-00009" num="00009"><img id="EMI-C00009" he="27.60mm" wi="68.41mm" file="US20230000843A1-20230105-C00009.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0058" num="0000">wherein R<sup>1 </sup>and R<sup>2 </sup>are each independently selected from the group consisting of hydrogen, halogen, C<sub>1-6</sub>alkyl, &#x2014;O&#x2014;C<sub>1-6</sub>alkyl, C<sub>1-6</sub>haloalkyl, &#x2014;O&#x2014;C<sub>1-6</sub>haloalkyl, C<sub>2-6</sub>alkenyl, C<sub>2-6</sub>alkynyl, 3-10-membered carbocyclyl, 3-10-membered heterocyclyl, &#x2014;CN, &#x2014;CF<sub>3</sub>, &#x2014;OR<sup>3</sup>, &#x2014;SR<sup>3</sup>, &#x2014;NR<sup>3</sup>R<sup>4</sup>, &#x2014;COR<sup>3</sup>, &#x2014;CO<sub>2</sub>R<sup>3</sup>, &#x2014;CONR<sup>3</sup>R<sup>4</sup>, &#x2014;NR<sup>3</sup>COR<sup>4</sup>, &#x2014;SO<sub>2</sub>R<sup>3</sup>, &#x2014;SO<sub>2</sub>NR<sup>3</sup>R<sup>4</sup>, and &#x2014;NR<sup>3</sup>SO<sub>2</sub>R<sup>4</sup>; wherein R<sup>3 </sup>and R<sup>4 </sup>are independently selected from the group consisting of hydrogen, C<sub>1-6</sub>alkyl, 3-7-membered carbocyclyl and 3-7-membered heterocyclyl; wherein each 3-10-membered carbocyclyl, 3-10-membered heterocyclyl, 3-7-membered carbocyclyl, and 3-7-membered heterocyclyl, is unsubstituted or substituted with one or more substituents selected from the group consisting of hydrogen, halogen, C<sub>1-6</sub>alkyl, &#x2014;O&#x2014;C<sub>1-6</sub>alkyl, C<sub>1-6</sub>haloalkyl, &#x2014;O&#x2014;C<sub>1-6</sub>haloalkyl, C<sub>2-6</sub>alkenyl, C<sub>2-6</sub>alkynyl, &#x2014;CN, &#x2014;CF<sub>3</sub>, &#x2014;OR<sup>5</sup>, &#x2014;SR<sup>5</sup>, &#x2014;NR<sup>5</sup>R<sup>6</sup>, &#x2014;COR<sup>5</sup>, &#x2014;CO<sub>2</sub>R<sup>5</sup>, &#x2014;CONR<sup>5</sup>R<sup>6</sup>, &#x2014;NR<sup>5</sup>COR<sup>6</sup>, &#x2014;SO<sub>2</sub>R<sup>5</sup>, &#x2014;SO<sub>2</sub>NR<sup>5</sup>R<sup>6</sup>, and &#x2014;NR<sup>5</sup>SO<sub>2</sub>R<sup>6</sup>; and wherein each R<sup>5 </sup>and R<sup>6 </sup>are independently selected from the group consisting of hydrogen and C<sub>1-6</sub>alkyl.</p><p id="p-0059" num="0046">In some embodiments, the compound of Formula Ia is:</p><p id="p-0060" num="0000"><chemistry id="CHEM-US-00010" num="00010"><img id="EMI-C00010" he="38.61mm" wi="70.10mm" file="US20230000843A1-20230105-C00010.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0061" num="0047">In a further aspect, there is provided use of a compound of Formula I, or a pharmaceutically acceptable salt, solvate or prodrug thereof:</p><p id="p-0062" num="0000"><chemistry id="CHEM-US-00011" num="00011"><img id="EMI-C00011" he="27.69mm" wi="67.82mm" file="US20230000843A1-20230105-C00011.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0063" num="0000">wherein R<sup>1 </sup>and R<sup>2 </sup>are each independently selected from the group consisting of hydrogen, halogen, C<sub>1-6</sub>alkyl, &#x2014;O&#x2014;C<sub>1-6</sub>alkyl, C<sub>1-6</sub>haloalkyl, &#x2014;O&#x2014;C<sub>1-6</sub>haloalkyl, C<sub>2-6</sub>alkenyl, C<sub>2-6</sub>alkynyl, 3-10-membered carbocyclyl, 3-10-membered heterocyclyl, &#x2014;CN, &#x2014;CF<sub>3</sub>, &#x2014;OR<sup>3</sup>, &#x2014;SR<sup>3</sup>, &#x2014;NR<sup>3</sup>R<sup>4</sup>, &#x2014;COR<sup>3</sup>, &#x2014;CO<sub>2</sub>R<sup>3</sup>, &#x2014;CONR<sup>3</sup>R<sup>4</sup>, &#x2014;NR<sup>3</sup>COR<sup>4</sup>, &#x2014;SO<sub>2</sub>R<sup>3</sup>, &#x2014;SO<sub>2</sub>NR<sup>3</sup>R<sup>4</sup>, and &#x2014;NR<sup>3</sup>SO<sub>2</sub>R<sup>4</sup>; wherein R<sup>3 </sup>and R<sup>4 </sup>are independently selected from the group consisting of hydrogen, C<sub>1-6</sub>alkyl, 3-7-membered carbocyclyl and 3-7-membered heterocyclyl; wherein each 3-10-membered carbocyclyl, 3-10-membered heterocyclyl, 3-7-membered carbocyclyl, and 3-7-membered heterocyclyl, is unsubstituted or substituted with one or more substituents selected from the group consisting of hydrogen, halogen, C<sub>1-6</sub>alkyl, &#x2014;O&#x2014;C<sub>1-6</sub>alkyl, C<sub>1-6</sub>haloalkyl, &#x2014;O&#x2014;C<sub>1-6</sub>haloalkyl, C<sub>2-6</sub>alkenyl, C<sub>2-6</sub>alkynyl, &#x2014;CN, &#x2014;CF<sub>3</sub>, &#x2014;OR<sup>5</sup>, &#x2014;SR<sup>5</sup>, &#x2014;NR<sup>5</sup>R<sup>6</sup>, &#x2014;COR<sup>5</sup>, &#x2014;CO<sub>2</sub>R<sup>5</sup>, &#x2014;CONR<sup>5</sup>R<sup>6</sup>, &#x2014;NR<sup>5</sup>COR<sup>6</sup>, &#x2014;SO<sub>2</sub>R<sup>5</sup>, &#x2014;SO<sub>2</sub>NR<sup>5</sup>R<sup>6</sup>, and &#x2014;NR<sup>5</sup>SO<sub>2</sub>R<sup>6</sup>; and wherein each R<sup>5 </sup>and R<sup>6 </sup>are independently selected from the group consisting of hydrogen and C<sub>1-6</sub>alkyl; for the prevention and/or treatment of cognitive decline in a cognitively healthy subject.</p><p id="p-0064" num="0048">In some embodiments, the compound of Formula I, or a pharmaceutically acceptable salt, solvate or prodrug thereof, is a compound of Formula Ia:</p><p id="p-0065" num="0000"><chemistry id="CHEM-US-00012" num="00012"><img id="EMI-C00012" he="27.60mm" wi="68.41mm" file="US20230000843A1-20230105-C00012.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0066" num="0000">wherein R<sup>1 </sup>and R<sup>2 </sup>are each independently selected from the group consisting of hydrogen, halogen, C<sub>1-6</sub>alkyl, &#x2014;O&#x2014;C<sub>1-6</sub>alkyl, C<sub>1-6</sub>haloalkyl, &#x2014;O&#x2014;C<sub>1-6</sub>haloalkyl, C<sub>2-6</sub>alkenyl, C<sub>2-6</sub>alkynyl, 3-10-membered carbocyclyl, 3-10-membered heterocyclyl, &#x2014;CN, &#x2014;CF<sub>3</sub>, &#x2014;OR<sup>3</sup>, &#x2014;SR<sup>3</sup>, &#x2014;NR<sup>3</sup>R<sup>4</sup>, &#x2014;COR<sup>3</sup>, &#x2014;CO<sub>2</sub>R<sup>3</sup>, &#x2014;CONR<sup>3</sup>R<sup>4</sup>, &#x2014;NR<sup>3</sup>COR<sup>4</sup>, &#x2014;SO<sub>2</sub>R<sup>3</sup>, &#x2014;SO<sub>2</sub>NR<sup>3</sup>R<sup>4</sup>, and &#x2014;NR<sup>3</sup>SO<sub>2</sub>R<sup>4</sup>; wherein R<sup>3 </sup>and R<sup>4 </sup>are independently selected from the group consisting of hydrogen, C<sub>1-6</sub>alkyl, 3-7-membered carbocyclyl and 3-7-membered heterocyclyl; wherein each 3-10-membered carbocyclyl, 3-10-membered heterocyclyl, 3-7-membered carbocyclyl, and 3-7-membered heterocyclyl, is unsubstituted or substituted with one or more substituents selected from the group consisting of hydrogen, halogen, C<sub>1-6</sub>alkyl, &#x2014;O&#x2014;C<sub>1-6</sub>alkyl, C<sub>1-6</sub>haloalkyl, &#x2014;O&#x2014;C<sub>1-6</sub>haloalkyl, C<sub>2-6</sub>alkenyl, C<sub>2-6</sub>alkynyl, &#x2014;CN, &#x2014;CF<sub>3</sub>, &#x2014;OR<sup>5</sup>, &#x2014;SR<sup>5</sup>, &#x2014;NR<sup>5</sup>R<sup>6</sup>, &#x2014;COR<sup>5</sup>, &#x2014;CO<sub>2</sub>R<sup>5</sup>, &#x2014;CONR<sup>5</sup>R<sup>6</sup>, &#x2014;NR<sup>5</sup>COR<sup>6</sup>, &#x2014;SO<sub>2</sub>R<sup>5</sup>, &#x2014;SO<sub>2</sub>NR<sup>5</sup>R<sup>6</sup>, and &#x2014;NR<sup>5</sup>SO<sub>2</sub>R<sup>6</sup>; and wherein each R<sup>5 </sup>and R<sup>6 </sup>are independently selected from the group consisting of hydrogen and C<sub>1-6</sub>alkyl.</p><p id="p-0067" num="0049">In some embodiments, the compound of Formula Ia is:</p><p id="p-0068" num="0000"><chemistry id="CHEM-US-00013" num="00013"><img id="EMI-C00013" he="33.10mm" wi="54.19mm" file="US20230000843A1-20230105-C00013.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0069" num="0050">Any embodiment herein shall be taken to apply mutatis mutandis to any other embodiment unless specifically stated otherwise.</p><p id="p-0070" num="0051">The present invention is not to be limited in scope by the specific embodiments described herein, which are intended for the purpose of exemplification only. Functionally-equivalent products, compositions and methods are clearly within the scope of the invention, as described herein.</p><p id="p-0071" num="0052">Throughout this specification, unless specifically stated otherwise or the context requires otherwise, reference to a single step, composition of matter, group of steps or group of compositions of matter shall be taken to encompass one and a plurality (i.e. one or more) of those steps, compositions of matter, groups of steps or group of compositions of matter.</p><?summary-of-invention description="Summary of Invention" end="tail"?><?brief-description-of-drawings description="Brief Description of Drawings" end="lead"?><description-of-drawings><heading id="h-0004" level="1">BRIEF DESCRIPTION OF THE DRAWINGS</heading><p id="p-0072" num="0053">Whilst it will be appreciated that a variety of embodiments of the disclosure may be utilised, in the following, we describe a number of examples of the disclosure with reference to the following drawings: the abbreviation &#x201c;LSMeans&#x201d; refers to &#x201c;Least Squares Means&#x201d;.</p><p id="p-0073" num="0054"><figref idref="DRAWINGS">FIG. <b>1</b>A</figref>(<b>1</b>) shows Means and 95% confidence intervals of the test scores of all the subjects who took Xanamem&#x2122;, which is a compound of Formula Ia as described herein, vs. all the subjects who took placebo in the Detection Test; and <figref idref="DRAWINGS">FIG. <b>1</b>A</figref>(<b>2</b>) shows LSMeans and 95% confidence intervals of the same.</p><p id="p-0074" num="0055"><figref idref="DRAWINGS">FIG. <b>1</b>B</figref>(<b>1</b>) shows Means and 95% confidence intervals of the test scores of all the female subjects who took Xanamem&#x2122; vs. all the female subjects who took placebo in the Detection Test; and <figref idref="DRAWINGS">FIG. <b>1</b>B</figref>(<b>2</b>) shows LSMeans and 95% confidence intervals of the same.</p><p id="p-0075" num="0056"><figref idref="DRAWINGS">FIG. <b>1</b>C</figref>(<b>1</b>) shows Means and 95% confidence intervals of the test scores of all the male subjects who took Xanamem&#x2122; vs. all the male subjects who took placebo in the Detection Test; and <figref idref="DRAWINGS">FIG. <b>1</b>C</figref>(<b>2</b>) shows LSMeans and 95% confidence intervals of the same.</p><p id="p-0076" num="0057"><figref idref="DRAWINGS">FIG. <b>1</b>D</figref> shows a linear plot of mean (+SD) Detection Test results over visit by treatment group.</p><p id="p-0077" num="0058"><figref idref="DRAWINGS">FIG. <b>2</b>A</figref>(<b>1</b>) shows Means and 95% confidence intervals of the test scores of all the subjects who took Xanamem&#x2122; vs. all the subjects who took placebo in the Identification Test; and <figref idref="DRAWINGS">FIG. <b>2</b>A</figref>(<b>2</b>) shows LSMeans and 95% confidence intervals of the same.</p><p id="p-0078" num="0059"><figref idref="DRAWINGS">FIG. <b>2</b>B</figref>(<b>1</b>) shows Means and 95% confidence intervals of the test scores of all the female subjects who took Xanamem&#x2122; vs. all the female subjects who took placebo in the Identification Test; and <figref idref="DRAWINGS">FIG. <b>2</b>B</figref>(<b>2</b>) shows LSMeans and 95% confidence intervals of the same.</p><p id="p-0079" num="0060"><figref idref="DRAWINGS">FIG. <b>2</b>C</figref>(<b>1</b>) shows Means and 95% confidence intervals of the test scores of all the male subjects who took Xanamem&#x2122; vs. all the male subjects who took placebo in the Identification Test; and <figref idref="DRAWINGS">FIG. <b>2</b>C</figref>(<b>2</b>) shows LSMeans and 95% confidence intervals of the same.</p><p id="p-0080" num="0061"><figref idref="DRAWINGS">FIG. <b>2</b>D</figref> shows a linear plot of mean (&#xb1;SD) Identification Test results over visit by treatment group.</p><p id="p-0081" num="0062"><figref idref="DRAWINGS">FIG. <b>3</b>A</figref>(<b>1</b>) shows Means and 95% confidence intervals of the test scores of all the subjects who took Xanamem&#x2122; vs. all the subjects who took placebo in the One Card Learning Test; and <figref idref="DRAWINGS">FIG. <b>3</b>A</figref>(<b>2</b>) shows LSMeans and 95% confidence intervals of the same.</p><p id="p-0082" num="0063"><figref idref="DRAWINGS">FIG. <b>3</b>B</figref>(<b>1</b>) shows Means and 95% confidence intervals of the test scores of all the female subjects who took Xanamem&#x2122; vs. all the female subjects who took placebo in the One Card Learning Test; and <figref idref="DRAWINGS">FIG. <b>3</b>B</figref>(<b>2</b>) shows LSMeans and 95% confidence intervals of the same.</p><p id="p-0083" num="0064"><figref idref="DRAWINGS">FIG. <b>3</b>C</figref>(<b>1</b>) shows Means and 95% confidence intervals of the test scores of all the male subjects who took Xanamem&#x2122; vs. all the male subjects who took placebo in the One Card Learning Test; and <figref idref="DRAWINGS">FIG. <b>3</b>C</figref>(<b>2</b>) shows LSMeans and 95% confidence intervals of the same.</p><p id="p-0084" num="0065"><figref idref="DRAWINGS">FIG. <b>3</b>D</figref> shows a linear plot of mean (&#xb1;SD) One Card Learning Test results over visit by treatment group.</p><p id="p-0085" num="0066"><figref idref="DRAWINGS">FIG. <b>4</b>A</figref>(<b>1</b>) shows Means and 95% confidence intervals of the test scores of all the subjects who took Xanamem&#x2122; vs. all the subjects who took placebo in the One Back Working Memory Test; <figref idref="DRAWINGS">FIG. <b>4</b>A</figref>(<b>2</b>) shows LSMeans and 95% confidence intervals of the same.</p><p id="p-0086" num="0067"><figref idref="DRAWINGS">FIG. <b>4</b>B</figref>(<b>1</b>) shows Means and 95% confidence intervals of the test scores of all the female subjects who took Xanamem&#x2122; vs. all the female subjects who took placebo in the One Back Working Memory Test; and <figref idref="DRAWINGS">FIG. <b>4</b>B</figref>(<b>2</b>) shows LSMeans and 95% confidence intervals of the same.</p><p id="p-0087" num="0068"><figref idref="DRAWINGS">FIG. <b>4</b>C</figref>(<b>1</b>) shows Means and 95% confidence intervals of the test scores of all the male subjects who took Xanamem&#x2122; vs. all the male subjects who took placebo in the One Back Working Memory Test; and <figref idref="DRAWINGS">FIG. <b>4</b>C</figref>(<b>2</b>) exhibits LSMeans and 95% confidence intervals of the same.</p><p id="p-0088" num="0069"><figref idref="DRAWINGS">FIG. <b>4</b>D</figref> shows a linear plot of mean (&#xb1;SD) One Back Test results over visit by treatment group.</p><p id="p-0089" num="0070"><figref idref="DRAWINGS">FIG. <b>5</b>A</figref>(<b>1</b>) shows Means and 95% confidence intervals of the test scores of all the subjects who took Xanamem&#x2122; vs. all the subjects who took placebo in the Continuous Paired Associate Learning Test; and <figref idref="DRAWINGS">FIG. <b>5</b>A</figref>(<b>2</b>) exhibits LSMeans and 95% confidence intervals of the same.</p><p id="p-0090" num="0071"><figref idref="DRAWINGS">FIG. <b>5</b>B</figref>(<b>1</b>) shows Means and 95% confidence intervals of the test scores of all the female subjects who took Xanamem&#x2122; vs. all the female subjects who took placebo in the Continuous Paired Associate Learning Test; and <figref idref="DRAWINGS">FIG. <b>5</b>B</figref>(<b>2</b>) exhibits LSMeans and 95% confidence intervals of the same.</p><p id="p-0091" num="0072"><figref idref="DRAWINGS">FIG. <b>5</b>C</figref>(<b>1</b>) shows Means and 95% confidence intervals of the test scores of all the male subjects who took Xanamem&#x2122; vs. all the male subjects who took placebo in the Continuous Paired Associate Learning Test; and <figref idref="DRAWINGS">FIG. <b>5</b>C</figref>(<b>2</b>) shows LSMeans and 95% confidence intervals of the same.</p><p id="p-0092" num="0073"><figref idref="DRAWINGS">FIG. <b>5</b>D</figref> shows a linear plot of mean (&#xb1;SD) Continuous Paired Associated Learning Test results over visit by treatment group.</p><p id="p-0093" num="0074"><figref idref="DRAWINGS">FIG. <b>6</b>A</figref>(<b>1</b>) shows Means and 95% confidence intervals of the test scores of all the subjects who took Xanamem&#x2122; vs. all the subjects who took placebo in the Continuous Paired Associate Learning-Delayed Test; and <figref idref="DRAWINGS">FIG. <b>6</b>A</figref>(<b>2</b>) shows LSMeans and 95% confidence intervals of the same.</p><p id="p-0094" num="0075"><figref idref="DRAWINGS">FIG. <b>6</b>B</figref>(<b>1</b>) shows Means and 95% confidence intervals of the test scores of all the female subjects who took Xanamem&#x2122; vs. all the female subjects who took placebo in the Continuous Paired Associate Learning-Delayed Test; and <figref idref="DRAWINGS">FIG. <b>6</b>B</figref>(<b>2</b>) exhibits LSMeans and 95% confidence intervals of the same.</p><p id="p-0095" num="0076"><figref idref="DRAWINGS">FIG. <b>6</b>C</figref>(<b>1</b>) shows Means and 95% confidence intervals of the test scores of all the male subjects who took Xanamem&#x2122; vs. all the male subjects who took placebo in the Continuous Paired Associate Learning-Delayed Test; and <figref idref="DRAWINGS">FIG. <b>6</b>C</figref>(<b>2</b>) exhibits LSMeans and 95% confidence intervals of the same.</p><p id="p-0096" num="0077"><figref idref="DRAWINGS">FIG. <b>6</b>D</figref> shows a linear plot of mean (&#xb1;SD) Continuous Paired Associate Learning-Delayed Test results over visit by treatment group.</p><p id="p-0097" num="0078"><figref idref="DRAWINGS">FIG. <b>7</b></figref> shows a linear plot of mean (&#xb1;SD) Plasma Xanamem&#x2122; concentrations (ng/mL) over visit by treatment group.</p></description-of-drawings><?brief-description-of-drawings description="Brief Description of Drawings" end="tail"?><?detailed-description description="Detailed Description" end="lead"?><heading id="h-0005" level="1">DETAILED DESCRIPTION</heading><heading id="h-0006" level="1">General Definitions</heading><p id="p-0098" num="0079">Unless specifically defined otherwise, all technical and scientific terms used herein shall be taken to have the same meaning as commonly understood by one of ordinary skill in the art (e.g., chemistry, biochemistry, medicinal chemistry, microbiology and the like).</p><p id="p-0099" num="0080">As used herein, the term &#x201c;and/or&#x201d;, e.g., &#x201c;X and/or Y&#x201d; shall be understood to mean either &#x201c;X and Y&#x201d; or &#x201c;X or Y&#x201d; and shall be taken to provide explicit support for both meanings or for either meaning, e.g. A and/or B includes the options i) A, ii) B or iii) A and B.</p><p id="p-0100" num="0081">As used herein, the term about, unless stated to the contrary, refers to +/&#x2212;20%, typically +/&#x2212;10%, typically +/&#x2212;5%, of the designated value.</p><p id="p-0101" num="0082">As used herein, the terms &#x201c;a&#x201d;, &#x201c;an&#x201d; and &#x201c;the&#x201d; include both singular and plural aspects, unless the context clearly indicates otherwise.</p><p id="p-0102" num="0083">It is to be appreciated that certain features that are, for clarity, described herein in the context of separate embodiments, may also be provided in combination in a single embodiment. Conversely, various features that are, for brevity, described in the context of a single embodiment, may also be provided separately or in any sub-combination.</p><p id="p-0103" num="0084">Throughout the present specification, various aspects and components of the invention can be presented in a range format. The range format is included for convenience and should not be interpreted as an inflexible limitation on the scope of the invention. Accordingly, the description of a range should be considered to have specifically disclosed all the possible sub-ranges as well as individual numerical values within that range, unless specifically indicated. For example, description of a range such as from 1 to 5 should be considered to have specifically disclosed sub-ranges such as from 1 to 3, from 1 to 4, from 1 to 5, from 2 to 4, from 2 to 5, from 3 to 5 etc., as well as individual and partial numbers within the recited range, for example, 1, 2, 3, 4, 5, 5.5 and 6, unless where integers are required or implicit from context. This applies regardless of the breadth of the disclosed range. Where specific values are required, these will be indicated in the specification.</p><p id="p-0104" num="0085">Throughout this specification the word &#x201c;comprise&#x201d;, or variations such as &#x201c;comprises&#x201d; or &#x201c;comprising&#x201d;, will be understood to imply the inclusion of a stated element, integer or step, or group of elements, integers or steps, but not the exclusion of any other element, integer or step, or group of elements, integers or steps.</p><p id="p-0105" num="0086">It will be clearly understood that, although a number of prior art publications are referred to herein, this reference does not constitute an admission that any of these documents forms part of the common general knowledge in the art, in Australia or in any other country.</p><p id="p-0106" num="0087">Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, suitable methods and materials are described below. In case of conflict, the present specification, including definitions, will prevail. In addition, the materials, methods, and examples are illustrative only and not intended to be limiting.</p><p id="p-0107" num="0088">As used herein, the term &#x201c;treating&#x201d; (or &#x201c;treat&#x201d;, &#x201c;treatment&#x201d; etc.) includes a reduction, alleviation and/or elimination of one or more symptoms associated with a specific disorder or condition. Such symptoms may be correlated with cognitive decline in cognitively healthy subjects, which includes age-related cognitive decline in cognitively healthy subjects. For example, as used herein, the phrase &#x201c;treating cognitive decline&#x201d; includes improving, reducing, alleviating and/or eliminating symptoms associated with cognitive decline, relative to the symptoms prior to treatment.</p><p id="p-0108" num="0089">As used herein, the term &#x201c;preventing&#x201d; (or &#x201c;prevention&#x201d;) includes prophylaxis of the specific disorder or condition. For example, as used herein, the phrase &#x201c;preventing cognitive decline&#x201d; refers to preventing the onset or duration of the symptoms associated with cognitive decline in cognitively healthy subjects, which includes age-related cognitive decline in cognitively healthy subjects. In some embodiments, the phrase &#x201c;preventing cognitive decline&#x201d; refers to slowing or halting the progression of cognitive decline. In some embodiments, the phrase &#x201c;preventing cognitive decline&#x201d; refers to delaying or preventing the onset of the symptoms of the cognitive decline. Prevention may be absolute (such that no cognitive decline occurs), or may be effective only in some individuals, to some extent, or for a limited amount of time.</p><p id="p-0109" num="0090">As used herein, the term &#x201c;halogen&#x201d; means fluorine, chlorine, bromine, or iodine.</p><p id="p-0110" num="0091">As used herein, the term &#x201c;alkyl&#x201d; encompasses both straight-chain (i.e., linear) and branched-chain hydrocarbon groups. Examples of alkyl groups include, but are not limited to, methyl, ethyl, n-propyl, iso-propyl, n-butyl, t-butyl, i-butyl, sec-butyl, pentyl, and hexyl groups. In one example, the alkyl group is of one to six carbon atoms (i.e. C<sub>1-6</sub>alkyl).</p><p id="p-0111" num="0092">As used herein, the term &#x201c;alkoxy&#x201d; refers to the group &#x2014;O-alkyl, where &#x201c;alkyl&#x201d; is as described above. Examples of alkoxy groups include, but are not limited to, methoxy, ethoxy, propoxy, and butoxy groups. In one example, the alkoxy group is of one to six carbon atoms (i.e. &#x2014;O&#x2014;C<sub>1-6</sub>alkyl).</p><p id="p-0112" num="0093">As used herein, the term &#x201c;alkenyl&#x201d; refers to both straight and branched chain unsaturated hydrocarbon groups with at least one carbon-carbon double bond. Examples of alkenyl groups include, but are not limited to, ethenyl, propenyl, butenyl, pentenyl, and hexenyl groups. In one example, the alkenyl group is of two to six carbon atoms (i.e. C<sub>2-6</sub>alkenyl).</p><p id="p-0113" num="0094">As used herein, the term &#x201c;alkynyl&#x201d; refers to both straight and branched chain unsaturated hydrocarbon groups with at least one carbon-carbon triple bond. Examples of alkynyl groups include, but are not limited to, ethynyl, propynyl, butynyl, pentynyl, and hexynyl groups. In one example, the alkynyl group is of two to six carbon atoms (i.e. C<sub>2-6</sub>alkynyl).</p><p id="p-0114" num="0095">As used herein, the term &#x201c;haloalkyl&#x201d; refers to an alkyl group having at least one halogen substituent, where &#x201c;alkyl&#x201d; and &#x201c;halogen&#x201d; are as described above. Similarly, the term &#x201c;dihaloalkyl&#x201d; means an alkyl group having two halogen substituents, and the term &#x201c;trihaloalkyl&#x201d; means an alkyl group having three halogen substituents. Examples of haloalkyl groups include fluoromethyl, chloromethyl, bromomethyl, iodomethyl, fluoropropyl, and fluorobutyl groups. Examples of dihaloalkyl groups include difluoromethyl and difluoroethyl groups. Examples of trihaloalkyl groups include trifluoromethyl and trifluoroethyl groups. In one example, the haloalkyl group is of one to six carbon atoms (i.e. C<sub>1-6</sub>haloalkyl).</p><p id="p-0115" num="0096">As used herein, the term &#x201c;oxyhaloalkyl&#x201d; refers to the group &#x2014;O-haloalkyl, where &#x201c;haloalkyl&#x201d; is as described above. Examples of &#x2014;O-haloalkoxy groups include &#x2014;O-fluoromethyl, &#x2014;O-chloromethyl, &#x2014;O-bromomethyl, &#x2014;O-iodomethyl, &#x2014;O-fluoropropyl, and &#x2014;Ofluorobutyl groups. In one example, the oxyhaloalkyl group is of one to six carbon atoms (i.e. &#x2014;O&#x2014;C<sub>1-6</sub>haloalkyl).</p><p id="p-0116" num="0097">As used herein, the term &#x201c;carbocyclyl&#x201d; refers to an aromatic or non-aromatic cyclic group of carbon atoms. A carbocyclyl group may, for example, be monocyclic or polycyclic (i.e. bicyclic, tricyclic). A polycyclic carbocyclyl group may contain fused rings. In one example, the carbocyclyl group is of three to ten carbon atoms (i.e. C<sub>3-10</sub>carbocyclyl). In one example, the carbocyclyl group is of three to seven carbon atoms (i.e. C<sub>3-7</sub>carbocyclyl). Examples of monocyclic non-aromatic carbocyclyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cycloheptyl, and cyclooctyl groups. Aromatic carbocyclyl groups include phenyl and napthalenyl.</p><p id="p-0117" num="0098">As used herein, the term &#x201c;heterocyclyl&#x201d; refers to an aromatic or non-aromatic cyclic group which is analogous to a carbocyclic group, but in which from one to three of the carbon atoms is/are replaced by one or more heteroatoms independently selected from nitrogen, oxygen, or sulfur. A heterocyclyl group may, for example, be monocyclic or polycyclic (e.g. bicyclic). A polycyclic heterocyclyl may for example contain fused rings. In a bicyclic heterocyclyl group there may be one or more heteroatoms in each ring, or heteroatoms only in one of the rings. A heteroatom may be N, O, or S. Heterocyclyl groups containing a suitable nitrogen atom include the corresponding N-oxides. In one example, the heterocyclyl group is of three to ten atoms (i.e. 3-10-membered heterocyclyl). In one example, the heterocyclyl group is of three to seven atoms (i.e. 3-7-membered heterocyclyl). Examples of monocyclic non-aromatic heterocyclyl groups include aziridinyl, azetidinyl, pyrrolidinyl, imidazolidinyl, pyrazolidinyl, piperidinyl, piperazinyl, tetrahydrofuranyl, tetrahydropyranyl, morpholinyl, thiomorpholinyl and azepanyl. Examples of bicyclic heterocyclyl groups in which one of the rings is non-aromatic include dihydrobenzofuranyl, indanyl, indolinyl, isoindolinyl, tetrahydroisoquinolinyl, tetrahydroquinolyl, and benzoazepanyl. Examples of monocyclic aromatic heterocyclyl groups (also referred to as monocyclic heteroaryl groups) include furanyl, thienyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, oxadiazolyl, thiadiazolyl, pyridyl, triazolyl, triazinyl, pyridazyl, isothiazolyl, isoxazolyl, pyrazinyl, pyrazolyl, and pyrimidinyl. Examples of bicyclic aromatic heterocyclyl groups (also referred to as bicyclic heteroaryl groups) include quinoxalinyl, quinazolinyl, pyridopyrazinyl, benzoxazolyl, benzothiophenyl, benzimidazolyl, naphthyridinyl, quinolinyl, benzofuranyl, indolyl, benzothiazolyl, oxazolyl[4,5-b]pyridyl, pyridopyrimidinyl, isoquinolinyl, and benzohydroxazole.</p><heading id="h-0007" level="2">Cognitive Decline</heading><p id="p-0118" num="0099">The subject matter of the present disclosure is predicated in part on the surprising discovery that a compound of Formula I improves cognition and/or treats cognitive decline in a cognitively healthy subject. Accordingly, in one aspect, there is provided a method of preventing and/or treating cognitive decline in a cognitively healthy subject.</p><p id="p-0119" num="0100">As used herein, &#x201c;cognitive decline&#x201d; refers to the deterioration, or loss, of cognitive ability. The skilled person will be aware that there are a multitude of reasons as to why a subject may present with cognitive decline. Further, it is understood that cognitive decline is a normal physiological process that occurs, to some extent, in all subjects.</p><p id="p-0120" num="0101">Although not limited to, cognitive decline has been demonstrated in an aging population. As used herein, &#x201c;age-related cognitive decline&#x201d; refers to the deterioration, or loss, of cognitive ability associated with increasing age in an otherwise cognitively healthy subject. As used herein, the term &#x201c;subject&#x201d; may be used interchangeably with the terms &#x201c;patient&#x201d; and &#x201c;individual&#x201d;. Also as used herein, the term &#x201c;subject&#x201d; refers to any organism that is susceptible to a disease or condition. In some embodiments, the subject is a mammal. In some embodiments, the subject is a human.</p><heading id="h-0008" level="2">Cognitively Healthy Subject</heading><p id="p-0121" num="0102">Such deterioration, or loss, of cognitive ability, may be evident in an otherwise cognitively healthy subject irrespective of whether that subject is suffering from another medical condition. In some embodiments, the subject is not suffering from another medical condition. In some embodiments, the subject is suffering from another medical condition. The other medical condition may be diagnosed or undiagnosed. The other medical condition may not have an association with cognitive decline or age-related cognitive decline. That is, the other medical condition may not be indicative of, more prevalent in, or linked to, cognitive decline or age related cognitive decline. In some embodiments, the subject is suffering from another, diagnosed medical condition that is not associated with cognitive decline or age related cognitive decline.</p><p id="p-0122" num="0103">Where the subject is not suffering from another, diagnosed medical condition that is associated with cognitive decline, the subject is considered cognitively healthy. That is, as used herein, the term &#x201c;cognitively healthy&#x201d; refers to a subject not having been diagnosed with another medical condition associated with cognitive decline. As would be understood by the person skilled in the art, the natural physiological process of cognitive decline is consistent with an otherwise cognitively healthy subject. Similarly, the natural aging process, and the natural age-related cognitive decline, is consistent with an otherwise cognitively healthy subject. That is, a subject may experience, or suffer from, age related cognitive decline and yet be considered &#x201c;cognitively healthy&#x201d;.</p><p id="p-0123" num="0104">Other medical conditions that may be associated with cognitive decline include medical conditions that primarily affect, or are highly associated with, the central nervous system (CNS). In some embodiments, the subject is not suffering from another, undiagnosed medical condition that is associated with the central nervous system (CNS). In some embodiments, the subject is not suffering from another, diagnosed medical condition that is associated with the central nervous system (CNS), for example mild cognitive impairment or Alzheimer's disease (AD). It is therefore understood that, in some embodiments, a &#x201c;cognitively healthy&#x201d; subject is a subject that is not suffering from another, undiagnosed or diagnosed, medical condition that is associated with the central nervous system (CNS).</p><p id="p-0124" num="0105">In further embodiments, the cognitively healthy subject may not have a disorder associated with a substantially elevated level of cortisol, such as dementia. Dementias include, but are not limited to Alzheimer's disease, multi-infarct dementia, dementia with Lewy bodies, fronto-temporal dementia (including Pick's disease), progressive supranuclear palsy, Korsakoff's syndrome, Biswanger's disease, HIV-associated dementia, Creutzfeldt-Jakob disease (CJD), multiple sclerosis, motor neurone disease, Parkinson's disease, Huntington's disease, Niemann-Pick disease type C, normal pressure hydrocephalus, and Down's syndrome.</p><p id="p-0125" num="0106">The cognitively healthy subject may have a cortisol level (in nmol/L) of less than about 450, 440, 430, 420, 410, 400, 390, 380, 370, 360, 250, 340, 330, 320, 310, 300, 290, 280, 270, 260, 250, 240, 230, 220, 210, or 200. The cognitively healthy subject may have a cortisol level (in nmol/L) of at least about 150, 160, 170, 180, 190, 200, 210, 220, 230, 240, 250, 260, 270, 280, 290, 300, 310, 320, 330, 340, or 350. The cognitively healthy subject may have a cortisol level (in nmol/L) in a range provided by any two of these upper and/or lower levels. For example, the cognitively healthy subject may have a cortisol level (in nmol/L) in a range between about 150 and 400, 170 and 350, or 200 and 330. The cortisol level may be measured from the plasma or serum of a subject. The cortisol level may represent an average daily or weekly measurement.</p><heading id="h-0009" level="2">Subjects</heading><p id="p-0126" num="0107">The cognitively healthy subject may be a human or an animal. For example, the methods as described herein may be used for human or veterinary applications. In addition to humans, domesticated animals may include dogs, cats, horses, cattle, sheep, pigs, or birds, for example.</p><heading id="h-0010" level="2">Age and Gender of Subjects</heading><p id="p-0127" num="0108">It is understood that cognitive decline varies greatly amongst different subjects. Such variations include, but are not limited to, age of onset and severity of symptoms. As used herein, &#x201c;age of onset&#x201d; refers to the subject's age in which symptoms of cognitive decline first present. It is generally understood that there is a link between increasing age, or &#x201c;aging&#x201d;, of the subject and the first presentation of the symptoms of cognitive decline, particularly age-related cognitive decline. That is, increasing age, or aging, is believed to coincide with the first presentation of the symptoms of cognitive decline. However, the age in which the symptoms of cognitive decline first present varies greatly amongst different subjects. For example, the symptoms of cognitive decline may first present in a subject being of about 5 years, about 10 years, about 15 years, about 20 years, about 30 years, about 40 years, about 50 years, about 60 years, about 70 years, about 80 years, about 90 years, about 100 years, about 110 years, or about 120 years of age. A subject may present with a low intelligence quotient, or &#x201c;IQ&#x201d;, but be otherwise cognitively healthy. Methods for assessing the IQ of an individual are known in the art. As used herein, the term &#x201c;low IQ&#x201d; refers to an IQ score of less than about 85. In some embodiments, the subject has an IQ score of less than about 85, 75, 65, 55, 45, 35, or about 25. It is foreseeable that the method disclosed herein would be beneficial in a subject having a low IQ. In some embodiments, the age (in years) of the subject is at least about 5, 10, 15, 20, 30, 40, 50, 60, 70, 80, 90, or 100. In some embodiments, the age of the subject (in years) is less than about 90, 80, 70, 60, 50, 40, 30, 20, or 10. The age of the subject may be in a range between any two of these upper and/or lower values.</p><p id="p-0128" num="0109">Cognitive decline may also be dependent upon the subject's gender. An earlier age of onset and an increase in severity of symptoms of cognitive decline can occur in males. In some embodiments, the subject is a male. In some embodiments, the subject is a cognitively healthy male subject. In some embodiments, the subject is a cognitively healthy male subject of at least 40 years of age. it will be appreciated that females also remain at risk of cognitive decline. In some embodiments, the subject is a female. In some embodiments, the subject is a cognitively healthy female subject. In some embodiments, the subject is a cognitively healthy female subject of at least 40 years of age.</p><p id="p-0129" num="0000">Subjects with Increased Risk of Cognitive Decline</p><p id="p-0130" num="0110">It will also be understood that the method disclosed herein may find application in the prevention and/or reduction of cognitive decline in a subject that is at increased risk of cognitive decline, but is otherwise a cognitively healthy subject. &#x201c;Increased risk&#x201d; of cognitive decline is used herein to refer to a subject that may have a higher likelihood of experiencing cognitive decline, or may have a higher likelihood of experiencing early-onset cognitive decline, or may have a higher likelihood of experiencing more severe cognitive decline. In some embodiments, the subject has an increased risk of cognitive decline. In some embodiments, the subject has an increased risk of age-related cognitive decline. In some embodiments, the subject has an increased risk of experiencing early-onset cognitive decline. In some embodiments, the subject has an increased risk of experiencing severe cognitive decline.</p><p id="p-0131" num="0111">The person skilled in the art will appreciate that there are a number of factors that may result in a subject having an increased risk of cognitive decline. Factors that may result in a subject having an increased risk of cognitive decline include, but are not limited to, increased risk of stroke, the presence of particular genetic markers, a family history of cognitive decline, suffering from particular medical conditions associated with cognitive decline, and/or environmental factors that are associated with cognitive decline, and/or societal factors that are associated with cognitive decline, and/or external factors that are associated with cognitive decline. In some embodiments, the subject has an increased risk of stroke. In some embodiments, the subject possesses a genetic marker associated with cognitive decline (e.g. apolipoprotein E, APOE, associated with AD). In some embodiments, the subject has a family history of cognitive decline. In some embodiments, the subject is suffering from a medical condition associated with cognitive decline. In some embodiments, the subject is exposed to environmental factors that are associated with cognitive decline. In some embodiments, the subject is exposed to societal factors that are associated with cognitive decline. Such societal factors include, but are not limited to, stress, family break-down, physical abuse, mental abuse, alcohol and/or substance abuse, and sleep deprivation. In some embodiments, the subject is exposed to external factors that are associated with, or may lead to, cognitive decline. Such external factors include, but are not limited to, recreational/professional hobby/sporting activities that result in concussion, physical stress, or mental stress. In some embodiments, the subject is exposed to therapeutic treatment, wherein the therapeutic treatment (e.g., chemotherapy, anaesthesia) is associated with side effects that include cognitive decline. In some embodiments, the subject is exposed to chemotherapy, wherein the chemotherapy is associated with side effects that include cognitive decline. In some embodiments, the subject is exposed to anaesthesia, wherein the anaesthesia is associated with side effects that include cognitive decline.</p><heading id="h-0011" level="2">Enhancement of Cognitive Ability</heading><p id="p-0132" num="0112">It will also be understood that the method disclosed herein may be beneficial in enhancing cognitive performance or ability in a cognitively healthy subject. As used herein, &#x201c;enhancing cognitive ability&#x201d; refers to an increase in cognitive ability compared to a subject's previous ability (i.e., before being administered a compound of Formula I, or a pharmaceutically acceptable salt, solvate or prodrug thereof). In some embodiments, the subject experiences enhanced cognitive ability. Such agents that are known to improve cognition are referred to in the art as &#x201c;noortropic&#x201d;. In some embodiments, the compound of Formula I, or a pharmaceutically acceptable salt, solvate or prodrug thereof, is a nootropic agent. In such circumstances, the subject may or may not be experiencing cognitive decline. The enhancement of cognitive ability may be experienced in relation to one or more facets of cognition including, for example, psychomotor function, visual attention, learning and memory, working memory, and visual associate memory. Such cognitive abilities may be measured using various techniques known in the field, such as those described below (e.g. Cogstate Battery Tests). In some embodiments, a subject experiences enhanced psychomotor function. In some embodiments, a subject experiences enhanced visual attention. In some embodiments, a subject experiences enhanced learning and memory. In some embodiments, a subject experiences enhanced working memory. In some embodiments, a subject experiences enhanced visual associate memory.</p><heading id="h-0012" level="2">Methods of Assessing Cognitive Ability</heading><p id="p-0133" num="0113">There are several tests through which the cognitive ability of a subject may be assessed. Accordingly, based on the results of these tests, it is possible to assess a subject's cognitive decline.</p><p id="p-0134" num="0114">The person skilled in the art will appreciate that there exists a variety of tests that can be employed to accurately assess the cognitive state, and similarly the cognitive decline, of a subject. Such tests include, but are not limited to, Cogstate Battery Tests, Cambridge Neuropsychological Test Automated Battery (CANTAB), Intelligence Quotient (IQ) Test, Kohs Block Design Test, Miller Analogies Test, Otis-Lennon School Ability Test (OLSAT), Raven's Progressive Matrices, Stanford-Binet Intelligence Scales, Wechsler Intelligence Scale for Children (WISC), Wonderlic Test, Porteus Maze Test, Pimsleur Language Aptitude Battery, Knox Cubes, Draw-a-Person Test, Mini-Mental State Exam (MMSE), the Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog, ADCOMs, Rey Auditory Visual Learning Test (RAVLT), NTB and NPI), and CDR Computerized Assessment System. Cogstate Battery Tests include, for example, Detection test, Identification test, One Card Learning test, One Back Working Memory test, and the Continuous Paired Associate Learning test. Each test is designed to assess various parameters that may be attributed to the cognitive ability of a subject. Accordingly, in some embodiments the administration of a compound of Formula I, or a pharmaceutically acceptable salt, solvate or prodrug thereof, provides improved cognitive testing (Cogstate Test Battery) of the treated subject relative to a non-treated subject. An improvement in cognitive testing, as determined by the Cogstate Test Battery results, may also be considered from a summation of each individual test results (e.g., Detection test, Identification test, One Card Learning test, One Back Working Memory test, and the Continuous Paired Associate Learning test).</p><p id="p-0135" num="0115">In some examples, any one or more cognitive tests measuring reaction time improvement may provide an improvement of at least about (log 10, milliseconds) 0.01, 0.02, 0.03, 0.04, 0.05, 0.06, 0.07, 0.08, 0.09, 0.10, 0.11, 0.12, 0.13, 0.14, 0.15, 0.16, 0.17, 0.18, 0.19, or 0.20. In some examples, any one or more cognitive tests may provide a &#x201c;p value&#x201d; probability measurement from a treated subject group of less than about 0.5, 0.4, 0.3, 0.2, 0.1, 0.09, 0.08, 0.07, 0.06, 0.05, 0.04, 0.03, 0.02, 0.01, 0.009, 0.008, 0.007, 0.006, 0.005, 0.004, 0.003, 0.002, or 0.001. In some examples, the cognitive testing may provide a Cohen's &#x201c;d-value&#x201d; standardised difference between two means (i.e. treated and untreated subject) of at least about 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, or 0.8. In some examples, the cognitive testing may provide a &#x201c;p-value&#x201d; and &#x201c;d-value&#x201d; according to any combination of individual embodiments thereof as described herein.</p><p id="p-0136" num="0116">In some embodiments, the administration of a compound of Formula I, or a pharmaceutically acceptable salt, solvate or prodrug thereof, provides an improvement of psychomotor function of the treated subject relative to a non-treated subject. Psychomotor function is evidenced by an improvement in simple reaction time, and is measured in speed of performance (Log<sub>10 </sub>milliseconds). As will be appreciated by the person skilled in the art, psychomotor function is critical in a subject's ability to execute both gross and fine motor skills. Accordingly, psychomotor function is an essential component of physical skills including, for example, movement, coordination, manipulation, dexterity, grace, strength, and speed. It is therefore foreseeable that the method described herein may find particular application in improving psychomotor function in a cognitively healthy subject. In some embodiments, the administration of a compound of Formula I, or a pharmaceutically acceptable salt, solvate or prodrug thereof, provides an improvement of psychomotor function in a cognitively healthy subject. In some embodiments, the administration of a compound of Formula I, or a pharmaceutically acceptable salt, solvate or prodrug thereof, provides an improvement in physical skill of a cognitively healthy subject. In some embodiments, the administration of a compound of Formula I, or a pharmaceutically acceptable salt, solvate or prodrug thereof, provides an improvement of gross motor skills in a cognitively healthy subject. In some embodiments, the administration of a compound of Formula I, or a pharmaceutically acceptable salt, solvate or prodrug thereof, provides an improvement of fine motor skills in a cognitively healthy subject.</p><p id="p-0137" num="0117">From here, it is foreseeable that the method described herein may also find particular application in assisting a subject in regaining psychomotor function. A loss of psychomotor function may result for any number of reasons including, but not limited to, accident and/or injury, a stroke, or other medical condition. Such a loss of psychomotor skills may affect any one or more areas of the subject's body including, but not limited to, the limbs. Accordingly, the administration of a compound of Formula I, or a pharmaceutically acceptable salt, solvate or prodrug thereof, may assist to restore psychomotor function. The term &#x201c;restore psychomotor function&#x201d; is used herein to mean a return, to some extent, of previous motor function. It is therefore foreseeable that a subject having suffered from a stroke, and experiencing a subsequent loss in motor skills, may benefit from the administration of a compound of Formula I, or a pharmaceutically acceptable salt, solvate or hydrate thereof. A subject having suffered from a stroke may have lost motor function in the limbs, such that the ability to walk is compromised. In some embodiments, the administration of a compound of Formula I, or a pharmaceutically acceptable salt, solvate or prodrug thereof, restores motor skills in a cognitively healthy subject. In some embodiments, the administration of a compound of Formula I, or a pharmaceutically acceptable salt, solvate or prodrug thereof, restores motor skills in a cognitively healthy subject that had previously lost motor function due to suffering from a stroke. In some embodiments, the administration of a compound of Formula I, or a pharmaceutically acceptable salt, solvate or prodrug thereof, restores motor skills of a limb in a cognitively healthy subject. In some embodiments, the administration of a compound of Formula I, or a pharmaceutically acceptable salt, solvate or prodrug thereof, restores motor skills such as to facilitate walking in a cognitively healthy subject.</p><p id="p-0138" num="0118">In some embodiments, the administration of a compound of Formula I, or a pharmaceutically acceptable salt, solvate or prodrug thereof, provides an improvement of psychomotor function speed of performance. The psychomotor function speed improvement may be measured between the treated subjects relative to non-treated subjects. In some examples, a psychomotor function speed improvement may be provided by a log 10 reaction time (milliseconds) of less than about 2.60. 2.59, 2.58, 2.57, 2.56, 2.55, 2.54, 2.53, 2.52, 2.51, or 2.50. In some examples, a psychomotor function speed improvement may be at least about (log 10, milliseconds) 0.01, 0.02, 0.03, 0.04, 0.05, 0.06, 0.07, 0.08, 0.09, 0.10, 0.11, 0.12, 0.13, 0.14, 0.15, 0.16, 0.17, 0.18, 0.19, or 0.20. In some examples, the psychomotor function testing has a p value probability measurement from a treated subject group of less than about 0.5, 0.4, 0.3, 0.2, 0.1, or 0.09. In some examples, the psychomotor function testing may provide a Cohen's d-value standardised difference between two means (i.e. treated and untreated subject) of at least about 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, or 0.7. In some examples, the psychomotor function testing may provide a &#x201c;p-value&#x201d; and &#x201c;d-value&#x201d; according to any combination of individual embodiments thereof, such as a p-value less than about 0.09 with a d-value effect size of greater than about 0.7.</p><p id="p-0139" num="0119">In some embodiments, the administration of a compound of Formula I, or a pharmaceutically acceptable salt, solvate or prodrug thereof, provides an improvement of visual attention of the treated subject relative to a non-treated subject. Visual attention is evidenced by an improvement in choice retention time, and is measured in speed of performance (Log<sub>10 </sub>milliseconds). In some embodiments, the improvement in visual attention is evidenced by an improvement in choice retention time. In some embodiments, the improvement in visual attention is assessed by the Cogstate Identification Test. In some embodiments, the administration of a compound of Formula I, or a pharmaceutically acceptable salt, solvate or prodrug thereof, provides an improvement of visual attention speed of performance of the treated subject relative to a non-treated subject. The visual attention speed improvement may be measured between the treated subjects relative to non-treated subjects. In some examples, a visual attention speed improvement may be provided by a log 10 reaction time (milliseconds) of less than about 2.80, 2.79, 2.78, 2.77, 2.76, 2.75, 2.74, 2.73, 2.72, 2.71, or 2.70. In some examples, a visual attention speed improvement may be at least about (log 10, milliseconds) 0.01, 0.02, 0.03, 0.04, 0.05, 0.06, 0.07, 0.08, 0.09, 0.10, 0.11, 0.12, 0.13, 0.14, 0.15, 0.16, 0.17, 0.18, 0.19, or 0.20. In some examples, the visual attention testing has a p value probability measurement from a treated subject group of less than about 0.5, 0.4, 0.3, 0.2, 0.1, or 0.09, 0.08, 0.07, 0.06, or 0.05. In some examples, the visual attention may provide a Cohen's d-value standardised difference between two means (i.e. treated and untreated subject) of at least about 0.1, 0.2, 0.3, 0.4, 0.5, or 0.6. In some examples, the visual attention testing may provide a &#x201c;p-value&#x201d; and &#x201c;d-value&#x201d; according to any combination of individual embodiments thereof, such as a p-value less than about 0.05 with a d-value effect size of greater than about 0.6.</p><p id="p-0140" num="0120">In some embodiments, the administration of a compound of Formula I, or a pharmaceutically acceptable salt, solvate or prodrug thereof, provides an improvement of learning and memory of the treated subject relative to a non-treated subject. Learning and memory is evidenced by an improvement in visual recognition learning, and is measured in accuracy of performance (arcsine proportion correct). In some embodiments, the improvement in learning and memory is evidenced by an improvement in visual recognition learning. In some embodiments, the improvement in learning and memory is assessed by the Cogstate One Card Learning Test. In some embodiments, the administration of a compound of Formula I, or a pharmaceutically acceptable salt, solvate or prodrug thereof, provides an improvement of learning and memory accuracy of proportion (i.e., arcsine proportion correct) of at least about X % of the treated subject relative to a non-treated subject. The learning and memory accuracy improvement may be measured between the treated subjects relative to non-treated subjects. In some examples, a learning and memory accuracy testing may be provided by an arcsine accuracy of at least about 1.0, 1.01, 1.02, 1.03, 1.04, 1.05, 1.06, 1.07, 1.08, 1.09. or 1.10. In some examples, the learning and memory accuracy testing has a p value probability measurement from a treated subject group of less than about 0.9. In some examples, the visual attention may provide a Cohen's d-value standardised difference between two means (i.e. treated and untreated subject) of at least about 0.1, 0.15, or 0.19. In some examples, the visual attention testing may provide a &#x201c;p-value&#x201d; and &#x201c;d-value&#x201d; according to any combination of individual embodiments thereof, such as a p-value less than about 0.9 with a d-value effect size of greater than about 0.15.</p><p id="p-0141" num="0121">In some embodiments, the administration of a compound of Formula I, or a pharmaceutically acceptable salt, solvate or prodrug thereof, provides an improvement of working memory of the treated subject relative to a non-treated subject. In some embodiments, the improvement in working memory is assessed by the Cogstate One Back Working Memory Test, and is measured in number of errors. In some embodiments, the administration of a compound of Formula I, or a pharmaceutically acceptable salt, solvate or prodrug thereof, provides an improvement of working memory number of errors of at least about X % of the treated subject relative to a non-treated subject. The working memory improvement may be measured between the treated subjects relative to non-treated subjects. In some examples, a working memory test may be provided by a log 10 reaction time of less than about 2.90, 2.89, 2.88, 2.87, 2.86, 2.85, 2.84, 2.83, 2.82, 2.81, or 2.80. In some examples, a working memory test improvement may be at least about (log 10, milliseconds) 0.01, 0.02, 0.03, 0.04, 0.05, 0.06, 0.07, 0.08, 0.09, 0.10, 0.11, 0.12, 0.13, 0.14, 0.15, 0.16, 0.17, 0.18, 0.19, or 0.20. In some examples, the working memory testing has a p value probability measurement from a treated subject group of less than about 0.5, 0.4, 0.3, 0.2, 0.1, or 0.09, 0.08, 0.07, 0.06, 0.05, 0.04, 0.03, 0.02, or 0.01. In some examples, the working memory testing may provide a Cohen's d-value standardised difference between two means (i.e. treated and untreated subject) of at least about 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, or 0.8. In some examples, the visual attention testing may provide a &#x201c;p-value&#x201d; and &#x201c;d-value&#x201d; according to any combination of individual embodiments thereof, such as a p-value less than about 0.01 with a d-value effect size of greater than about 0.8.</p><p id="p-0142" num="0122">In some embodiments, the administration of a compound of Formula I, or a pharmaceutically acceptable salt, solvate or prodrug thereof, provides an improvement of visual associate memory of the treated subject relative to a non-treated subject. In some embodiments, visual associate memory is assessed by the Cogstate Continuous Paired Associate Learning Test, and is measured in number of errors. The visual associate memory improvement may be measured between the treated subjects relative to non-treated subjects. In some examples, a visual associate memory testing may be provided by an error score out of 30 of less than 25, 24, 23, 22, 21, 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, or 10. In some examples, a visual associate memory testing may be provided by an improvement in error score of at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30. In some examples, the visual associate memory testing has a p value probability measurement from a treated subject group of less than about 0.5. In some examples, the visual associate memory testing may provide a Cohen's d-value standardised difference between two means (i.e. treated and untreated subject) of at least about 0.1, 0.2, 0.3, or 0.4. In some examples, the visual associate memory testing may provide a &#x201c;p-value&#x201d; and &#x201c;d-value&#x201d; according to any combination of individual embodiments thereof, such as a p-value less than about 0.5 with a d-value effect size of greater than about 0.4.</p><heading id="h-0013" level="2">Compound of Formula I</heading><p id="p-0143" num="0123">It has been surprisingly found that a compound of Formula I is useful in a method of preventing and/or treating cognitive decline in a cognitively healthy subject. Embodiments of the methods and uses described herein comprise administering a compound of Formula I, or a pharmaceutically acceptable salt, solvate or prodrug thereof.</p><p id="p-0144" num="0124">As used herein, a compound of Formula I has the following chemical structure:</p><p id="p-0145" num="0000"><chemistry id="CHEM-US-00014" num="00014"><img id="EMI-C00014" he="27.60mm" wi="67.82mm" file="US20230000843A1-20230105-C00014.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0146" num="0000">wherein R<sup>1 </sup>and R<sup>2 </sup>are each independently selected from the group consisting of hydrogen, halogen, C<sub>1-6</sub>alkyl, &#x2014;O&#x2014;C<sub>1-6</sub>alkyl, C<sub>1-6</sub>haloalkyl, &#x2014;O&#x2014;C<sub>1-6</sub>haloalkyl, C<sub>2-6</sub>alkenyl, C<sub>2-6</sub>alkynyl, 3-10-membered carbocyclyl, 3-10-membered heterocyclyl, &#x2014;CN, &#x2014;CF<sub>3</sub>, &#x2014;OR<sup>3</sup>, &#x2014;SR<sup>3</sup>, &#x2014;NR<sup>3</sup>R<sup>4</sup>, &#x2014;COR<sup>3</sup>, &#x2014;CO<sub>2</sub>R<sup>3</sup>, &#x2014;CONR<sup>3</sup>R<sup>4</sup>, &#x2014;NR<sup>3</sup>COR<sup>4</sup>, &#x2014;SO<sub>2</sub>R<sup>3</sup>, &#x2014;SO<sub>2</sub>NR<sup>3</sup>R<sup>4</sup>, and &#x2014;NR<sup>3</sup>SO<sub>2</sub>R<sup>4</sup>.</p><p id="p-0147" num="0125">In some embodiments, R<sup>1 </sup>is hydrogen. In some embodiments, R<sup>1 </sup>is halogen. In some embodiments, R<sup>1 </sup>is chlorine. In some embodiments, R<sup>1 </sup>is fluorine. In some embodiments, R<sup>1 </sup>is bromine. In some embodiments, R<sup>1 </sup>is iodine. In some embodiments, R<sup>1 </sup>is C<sub>1-6</sub>alkyl. In some embodiments, R<sup>1 </sup>is &#x2014;O&#x2014;C<sub>1-6</sub>alkyl. In some embodiments, R<sup>1 </sup>is C<sub>1-6</sub>haloalkyl. In some embodiments, R<sup>1 </sup>is &#x2014;O&#x2014;C<sub>1-6</sub>haloalkyl. In some embodiments, R<sup>1 </sup>is C<sub>2-6</sub>alkenyl. In some embodiments, R<sup>1 </sup>is C<sub>2-6</sub>alkynyl. In some embodiments, R<sup>1 </sup>is 3-10-membered carbocyclyl. In some embodiments, R<sup>1 </sup>is a 6-membered carbocyclyl. In some embodiments, R<sup>1 </sup>is a 5-membered carbocyclyl. In some embodiments, R<sup>1 </sup>is 3-10-membered heterocyclyl. In some embodiments, R<sup>1 </sup>is a 6-membered heterocyclyl. In some embodiments, R<sup>1 </sup>is a 5-membered heterocyclyl. In some embodiments, R<sup>1 </sup>is &#x2014;CN. In some embodiments, R<sup>1 </sup>is &#x2014;CF<sub>3</sub>. In some embodiments, R<sup>1 </sup>is &#x2014;OR<sup>3</sup>. In some embodiments, R<sup>1 </sup>is &#x2014;SR<sup>3</sup>. In some embodiments, R<sup>1 </sup>is &#x2014;NR<sup>3</sup>R<sup>4</sup>. In some embodiments, R<sup>1 </sup>is &#x2014;COR<sup>3</sup>. In some embodiments, R<sup>1 </sup>is &#x2014;CO<sub>2</sub>R<sup>3</sup>. In some embodiments, R<sup>1 </sup>is &#x2014;CONR<sup>3</sup>R<sup>4</sup>. In some embodiments, R<sup>1 </sup>is &#x2014;NR<sup>3</sup>COR<sup>4</sup>. In some embodiments, R<sup>1 </sup>is &#x2014;SO<sub>2</sub>R<sup>3</sup>. In some embodiments, R<sup>1 </sup>is &#x2014;SO<sub>2</sub>NR<sup>3</sup>R<sup>4</sup>. In some embodiments, R<sup>1 </sup>is &#x2014;NR<sup>3</sup>SO<sub>2</sub>R<sup>4</sup>.</p><p id="p-0148" num="0126">In some embodiments, R<sup>2 </sup>is hydrogen. In some embodiments, R<sup>2 </sup>is halogen. In some embodiments, R<sup>2 </sup>is chlorine. In some embodiments, R<sup>2 </sup>is fluorine. In some embodiments, R<sup>2 </sup>is bromine. In some embodiments, R<sup>2 </sup>is iodine. In some embodiments, R<sup>2 </sup>is C<sub>1-6</sub>alkyl. In some embodiments, R<sup>2 </sup>is &#x2014;O&#x2014;C<sub>1-6</sub>alkyl. In some embodiments, R<sup>2 </sup>is C<sub>1-6</sub>haloalkyl. In some embodiments, R<sup>2 </sup>is &#x2014;O&#x2014;C<sub>1-6</sub>haloalkyl. In some embodiments, R<sup>2 </sup>is C<sub>2-6</sub>alkenyl. In some embodiments, R<sup>2 </sup>is C<sub>2-6</sub>alkynyl. In some embodiments, R<sup>2 </sup>is 3-10-membered carbocyclyl. In some embodiments, R<sup>2 </sup>is a 6-membered carbocyclyl. In some embodiments, R<sup>2 </sup>is a 5-membered carbocyclyl. In some embodiments, R<sup>2 </sup>is 3-10-membered heterocyclyl. In some embodiments, R<sup>2 </sup>is a 6-membered heterocyclyl. In some embodiments, R<sup>2 </sup>is a 5-membered heterocyclyl. In some embodiments, R<sup>2 </sup>is &#x2014;CN. In some embodiments, R<sup>2 </sup>is &#x2014;CF<sub>3</sub>. In some embodiments, R<sup>2 </sup>is &#x2014;OR<sup>3</sup>. In some embodiments, R<sup>2 </sup>is &#x2014;SR<sup>3</sup>. In some embodiments, R<sup>2 </sup>is &#x2014;NR<sup>3</sup>R<sup>4</sup>. In some embodiments, R<sup>2 </sup>is &#x2014;COR<sup>3</sup>. In some embodiments, R<sup>2 </sup>is &#x2014;CO<sub>2</sub>R<sup>3</sup>. In some embodiments, R<sup>2 </sup>is &#x2014;CONR<sup>3</sup>R<sup>4</sup>. In some embodiments, R<sup>2 </sup>is &#x2014;NR<sup>3</sup>COR<sup>4</sup>. In some embodiments, R<sup>2 </sup>is &#x2014;SO<sub>2</sub>R<sup>3</sup>. In some embodiments, R<sup>2 </sup>is &#x2014;SO<sub>2</sub>NR<sup>3</sup>R<sup>4</sup>. In some embodiments, R<sup>2 </sup>is &#x2014;NR<sup>3</sup>SO<sub>2</sub>R<sup>4</sup>.</p><p id="p-0149" num="0127">If present, each 3-10-membered carbocyclyl and 3-10-membered heterocyclyl may be further substituted with one or more substituents selected from the group consisting of hydrogen, halogen, C<sub>1-6</sub>alkyl, &#x2014;O&#x2014;C<sub>1-6</sub>alkyl, C<sub>1-6</sub>haloalkyl, &#x2014;O&#x2014;C<sub>1-6</sub>haloalkyl, C<sub>2-6</sub>alkenyl, C<sub>2-6</sub>alkynyl, &#x2014;CN, &#x2014;CF<sub>3</sub>, &#x2014;OR<sup>5</sup>, &#x2014;SR<sup>5</sup>, &#x2014;NR<sup>5</sup>R<sup>6</sup>, &#x2014;COR<sup>5</sup>, &#x2014;CO<sub>2</sub>R<sup>5</sup>, &#x2014;CONR<sup>5</sup>R<sup>6</sup>, &#x2014;NR<sup>5</sup>COR<sup>6</sup>, &#x2014;SO<sub>2</sub>R<sup>5</sup>, &#x2014;SO<sub>2</sub>NR<sup>5</sup>R<sup>6</sup>, and &#x2014;NR<sup>5</sup>SO<sub>2</sub>R<sup>6</sup>.</p><p id="p-0150" num="0128">In some embodiments, the 3-10-membered carbocyclyl is substituted with one or more halogen substituents. In some embodiments, the 3-10-membered carbocyclyl is substituted with one or more C<sub>1-6</sub>alkyl substituents. In some embodiments, the 3-10-membered carbocyclyl is substituted with one or more &#x2014;O&#x2014;C<sub>1-6</sub>alkyl substituents. In some embodiments, the 3-10-membered carbocyclyl is substituted with one or more C<sub>1-6</sub>haloalkyl substituents. In some embodiments, the 3-10-membered carbocyclyl is substituted with one or more &#x2014;O&#x2014;C<sub>1-6</sub>haloalkyl substituents. In some embodiments, the 3-10-membered carbocyclyl is substituted with one or more C<sub>2-6</sub>alkenyl substituents. In some embodiments, the 3-10-membered carbocyclyl is substituted with one or more C<sub>2-6</sub>alkynyl substituents. In some embodiments, the 3-10-membered carbocyclyl is substituted with one or more &#x2014;CN substituents. In some embodiments, the 3-10-membered carbocyclyl is substituted with one or more &#x2014;CF<sub>3 </sub>substituents. In some embodiments, the 3-10-membered carbocyclyl is substituted with one or more &#x2014;OR<sup>5 </sup>substituents. In some embodiments, the 3-10-membered carbocyclyl is substituted with one or more &#x2014;SR<sup>5 </sup>substituents. In some embodiments, the 3-10-membered carbocyclyl is substituted with one or more &#x2014;COR<sup>5 </sup>substituents. In some embodiments, the 3-10-membered carbocyclyl is substituted with one or more halogen substituents. In some embodiments, the 3-10-membered carbocyclyl is substituted with one or more &#x2014;CO<sub>2</sub>R<sup>5 </sup>substituents. In some embodiments, the 3-10-membered carbocyclyl is substituted with one or more &#x2014;CONR<sup>5</sup>R<sup>6 </sup>substituents. In some embodiments, the 3-10-membered carbocyclyl is substituted with one or more &#x2014;NR<sup>5</sup>COR<sup>6 </sup>substituents. In some embodiments, the 3-10-membered carbocyclyl is substituted with one or more &#x2014;SO<sub>2</sub>R<sup>5 </sup>substituents. In some embodiments, the 3-10-membered carbocyclyl is substituted with one or more &#x2014;SO<sub>2</sub>NR<sup>5</sup>R<sup>6 </sup>substituents. In some embodiments, the 3-10-membered carbocyclyl is substituted with one or more &#x2014;NR<sup>5</sup>SO<sub>2</sub>R<sup>6 </sup>substituents.</p><p id="p-0151" num="0129">In some embodiments, R<sup>1 </sup>is a 6-membered carbocyclyl and is substituted with one or more substituents selected from the group consisting of hydrogen, halogen, C<sub>1-6</sub>alkyl, &#x2014;O&#x2014;C<sub>1-6</sub>alkyl, C<sub>1-6</sub>haloalkyl, &#x2014;O&#x2014;C<sub>1-6</sub>haloalkyl, C<sub>2-6</sub>alkenyl, C<sub>2-6</sub>alkynyl, &#x2014;CN, &#x2014;CF<sub>3</sub>, &#x2014;OR<sup>5</sup>, &#x2014;SR<sup>5</sup>, &#x2014;NR<sup>5</sup>R<sup>6</sup>, &#x2014;COR<sup>5</sup>, &#x2014;CO<sub>2</sub>R<sup>5</sup>, &#x2014;CONR<sup>5</sup>R<sup>6</sup>, &#x2014;NR<sup>5</sup>COR<sup>6</sup>, &#x2014;SO<sub>2</sub>R<sup>5</sup>, &#x2014;SO<sub>2</sub>NR<sup>5</sup>R<sup>6</sup>, and &#x2014;NR<sup>5</sup>SO<sub>2</sub>R<sup>6</sup>. In some embodiments, R<sup>1 </sup>is a 5-membered carbocyclyl and is substituted with one or more substituents selected from the group consisting of hydrogen, halogen, C<sub>1-6</sub>alkyl, &#x2014;O&#x2014;C<sub>1-6</sub>alkyl, C<sub>1-6</sub>haloalkyl, &#x2014;O&#x2014;C<sub>1-6</sub>haloalkyl, C<sub>2-6</sub>alkenyl, C<sub>2-6</sub>alkynyl, &#x2014;CN, &#x2014;CF<sub>3</sub>, &#x2014;OR<sup>5</sup>, &#x2014;SR<sup>5</sup>, &#x2014;NR<sup>5</sup>R<sup>6</sup>, &#x2014;COR<sup>5</sup>, &#x2014;CO<sub>2</sub>R<sup>5</sup>, &#x2014;CONR<sup>5</sup>R<sup>6</sup>, &#x2014;NR<sup>5</sup>COR<sup>6</sup>, &#x2014;SO<sub>2</sub>R<sup>5</sup>, &#x2014;SO<sub>2</sub>NR<sup>5</sup>R<sup>6</sup>, and &#x2014;NR<sup>5</sup>SO<sub>2</sub>R<sup>6</sup>.</p><p id="p-0152" num="0130">In some embodiments, the 3-10-membered heterocyclyl is substituted with one or more halogen substituents. In some embodiments, the 3-10-membered heterocyclyl is substituted with one or more C<sub>1-6</sub>alkyl substituents. In some embodiments, the 3-10-membered heterocyclyl is substituted with one or more &#x2014;O&#x2014;C<sub>1-6</sub>alkyl substituents. In some embodiments, the 3-10-membered heterocyclyl is substituted with one or more C<sub>1-6</sub>haloalkyl substituents. In some embodiments, the 3-10-membered heterocyclyl is substituted with one or more &#x2014;O&#x2014;C<sub>1-6</sub>haloalkyl substituents. In some embodiments, the 3-10-membered heterocyclyl is substituted with one or more C<sub>2-6</sub>alkenyl substituents. In some embodiments, the 3-10-membered heterocyclyl is substituted with one or more C<sub>2-6</sub>alkynyl substituents. In some embodiments, the 3-10-membered heterocyclyl is substituted with one or more &#x2014;CN substituents. In some embodiments, the 3-10-membered heterocyclyl is substituted with one or more &#x2014;CF<sub>3 </sub>substituents. In some embodiments, the 3-10-membered heterocyclyl is substituted with one or more &#x2014;OR<sup>5 </sup>substituents. In some embodiments, the 3-10-membered heterocyclyl is substituted with one or more &#x2014;SR<sup>5 </sup>substituents. In some embodiments, the 3-10-membered heterocyclyl is substituted with one or more &#x2014;COR<sup>5 </sup>substituents. In some embodiments, the 3-10-membered heterocyclyl is substituted with one or more halogen substituents. In some embodiments, the 3-10-membered heterocyclyl is substituted with one or more &#x2014;CO<sub>2</sub>R<sup>5 </sup>substituents. In some embodiments, the 3-10-membered heterocyclyl is substituted with one or more &#x2014;CONR<sup>5</sup>R<sup>6 </sup>substituents. In some embodiments, the 3-10-membered heterocyclyl is substituted with one or more &#x2014;NR<sup>5</sup>COR<sup>6 </sup>substituents. In some embodiments, the 3-10-membered heterocyclyl is substituted with one or more &#x2014;SO<sub>2</sub>R<sup>5 </sup>substituents. In some embodiments, the 3-10-membered heterocyclyl is substituted with one or more &#x2014;SO<sub>2</sub>NR<sup>5</sup>R<sup>6 </sup>substituents. In some embodiments, the 3-10-membered heterocyclyl is substituted with one or more &#x2014;NR<sup>5</sup>SO<sub>2</sub>R<sup>6 </sup>substituents.</p><p id="p-0153" num="0131">In some embodiments, R<sup>2 </sup>is a 6-membered carbocyclyl and is substituted with one or more substituents selected from the group consisting of hydrogen, halogen, C<sub>1-6</sub>alkyl, &#x2014;O&#x2014;C<sub>1-6</sub>alkyl, C<sub>1-6</sub>haloalkyl, &#x2014;O&#x2014;C<sub>1-6</sub>haloalkyl, C<sub>2-6</sub>alkenyl, C<sub>2-6</sub>alkynyl, &#x2014;CN, &#x2014;CF<sub>3</sub>, &#x2014;OR<sup>5</sup>, &#x2014;SR<sup>5</sup>, &#x2014;NR<sup>5</sup>R<sup>6</sup>, &#x2014;COR<sup>5</sup>, &#x2014;CO<sub>2</sub>R<sup>5</sup>, &#x2014;CONR<sup>5</sup>R<sup>6</sup>, &#x2014;NR<sup>5</sup>COR<sup>6</sup>, &#x2014;SO<sub>2</sub>R<sup>5</sup>, &#x2014;SO<sub>2</sub>NR<sup>5</sup>R<sup>6</sup>, and &#x2014;NR<sup>5</sup>SO<sub>2</sub>R<sup>6</sup>. In some embodiments, R<sup>2 </sup>is a 5-membered carbocyclyl and is substituted with one or more substituents selected from the group consisting of hydrogen, halogen, C<sub>1-6</sub>alkyl, &#x2014;O&#x2014;C<sub>1-6</sub>alkyl, C<sub>1-6</sub>haloalkyl, &#x2014;O&#x2014;C<sub>1-6</sub>haloalkyl, C<sub>2-6</sub>alkenyl, C<sub>2-6</sub>alkynyl, &#x2014;CN, &#x2014;CF<sub>3</sub>, &#x2014;OR<sup>5</sup>, &#x2014;SR<sup>5</sup>, &#x2014;NR<sup>5</sup>R<sup>6</sup>, &#x2014;COR<sup>5</sup>, &#x2014;CO<sub>2</sub>R<sup>5</sup>, &#x2014;CONR<sup>5</sup>R<sup>6</sup>, &#x2014;NR<sup>5</sup>COR<sup>6</sup>, &#x2014;SO<sub>2</sub>R<sup>5</sup>, &#x2014;SO<sub>2</sub>NR<sup>5</sup>R<sup>6</sup>, and &#x2014;NR<sup>5</sup>SO<sub>2</sub>R<sup>6</sup>.</p><p id="p-0154" num="0132">If present, each R<sup>3 </sup>and R<sup>4 </sup>are independently selected from the group consisting of hydrogen, C<sub>1-6</sub>alkyl, 3-7-membered carbocyclyl and 3-7-membered heterocyclyl.</p><p id="p-0155" num="0133">In some embodiments, R<sup>3 </sup>is hydrogen. In some embodiments, R<sup>3 </sup>is C<sub>1-6</sub>alkyl. In some embodiments, R<sup>3 </sup>is 3-7-membered carbocyclyl. In some embodiments, R<sup>3 </sup>is 3-7-membered carbocyclyl. In some embodiments, R<sup>3 </sup>is a 5-membered carbocyclyl. In some embodiments R<sup>3 </sup>is a 6-membered carbocyclyl.</p><p id="p-0156" num="0134">In some embodiments, R<sup>4 </sup>is hydrogen. In some embodiments, R<sup>4 </sup>is C<sub>1-6</sub>alkyl. In some embodiments, R<sup>4 </sup>is 3-7-membered carbocyclyl. In some embodiments, R<sup>4 </sup>is 3-7-membered carbocyclyl. In some embodiments, R<sup>4 </sup>is a 5-membered carbocyclyl. In some embodiments R<sup>4 </sup>is a 6-membered carbocyclyl.</p><p id="p-0157" num="0135">If present, each R<sup>5 </sup>and R<sup>6 </sup>are independently selected from the group consisting of hydrogen and C<sub>1-6</sub>alkyl.</p><p id="p-0158" num="0136">In some embodiments, R<sup>5 </sup>is hydrogen. In some embodiments, R<sup>5 </sup>is C<sub>1-6</sub>alkyl.</p><p id="p-0159" num="0137">In some embodiments, R<sup>6 </sup>is hydrogen. In some embodiments, R<sup>6 </sup>is C<sub>1-6</sub>alkyl.</p><p id="p-0160" num="0138">In some embodiments, R<sup>1 </sup>and R<sup>2 </sup>are each independently selected from the group consisting of hydrogen, halogen, 3-10-membered carbocyclyl, 3-10-membered heterocyclyl, &#x2014;OH, &#x2014;CN, and &#x2014;NH<sub>2</sub>. If present, each 3-10-membered carbocyclyl and 3-10-membered heterocyclyl may be further substituted with one or more substituents selected from the group consisting of hydrogen, halogen, &#x2014;OH, &#x2014;CN, &#x2014;CF<sub>3</sub>, &#x2014;NH<sub>2</sub>, and C<sub>1-6</sub>alkyl.</p><p id="p-0161" num="0139">In some embodiments, R<sup>1 </sup>and R<sup>2 </sup>are each independently selected from the group consisting of hydrogen, halogen, 6-membered carbocyclyl, 6-membered heterocyclyl, &#x2014;OH, &#x2014;CN, and &#x2014;NH<sub>2</sub>. If present, each 6-membered carbocyclyl and 6-membered heterocyclyl may be further substituted with one or more substituents selected from the group consisting of hydrogen, halogen, &#x2014;OH, &#x2014;CN, &#x2014;CF<sub>3</sub>, &#x2014;NH<sub>2</sub>, and C<sub>1-6</sub>alkyl.</p><p id="p-0162" num="0140">In some embodiments, R<sup>1 </sup>is selected from the group consisting of hydrogen, halogen, &#x2014;OH, &#x2014;CN, &#x2014;CF<sub>3</sub>, &#x2014;NH<sub>2</sub>, and C<sub>1-6</sub>alkyl, and R<sup>2 </sup>is independently selected from the group consisting of:</p><p id="p-0163" num="0000"><chemistry id="CHEM-US-00015" num="00015"><img id="EMI-C00015" he="62.91mm" wi="62.74mm" file="US20230000843A1-20230105-C00015.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0164" num="0141">In some embodiments, R<sup>1 </sup>is hydrogen and R<sup>2 </sup>is independently selected from the group consisting of:</p><p id="p-0165" num="0000"><chemistry id="CHEM-US-00016" num="00016"><img id="EMI-C00016" he="62.91mm" wi="62.74mm" file="US20230000843A1-20230105-C00016.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0166" num="0142">In some embodiments, R<sup>1 </sup>is halogen and R<sup>2 </sup>is independently selected from the group consisting of:</p><p id="p-0167" num="0000"><chemistry id="CHEM-US-00017" num="00017"><img id="EMI-C00017" he="62.91mm" wi="62.74mm" file="US20230000843A1-20230105-C00017.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0168" num="0143">In some embodiments, R<sup>1 </sup>is &#x2014;OH and R<sup>2 </sup>is independently selected from the group consisting of:</p><p id="p-0169" num="0000"><chemistry id="CHEM-US-00018" num="00018"><img id="EMI-C00018" he="62.91mm" wi="62.74mm" file="US20230000843A1-20230105-C00018.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0170" num="0144">In some embodiments, R<sup>1 </sup>is &#x2014;CN and R<sup>2 </sup>is independently selected from the group consisting of:</p><p id="p-0171" num="0000"><chemistry id="CHEM-US-00019" num="00019"><img id="EMI-C00019" he="62.91mm" wi="62.74mm" file="US20230000843A1-20230105-C00019.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0172" num="0145">In some embodiments, R<sup>1 </sup>is &#x2014;CF<sub>3 </sub>and R<sup>2 </sup>is independently selected from the group consisting of:</p><p id="p-0173" num="0000"><chemistry id="CHEM-US-00020" num="00020"><img id="EMI-C00020" he="62.91mm" wi="62.74mm" file="US20230000843A1-20230105-C00020.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0174" num="0146">In some embodiments, R<sup>1 </sup>is &#x2014;NH<sub>2 </sub>and R<sup>2 </sup>is independently selected from the group consisting of:</p><p id="p-0175" num="0000"><chemistry id="CHEM-US-00021" num="00021"><img id="EMI-C00021" he="62.91mm" wi="62.74mm" file="US20230000843A1-20230105-C00021.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0176" num="0147">In some embodiments, R<sup>1 </sup>is C<sub>1-6</sub>alkyl and R<sup>2 </sup>is independently selected from the group consisting of:</p><p id="p-0177" num="0000"><chemistry id="CHEM-US-00022" num="00022"><img id="EMI-C00022" he="62.91mm" wi="62.74mm" file="US20230000843A1-20230105-C00022.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0178" num="0148">In some embodiments, R<sup>1 </sup>is chlorine and R<sup>2 </sup>is independently selected from the group consisting of:</p><p id="p-0179" num="0000"><chemistry id="CHEM-US-00023" num="00023"><img id="EMI-C00023" he="101.43mm" wi="50.72mm" file="US20230000843A1-20230105-C00023.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0180" num="0149">In some embodiments, R<sup>1 </sup>is bromine and R<sup>2 </sup>is independently selected from the group consisting of:</p><p id="p-0181" num="0000"><chemistry id="CHEM-US-00024" num="00024"><img id="EMI-C00024" he="101.43mm" wi="50.72mm" file="US20230000843A1-20230105-C00024.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0182" num="0150">In some embodiments, R<sup>1 </sup>is fluorine and R<sup>2 </sup>is independently selected from the group consisting of:</p><p id="p-0183" num="0000"><chemistry id="CHEM-US-00025" num="00025"><img id="EMI-C00025" he="67.65mm" wi="67.23mm" file="US20230000843A1-20230105-C00025.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0184" num="0151">In some embodiments, R<sup>1 </sup>is iodine and R<sup>2 </sup>is independently selected from the group consisting of:</p><p id="p-0185" num="0000"><chemistry id="CHEM-US-00026" num="00026"><img id="EMI-C00026" he="101.43mm" wi="50.72mm" file="US20230000843A1-20230105-C00026.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0186" num="0152">In some embodiments, R<sup>2 </sup>is selected from the group consisting of hydrogen, halogen, &#x2014;OH, &#x2014;CN, &#x2014;CF<sub>3</sub>, &#x2014;NH<sub>2</sub>, and C<sub>1-6</sub>alkyl, and R<sup>1 </sup>is independently selected from the group consisting of:</p><p id="p-0187" num="0000"><chemistry id="CHEM-US-00027" num="00027"><img id="EMI-C00027" he="101.43mm" wi="50.72mm" file="US20230000843A1-20230105-C00027.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0188" num="0153">In some embodiments, R<sup>2 </sup>is hydrogen and R<sup>1 </sup>is independently selected from the group consisting of:</p><p id="p-0189" num="0000"><chemistry id="CHEM-US-00028" num="00028"><img id="EMI-C00028" he="101.43mm" wi="50.72mm" file="US20230000843A1-20230105-C00028.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0190" num="0154">In some embodiments, R<sup>2 </sup>is halogen and R<sup>1 </sup>is independently selected from the group consisting of:</p><p id="p-0191" num="0000"><chemistry id="CHEM-US-00029" num="00029"><img id="EMI-C00029" he="101.43mm" wi="50.72mm" file="US20230000843A1-20230105-C00029.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0192" num="0155">In some embodiments, R<sup>2 </sup>is &#x2014;OH and R<sup>1 </sup>is independently selected from the group consisting of:</p><p id="p-0193" num="0000"><chemistry id="CHEM-US-00030" num="00030"><img id="EMI-C00030" he="101.43mm" wi="50.72mm" file="US20230000843A1-20230105-C00030.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0194" num="0156">In some embodiments, R<sup>2 </sup>is &#x2014;CN and R<sup>1 </sup>is independently selected from the group consisting of:</p><p id="p-0195" num="0000"><chemistry id="CHEM-US-00031" num="00031"><img id="EMI-C00031" he="101.43mm" wi="50.72mm" file="US20230000843A1-20230105-C00031.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0196" num="0157">In some embodiments, R<sup>2 </sup>is &#x2014;CF<sub>3 </sub>and R<sup>1 </sup>is independently selected from the group consisting of:</p><p id="p-0197" num="0000"><chemistry id="CHEM-US-00032" num="00032"><img id="EMI-C00032" he="101.43mm" wi="50.72mm" file="US20230000843A1-20230105-C00032.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0198" num="0158">In some embodiments, R<sup>2 </sup>is &#x2014;NH<sub>2 </sub>and R<sup>1 </sup>is independently selected from the group consisting of:</p><p id="p-0199" num="0000"><chemistry id="CHEM-US-00033" num="00033"><img id="EMI-C00033" he="101.43mm" wi="50.72mm" file="US20230000843A1-20230105-C00033.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0200" num="0159">In some embodiments, R<sup>2 </sup>is C<sub>1-6</sub>alkyl and R<sup>1 </sup>is independently selected from the group consisting of:</p><p id="p-0201" num="0000"><chemistry id="CHEM-US-00034" num="00034"><img id="EMI-C00034" he="101.43mm" wi="50.72mm" file="US20230000843A1-20230105-C00034.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0202" num="0160">In some embodiments, R<sup>2 </sup>is chlorine and R<sup>1 </sup>is independently selected from the group consisting of:</p><p id="p-0203" num="0000"><chemistry id="CHEM-US-00035" num="00035"><img id="EMI-C00035" he="101.43mm" wi="50.72mm" file="US20230000843A1-20230105-C00035.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0204" num="0161">In some embodiments, R<sup>2 </sup>is bromine and R<sup>1 </sup>is independently selected from the group consisting of:</p><p id="p-0205" num="0000"><chemistry id="CHEM-US-00036" num="00036"><img id="EMI-C00036" he="67.23mm" wi="71.20mm" file="US20230000843A1-20230105-C00036.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0206" num="0162">In some embodiments, R<sup>2 </sup>is fluorine and R<sup>1 </sup>is independently selected from the group consisting of:</p><p id="p-0207" num="0000"><chemistry id="CHEM-US-00037" num="00037"><img id="EMI-C00037" he="101.43mm" wi="50.72mm" file="US20230000843A1-20230105-C00037.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0208" num="0163">In some embodiments, R<sup>2 </sup>is iodine and R<sup>1 </sup>is independently selected from the group consisting of:</p><p id="p-0209" num="0000"><chemistry id="CHEM-US-00038" num="00038"><img id="EMI-C00038" he="101.43mm" wi="50.72mm" file="US20230000843A1-20230105-C00038.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0210" num="0164">In some embodiments, R<sup>1 </sup>and R<sup>2 </sup>are each independently selected from the group consisting of:</p><p id="p-0211" num="0000"><chemistry id="CHEM-US-00039" num="00039"><img id="EMI-C00039" he="101.43mm" wi="50.72mm" file="US20230000843A1-20230105-C00039.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0212" num="0165">In some embodiments, the compound of Formula I is selected from the group consisting of:</p><p id="p-0213" num="0000"><chemistry id="CHEM-US-00040" num="00040"><img id="EMI-C00040" he="239.61mm" wi="54.78mm" file="US20230000843A1-20230105-C00040.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry><chemistry id="CHEM-US-00041" num="00041"><img id="EMI-C00041" he="82.72mm" wi="62.74mm" file="US20230000843A1-20230105-C00041.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0214" num="0166">In some embodiments, the compound of Formula I is:</p><p id="p-0215" num="0000"><chemistry id="CHEM-US-00042" num="00042"><img id="EMI-C00042" he="33.53mm" wi="54.69mm" file="US20230000843A1-20230105-C00042.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0216" num="0167">In some embodiments, the compound of Formula I is:</p><p id="p-0217" num="0000"><chemistry id="CHEM-US-00043" num="00043"><img id="EMI-C00043" he="33.53mm" wi="54.69mm" file="US20230000843A1-20230105-C00043.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0218" num="0168">In some embodiments, the compound of Formula I is:</p><p id="p-0219" num="0000"><chemistry id="CHEM-US-00044" num="00044"><img id="EMI-C00044" he="33.53mm" wi="54.69mm" file="US20230000843A1-20230105-C00044.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0220" num="0169">In some embodiments, the compound of Formula I is:</p><p id="p-0221" num="0000"><chemistry id="CHEM-US-00045" num="00045"><img id="EMI-C00045" he="33.53mm" wi="54.69mm" file="US20230000843A1-20230105-C00045.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0222" num="0170">In some embodiments, the compound of Formula I is:</p><p id="p-0223" num="0000"><chemistry id="CHEM-US-00046" num="00046"><img id="EMI-C00046" he="34.21mm" wi="54.69mm" file="US20230000843A1-20230105-C00046.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0224" num="0171">In some embodiments, the compound of Formula I is:</p><p id="p-0225" num="0000"><chemistry id="CHEM-US-00047" num="00047"><img id="EMI-C00047" he="33.53mm" wi="54.69mm" file="US20230000843A1-20230105-C00047.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0226" num="0172">In some embodiments, the compound of Formula I is:</p><p id="p-0227" num="0000"><chemistry id="CHEM-US-00048" num="00048"><img id="EMI-C00048" he="33.53mm" wi="54.69mm" file="US20230000843A1-20230105-C00048.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0228" num="0173">In some embodiments, the compound of Formula I is:</p><p id="p-0229" num="0000"><chemistry id="CHEM-US-00049" num="00049"><img id="EMI-C00049" he="33.53mm" wi="54.69mm" file="US20230000843A1-20230105-C00049.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0230" num="0174">As would be understood by the person skilled in the art, the compound of Formula I includes any stereoisomers of the depicted structure. That is, the compound of Formula I includes a racemic mixture.</p><p id="p-0231" num="0175">As used herein, a compound of Formula Ia has the following chemical structure:</p><p id="p-0232" num="0000"><chemistry id="CHEM-US-00050" num="00050"><img id="EMI-C00050" he="28.45mm" wi="67.56mm" file="US20230000843A1-20230105-C00050.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0233" num="0176">The definitions of R<sup>1 </sup>and R<sup>2 </sup>are the same as those provided for a compound of Formula I. That is, the difference between a compound of Formula I and a compound of Formula Ia is that the stereochemistry in a compound of Formula Ia has been resolved.</p><p id="p-0234" num="0177">In some embodiments, the compound of Formula I, or a pharmaceutically acceptable salt, solvate or prodrug thereof, has a particular stereochemistry as depicted in the following chemical structure:</p><p id="p-0235" num="0000"><chemistry id="CHEM-US-00051" num="00051"><img id="EMI-C00051" he="31.07mm" wi="73.32mm" file="US20230000843A1-20230105-C00051.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></p><p id="p-0236" num="0178">The compound of Formula Ia, when having such particular stereochemistry, is also referred to as &#x201c;UE2343&#x201d; or &#x201c;Xanamem&#x201d;, and has CAS No.: 1346013-80-6. The chemical name (i.e., IUPAC name) of Formula Ia is (5-(1H-Pyrazol-4-yl)thiophen-3-yl)(3-hydroxy-3-(pyrimidin-2-yl)-8-azabicyclo[3.2.1] octan-8-yl)methanone.</p><p id="p-0237" num="0179">A compound of Formula I, or a pharmaceutically acceptable salt, solvate or prodrug thereof, may be prepared by any suitable method as would be understood by the person skilled in the art. A compound of Formula I, or a pharmaceutically acceptable salt, solvate or prodrug thereof, may be prepared in accordance with the procedure described in WO2011135276. Salts</p><p id="p-0238" num="0180">It may be convenient or desirable to prepare, purify and/or handle a corresponding salt of the compound, such as, for example, a pharmaceutically acceptable salt. As used herein, the term &#x201c;pharmaceutically acceptable salt&#x201d; refers to pharmaceutically acceptable organic or inorganic salts. Examples of pharmaceutically acceptable salts are discussed in Berge et al., 1977, &#x201c;Pharmaceutically Acceptable Salts,&#x201d; <i>J. Pharm. Sci., vol. </i>66, p 1-19.</p><p id="p-0239" num="0181">For example, if the compound is anionic, or has a functional group that may be anionic (e.g., &#x2014;COOH may be &#x2014;COO<sup>&#x2212;</sup>), then a salt may be formed with a suitable cation. Examples of suitable inorganic cations include, but are not limited to, alkali metal ions such as Na<sup>+</sup> and K<sup>+</sup>, alkaline earth cations such as Ca<sup>2+</sup> and Mg<sup>2+</sup>, and other cations such as Al<sup>3+</sup>. Examples of suitable organic cations include, but are not limited to, ammonium ion (i.e., NH<sub>4</sub><sup>+</sup>) and substituted ammonium ions (e.g., NH<sub>3</sub>R<sup>+</sup>, NH<sub>2</sub>R<sub>2</sub><sup>+</sup>, NHR<sub>3</sub><sup>+</sup>, NR<sub>4</sub><sup>+</sup>). Examples of suitable substituted ammonium ions include, but are not limited to, those derived from ethylamine, diethylamine, dicyclohexylamine, triethylamine, butylamine, ethylenediamine, ethanolamine, diethanolamine, piperazine, benzylamine, phenylbenzylamine, choline, meglumine, and tromethamine, as well as amino acids, such as lysine and arginine. An example of a common quaternary ammonium ion is N(CH<sub>3</sub>)<sub>4</sub><sup>+</sup>.</p><p id="p-0240" num="0182">If the compound is cationic, or has a functional group that may be cationic (e.g., &#x2014;NH<sub>2 </sub>may be &#x2014;NH<sub>3</sub><sup>+</sup>), then a salt may be formed with a suitable anion. Examples of suitable inorganic cations include, but are not limited to, those derived from the inorganic acids including hydrochloric, hydrobromic, hydroiodic, sulfuric, sulfurous, nitric, nitrous, phosphoric, and phosphorous. Examples of suitable organic anions include, but are not limited to, those derived from the organic acids including 2-acetyoxybenzoic, acetic, ascorbic, aspartic, benzoic, camphorsulfonic, cinnamic, citric, edetic, ethanedisulfonic, ethanesulfonic, fumaric, glucheptonic, gluconic, glutamic, glycolic, hydroxymaleic, hydroxynaphthalene carboxylic, isethionic, lactic, lactobionic, lauric, maleic, malic, methanesulfonic, mucic, oleic, oxalic, palmitic, pamoic, pantothenic, phenylacetic, phenylsulfonic, propionic, pyruvic, salicyclic, stearic, succinic, sulfanilic, tartaric, toluenesulfonic, and valeric. Examples of suitable polymeric organic anions include, but are not limited to, those derived from polymeric acids including tannic acid and carboxymethyl cellulose.</p><p id="p-0241" num="0183">A pharmaceutically acceptable salt may involve the inclusion of another molecule such as an acetate ion, a succinate ion or other counterion. The counterion may be any organic or inorganic moiety that stabilises the charge on the parent compound. Furthermore, a pharmaceutically acceptable salt may have more than one charged atom in its structure. Instances where multiple charged atoms are part of the pharmaceutically acceptable salt can have multiple counter ions. Hence, a pharmaceutically acceptable salt can have one or more charged atoms and/or one or more counterion. It will also be appreciated that non-pharmaceutically acceptable salts also fall within the scope of the present disclosure since these may be useful as intermediates in the preparation of pharmaceutically acceptable salts or may be useful during storage or transport. Unless otherwise specified herein, reference to a particular compound also includes salts thereof.</p><heading id="h-0014" level="2">Solvates and Hydrates</heading><p id="p-0242" num="0184">It may be convenient or desirable to prepare, purify and/or handle a corresponding solvate of the compound. Those skilled in the art of organic chemistry and/or medicinal chemistry will appreciate that many organic compounds can form complexes with solvents in which they are reacted or from which they are precipitated or crystallised. Such complexes are referred to as &#x201c;solvates&#x201d;, and as used herein, the term &#x201c;solvate&#x201d; refers to such a complex of solute (e.g., a compound, salt of a compound) and solvent. Examples of solvents that may form pharmaceutically acceptable solvates include, but are not limited to, isopropanol, ethanol, methanol, DMSO, ethylacetate, acetic acid, and ethanolamine. If the solvate is water, the solvate may be conventionally referred to as a &#x201c;hydrate&#x201d;. In some embodiments, the pharmaceutically acceptable solvate is a pharmaceutically acceptable hydrate. The hydrate may be, for example, a mono-hydrate, a di-hydrate, a tri-hydrate, etc. Unless otherwise specified herein, reference to a particular compound also includes solvates thereof.</p><heading id="h-0015" level="2">Prodrugs</heading><p id="p-0243" num="0185">It may be convenient or desirable to prepare, purify, and/or handle the compound in the form of a prodrug. The term &#x201c;prodrug&#x201d;, as used herein, pertains to compound which, when metabolised (e.g., in vivo), yields the desired active compound. Typically, the prodrug is inactive, or less active that the desired active compound, but may provide advantageous handling, administration, or metabolic properties.</p><p id="p-0244" num="0186">Also, as would be understood by a person skilled in the art of organic chemistry and/or medicinal chemistry, some prodrugs are activated enzymatically to yield the active compound, or a compound which, upon further chemical reaction, yields the active compound. For example, the prodrug may be a sugar derivative or other glycoside conjugate, or may be an amino acid ester derivative.</p><heading id="h-0016" level="2">Methods and Uses</heading><p id="p-0245" num="0187">The present disclosure provides for a method of preventing and/or treating cognitive decline in a cognitively healthy subject comprising administering to the cognitively healthy subject a therapeutically effective amount of a compound of Formula I, or a pharmaceutically acceptable salt, solvate or prodrug thereof. The present disclosure also provides for use of a compound of Formula I, or a pharmaceutically acceptable salt, solvate or prodrug thereof, for the prevention and/or treatment of cognitive decline in a cognitively healthy subject. A compound of Formula I, or a pharmaceutically acceptable salt, solvate or prodrug thereof, may be used in the manufacture of a medicament for the prevention and/or treatment of cognitive decline in a cognitively healthy subject.</p><p id="p-0246" num="0188">The present disclosure provides for a method of improving cognition in a cognitively healthy subject comprising administering to the cognitively healthy subject a therapeutically effective amount of a compound of Formula I, or a pharmaceutically acceptable salt, solvate or prodrug thereof. The present disclosure also provides for use of a compound of Formula I, or a pharmaceutically acceptable salt, solvate or prodrug thereof, for improving cognition in a cognitively healthy subject. A compound of Formula I, or a pharmaceutically acceptable salt, solvate or prodrug thereof, may be used in the manufacture of a medicament for improving cognition in a cognitively healthy subject.</p><p id="p-0247" num="0189">It will be appreciated that the dosage regimens and compositions as described herein may apply to any of the embodiments or examples of the methods as described herein.</p><heading id="h-0017" level="2">Dosage Regimen</heading><p id="p-0248" num="0190">As used herein, &#x201c;therapeutically effective amount&#x201d; refers to a compound of Formula I, or a pharmaceutically acceptable salt, solvate or prodrug thereof, being administered in an amount sufficient to alleviate or prevent to some extent one or more of the symptoms of the disorder or condition being treated, typically without undue adverse side effects or to achieve a desired pharmacological effect or therapeutic improvement with a reduced side effect profile. The results can be the reduction and/or alleviation of the signs, symptoms, or causes of a disease or condition, or any other desired alteration of a biological system. In some embodiments, the term &#x201c;therapeutically effective amount&#x201d; refers to a compound of Formula I, or a pharmaceutically acceptable salt, solvate or prodrug thereof, being administered in an amount sufficient to result in a reduction of symptoms associated with cognitive decline. Therapeutically effective amounts may, for example, be determined by routine experimentation, including but not limited to a dose escalation clinical trial. The phrase &#x201c;therapeutically effective amount&#x201d; includes, for example, a prophylactically effective amount. In some embodiments, a prophylactically effective amount is an amount sufficient to prevent cognitive decline. It is understood that &#x201c;an effective amount&#x201d; or &#x201c;a therapeutically effective amount&#x201d; can vary from subject to subject, due to variation in metabolism of the compound and any of age, weight, general condition of the subject, the condition being treated, the severity of the condition being treated, and the judgment of the prescribing physician. An appropriate an effective amount&#x201d; or &#x201c;a therapeutically effective amount&#x201d; in any individual case may be determined by one of ordinary skill in the art using routine experimentation.</p><p id="p-0249" num="0191">The amount of a compound of Formula I, or a pharmaceutically acceptable salt, solvate or prodrug thereof, that will be effective in the treatment and/or prevention of a particular disorder or condition disclosed herein will depend on the nature of the disorder or condition, and can be determined by standard clinical techniques. In addition, in vitro or in vivo assays may optionally be employed to help identify optimal dosage ranges. Such techniques are known to the person skilled in the art.</p><p id="p-0250" num="0192">The precise dose to be administered to the subject will also depend on the route of administration, and the seriousness of the disease or disorder, and should be decided according to the judgment of the practitioner and each subject's circumstances. For example, suitable dosage ranges for oral administration, are generally from about 0.001 milligram to 1000 milligrams of the compound of Formula I, or a pharmaceutically acceptable salt, solvate or prodrug thereof per kilogram body weight.</p><p id="p-0251" num="0193">In some embodiments, the compound of Formula I, or a pharmaceutically acceptable salt, solvate or prodrug thereof, is administered in an amount so as to deliver a total daily dosage (in mg) of at least about 1, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 60, 75, 100, 150, or 200. In some embodiments, the compound of Formula I, or a pharmaceutically acceptable salt, solvate or prodrug thereof, is administered in an amount so as to deliver a total daily dosage (in mg) of less than about 200, 150, 100, 75, 60, 50, 45, 40, 35, 30, 25, 20, 15, 10, 5, or 1. The total daily dosage may be provided in a range between at any two of these upper and/or lower amounts. For example, a total daily dosage may be provided in an amount of between about 1 and 100 mg, about 5 and 75 mg, about 10 and 50 mg, about 15 and 45 mg, or about 20 and 40 mg.</p><p id="p-0252" num="0194">In some embodiments, a therapeutically effective amount of a compound of Formula I, or a pharmaceutically acceptable salt, solvate or prodrug thereof, is administered to the subject at a predetermined frequency. In some embodiments, a compound of Formula I, or a pharmaceutically acceptable salt, solvate or prodrug thereof, is administered to the subject according to a dosage regimen in which a compound of Formula I, or a pharmaceutically acceptable salt, solvate or prodrug thereof is administered once daily, twice daily, three times daily, or four times daily. In some embodiments, the a compound of Formula I, or a pharmaceutically acceptable salt, solvate or prodrug thereof is administered to the subject according to a dosage regimen in which a compound of Formula I, or a pharmaceutically acceptable salt, solvate or prodrug thereof is administered once daily. In some embodiments, a compound of Formula I, or a pharmaceutically acceptable salt, solvate or prodrug thereof is administered to the subject according to a dosage regimen in which a compound of Formula I, or a pharmaceutically acceptable salt, solvate or prodrug thereof is administered twice daily. In some embodiments, a compound of Formula I, or a pharmaceutically acceptable salt, solvate or prodrug thereof is administered to the subject according to a dosage regimen in which a compound of Formula I, or a pharmaceutically acceptable salt, solvate or prodrug thereof is administered three times daily. In some embodiments, a compound of Formula I, or a pharmaceutically acceptable salt, solvate or prodrug thereof is administered to the subject according to a dosage regimen in which a compound of Formula I, or a pharmaceutically acceptable salt, solvate or prodrug thereof is administered four times daily. In some embodiments, a compound of Formula I, or a pharmaceutically acceptable salt, solvate or prodrug thereof is administered to the subject according to a dosage regimen in which a compound of Formula I, or a pharmaceutically acceptable salt, solvate or prodrug thereof is administered multiple times daily. In some examples, a compound of Formula I, or a pharmaceutically acceptable salt, solvate or prodrug thereof is administered as a once daily dose of between about 10 mg and 30 mg, for example at about 20 mg. In other examples, a compound of Formula I, or a pharmaceutically acceptable salt, solvate or prodrug thereof is administered as a twice daily dose of between about 5 mg and 20 mg per dose, for example at about 10 mg per dose. In some embodiments, a compound of Formula I, or a pharmaceutically acceptable salt, solvate or prodrug thereof is administered as a three-times daily dose of between about 5 mg and 15 mg per dose, for example at about 10 mg per dose.</p><p id="p-0253" num="0195">In some embodiments, a therapeutically effective amount of a compound of Formula I, or a pharmaceutically acceptable salt, solvate or prodrug thereof, is administered to the subject at a predetermined frequency and/or duration. For example, administration according to any embodiments (e.g. frequency) as described herein may be for a duration of about, or at least about, 1 day, 1 week, 2 weeks, 3 weeks, 1 month, 2 months, 3 months, 4 months, 5 months, 6 months, 12 months, 2 years, or 5 years. Administration of the therapeutically effective amount of a compound of Formula I, or a pharmaceutically acceptable salt, solvate or prodrug thereof, may be ongoing so long as a therapeutic effect is received by the subject.</p><p id="p-0254" num="0196">As used herein, the term &#x201c;administer&#x201d; and &#x201c;administering&#x201d; are used to mean introducing the compound of Formula I, or a pharmaceutically acceptable salt, solvate or prodrug thereof, into a subject. When administration is for the purpose of treatment, the compound of Formula I, or a pharmaceutically acceptable salt, solvate or prodrug thereof, is provided at, or after the onset of, a symptom of cognitive decline. The therapeutic administration of this substance serves to attenuate any symptom, or prevent additional symptoms from arising. When administration is for the purposes of preventing or reducing the likelihood cognitive decline, the compound of Formula I, or a pharmaceutically acceptable salt, solvate or prodrug thereof, is provided in advance of any visible or detectable symptom. The prophylactic administration of the compound of Formula I, or a pharmaceutically acceptable salt, solvate or prodrug thereof, serves to attenuate subsequently arising symptoms or prevent or reduce the likelihood of the symptoms from arising altogether.</p><p id="p-0255" num="0197">A compound of Formula I, or a pharmaceutically acceptable salt, solvate or prodrug thereof, may be administered by any suitable route. Examples include, but are not limited to, oral, topical, transdermal, intranasal, vaginal, rectal, intraarterial, intramuscular, intraosseous, intraperitoneal, epidural and intrathecal. In some embodiments, a compound of Formula I, or a pharmaceutically acceptable salt, solvate or prodrug thereof, is administered orally.</p><p id="p-0256" num="0198">A compound of Formula I, or a pharmaceutically acceptable salt, solvate or prodrug thereof, may be administered to the subject with respect to the subject's fasted state, as would be understood by the person skilled in the art. For example, the subject may be administered a compound of Formula I, or a pharmaceutically acceptable salt, solvate or prodrug thereof before, with, or after a meal. In some embodiments, a compound of Formula I, or a pharmaceutically acceptable salt, solvate or prodrug thereof is administered to the subject before a meal (i.e., the subject being in a fasted state). In some embodiments, a compound of Formula I, or a pharmaceutically acceptable salt, solvate or prodrug thereof is administered to the subject with a meal. In some embodiments, a compound of Formula I, or a pharmaceutically acceptable salt, solvate or prodrug thereof is administered at a certain interval (i.e., 30 mins, 1 hour, 2 hours, 3 hours, etc.) following a meal.</p><heading id="h-0018" level="2">Compositions</heading><p id="p-0257" num="0199">Compositions suitable for use in the methods and uses described herein comprise a compound of Formula I, or a pharmaceutically acceptable salt, solvate or prodrug thereof. In some embodiments, a compound of Formula I, or a pharmaceutically acceptable salt, solvate or prodrug thereof, is presented as a composition. In some embodiments, a compound of Formula I, or a pharmaceutically acceptable salt, solvate or prodrug thereof, is presented as a pharmaceutical composition.</p><p id="p-0258" num="0200">The present disclosure also provides pharmaceutical compositions that comprise a compound of Formula I, or a pharmaceutically acceptable salt, solvate or prodrug thereof, with one or more pharmaceutically acceptable carriers, and optionally any other therapeutic ingredients, stabilisers, or the like. The carrier(s) must be pharmaceutically acceptable in the sense of being compatible with the other ingredients of the formulation and not unduly deleterious to the recipient thereof. Generally, suitable pharmaceutically acceptable carriers are known in the art and are selected based on the end use application. The pharmaceutically acceptable carrier may act as a diluent, dispersant or carrier for the active agents and other optional components of the composition. The pharmaceutically acceptable carrier may also contain materials commonly used in pharmaceutically products and can be in a wide variety of forms. For example, the carrier may be water, liquid or solid emollients, silicone oils, emulsifiers, surfactants, solvents, humectants, thickeners, powders, propellants and the like.</p><p id="p-0259" num="0201">In some embodiments, the composition is a pharmaceutical composition, and wherein the composition comprises a pharmaceutically acceptable excipient.</p><p id="p-0260" num="0202">The composition may for example contain a solvent, such as water (e.g. water for injection) or a pharmaceutically acceptable organic solvent.</p><p id="p-0261" num="0203">The compositions may further include diluents, buffers, citrate, trehalose, binders, disintegrants, thickeners, lubricants, preservatives (including antioxidants), inorganic salts (e.g., sodium chloride), antimicrobial agents (e.g., benzalkonium chloride), sweeteners, antistatic agents, sorbitan esters, lipids (e.g., phospholipids such as lecithin and other phosphatidylcholines, phosphatidylethanolamines, fatty acids and fatty esters, steroids (e.g., cholesterol)), and chelating agents (e.g., EDTA, zinc and other such suitable cations).</p><p id="p-0262" num="0204">The compositions of the present disclosure may also include polymeric excipients/additives or carriers, e.g., polyvinylpyrrolidones, derivatised celluloses such as hydroxymethylcellulose, hydroxyethylcellulose, and hydroxypropylmethylcellulose, Ficolls (a polymeric sugar), hydroxyethylstarch (HES), dextrates (e.g., cyclodextrins, such as 2-hydroxypropyl-&#x3b2;-cyclodextrin and sulfobutylether-&#x3b2;-cyclodextrin), polyethylene glycols, and pectin.</p><p id="p-0263" num="0205">Other pharmaceutical carriers, excipients, optional ingredients and/or additives suitable for use in the compositions according to the present disclosure are listed in &#x201c;Remington: The Science &#x26; Practice of Pharmacy&#x201d;, 19.sup.th ed., Williams &#x26; Williams, (1995), and in the &#x201c;Physician's Desk Reference&#x201d;, 52.sup.nd ed., Medical Economics, Montvale, N.J. (1998), and in &#x201c;Handbook of Pharmaceutical Excipients&#x201d;, Third Ed., Ed. A. H. Kibbe, Pharmaceutical Press, 2000.</p><p id="p-0264" num="0206">A compound of Formula I, or a pharmaceutically acceptable salt, solvate or prodrug thereof, of the present disclosure may be formulated in compositions including those suitable for inhalation to the lung, by aerosol, parenteral (including intraperitoneal, intravenous, subcutaneous, or intramuscular injection) or oral administration.</p><p id="p-0265" num="0207">The compositions may conveniently be presented in unit dosage form and may be prepared by any of the methods well known in the art of pharmacy. All methods include the step of bringing a compound of Formula I, or a pharmaceutically acceptable salt, solvate or prodrug thereof, into association with a carrier that constitutes one or more accessory ingredients.</p><p id="p-0266" num="0208">In general, the compositions are prepared by bringing a compound of Formula I, or a pharmaceutically acceptable salt, solvate or prodrug thereof into association with a liquid carrier to form a solution or a suspension, or alternatively, by bringing a compound of Formula I, or a pharmaceutically acceptable salt, solvate or prodrug thereof into association with formulation components suitable for forming a solid, optionally a particulate product, and then, if warranted, shaping the product into a desired delivery form.</p><p id="p-0267" num="0209">In some embodiments, the composition is formulated for oral delivery. Compositions for oral delivery may, for example, be in the form of tablets, lozenges, aqueous or oily suspensions, granules, powders, emulsions, capsules, syrups, or elixirs. Orally administered compositions may contain one or more optional agents, for example, sweetening agents such as fructose, aspartame or saccharin; flavoring agents such as peppermint, oil of wintergreen, or cherry; coloring agents; and preserving agents, to provide a pharmaceutically palatable preparation. Moreover, where in a tablet or pill form, the compositions may be coated to delay disintegration and absorption in the gastrointestinal tract thereby providing a sustained action over an extended period of time. Oral compositions can include standard vehicles such as mannitol, lactose, starch, magnesium stearate, sodium saccharine, cellulose, magnesium carbonate, etc. Such vehicles are preferably of pharmaceutical grade. The oral compositions described herein may contain from about 1% to about 95% of a compound of Formula I, or a pharmaceutically acceptable salt, solvate or prodrug thereof by weight, and the oral compositions may be dosed 1, 2, 3, 4, 5 or more times daily. The oral compositions described herein may contain a compound of Formula I, or a pharmaceutically acceptable salt, solvate or prodrug thereof by weight % in at least about 1, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, or 90. The oral compositions described herein may contain a compound of Formula I, or a pharmaceutically acceptable salt, solvate or prodrug thereof by weight % in less than about 95, 90, 85, 80, 75, 70, 65, 60, 55, 50, 45, 40, 35, 30, 25, 20, 15, 10, or 5. The oral compositions described herein may contain a compound of Formula I, or a pharmaceutically acceptable salt, solvate or prodrug thereof by weight % in a range provided by any two of these upper and/or lower values, for example between about 5 and 20 wt %.</p><p id="p-0268" num="0210">In some embodiments, the composition is formulated for parenteral delivery. For example, in one embodiment, the composition may be a sterile, lyophilized, crystalized or amorphous composition that is suitable for reconstitution in an aqueous vehicle prior to injection.</p><p id="p-0269" num="0211">In one embodiment, a composition suitable for parenteral administration conveniently comprises a sterile aqueous preparation of a compound of Formula I, or a pharmaceutically acceptable salt, solvate or prodrug thereof, which may for example be formulated to be isotonic with the blood of the recipient.</p><p id="p-0270" num="0212">Pharmaceutical compositions are also provided which are suitable for administration as an aerosol, by inhalation. These formulations comprise a solution or suspension of a compound of Formula I, or a pharmaceutically acceptable salt, solvate or prodrug thereof. The desired formulation may be placed in a small chamber and nebulized. Nebulization may be accomplished by compressed air or by ultrasonic energy to form a plurality of liquid droplets or solid particles comprising a compound of Formula I, or a pharmaceutically acceptable salt, solvate or prodrug thereof.</p><p id="p-0271" num="0213">As discussed below, a compound of Formula I, or a pharmaceutically acceptable salt, solvate or prodrug thereof of the present disclosure may for example be administered in combination with one or more additional pharmaceutically active agents. Thus, in some embodiments, the composition comprises a compound of Formula I, or a pharmaceutically acceptable salt, solvate or prodrug thereof as defined herein, or a pharmaceutically acceptable salt thereof, one or more pharmaceutically acceptable carriers, and one or more additional pharmaceutically active agents, e.g. an additional cognitive enhancing agent.</p><p id="p-0272" num="0214">Generally, the composition comprises a compound of Formula I, or a pharmaceutically acceptable salt, solvate or prodrug thereof in an amount that is therapeutically effective amount. In some embodiments, the therapeutically effective amount is provided by a single dose. In some embodiments, the therapeutically effective amount is provided by one or more doses administered as part of a course of treatment, for example, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27 or greater than 27 doses.</p><p id="p-0273" num="0215">The person skilled in the art would understand that the amount of a compound of Formula I, or a pharmaceutically acceptable salt, solvate or prodrug thereof present in the composition will vary depending on the other ingredients present in the composition, the desired effect and the like. In some embodiments, the composition comprises a compound of Formula I, or a pharmaceutically acceptable salt, solvate or prodrug thereof in a concentration between about 0.001 to 1000 mg/mL, 0.01 to 500 mg/mL, 0.1 to 50 mg/mL. In some embodiments, the composition comprises a compound of Formula I, or a pharmaceutically acceptable salt, solvate or prodrug thereof in a concentration between about 1 to 99 wt %, 1 to 90 wt %, 1 to 85 wt %, 1 to 80 wt %, 1 to 75 wt %, 1 to 70 wt %, 1 to 65 wt %, 1 to 60 wt %, 1 to 55 wt %, 1 to 50 wt %, 1 to 45 wt %, 1 to 40 wt %, 1 to 35 wt %, 1 to 30 wt %, 5 to 99 wt %, 10 to 99 wt %, 15 to 99 wt %, 20 to 99 wt %, 25 to 99 wt %, 30 to 99 wt %, 35 to 99 wt %, 40 to 99 wt %, 45 to 99 wt %, 50 to 99 wt %, 54 to 99 wt %, 60 to 99 wt %, 65 to 99 wt %, 70 to 99 wt %, 75 to 99 wt %, 80 to 99 wt %, 85 to 99 wt %, 90 to 99 wt %, 5 to 90 wt %, 20 to 80 wt %, 30 to 70 wt %, or 40 to 60 wt %.</p><p id="p-0274" num="0216">In some embodiments, a compound of Formula I, or a pharmaceutically acceptable salt, solvate or prodrug thereof may be administered in combination with a further therapeutic agent. In some embodiments, the methods and uses described herein also relate to co-administering one or more substances in addition to a compound of Formula I, or a pharmaceutically acceptable salt, solvate or prodrug thereof to the subject. The term &#x201c;co-administer&#x201d; indicates that each of at least two compounds are administered during a time frame wherein the respective periods of biological activity or effects overlap. Thus, the term includes sequential as well as coextensive administration of compounds. Similar to administering compounds, co-administration of more than one substance can be for therapeutic and/or prophylactic purposes. If more than one substance or compound is co-administered, the routes of administration of the two or more substances need not be the same. The scope of the methods and uses described herein are not limited by the identity of the substance or substances which may be co-administered with a compound of Formula I, or a pharmaceutically acceptable salt, solvate or prodrug thereof. For example, compositions comprising a compound of Formula I, or a pharmaceutically acceptable salt, solvate or prodrug thereof may be co-administered with fluids or other substances that are capable of alleviating, attenuating, preventing or removing symptoms in a subject suffering from, exhibiting the symptoms of, or at risk of suffering from cognitive decline. Types of fluid that can be co-administered with a compound of Formula I, or a pharmaceutically acceptable salt, solvate or prodrug thereof should be specific to the circumstances surrounding the particular subject that is suffering from, exhibiting the symptoms of, or at risk of suffering from a bacterial infection. For example, fluids that may be co-administered with a compound of Formula I, or a pharmaceutically acceptable salt, solvate or prodrug thereof include but are not limited to, electrolytes and/or water, salt solutions, such as sodium chloride and sodium bicarbonate, as well as whole blood, plasma, serum, serum albumin and colloid solutions.</p><p id="p-0275" num="0217">The composition may be a food or beverage, or provided into a food or beverage. The composition may be a veterinary product, such as a dog or cat food product. The composition may be a feed additive, a supplement, or a medical food. In some embodiments, a compound of Formula I, or a pharmaceutically acceptable salt, solvate or prodrug thereof, may be incorporated into food products and beverages. The compound of Formula I, or pharmaceutically acceptable salt, solvate or prodrug thereof, may be impregnated, mixed, emulsified, sprayed or coated onto carriers such as cellulose, methylcellulose, dextrose, cyclodextrose, cyclodextrin, maltitol, and fibre. Delivery may also be enhanced with a range of surfactants, lipids, complexes, solvents and co-solvent pharmaceutical delivery systems known in the pharmaceutical art to improve bioavailability, absorption and efficacy. As used herein, the term &#x201c;food&#x201d; or &#x201c;food product&#x201d; includes any edible product for human or non-human consumption, such as but not limited to supplements, snacks (sweet and savory), cocoa-containing foods, flavours, beverages, dietary supplements and formulations including supplements used in animal health and nutrition. Additional ingredients desired in the resulting food product may be added at any point in the process.</p><p id="p-0276" num="0218">The present disclosure includes food products comprising one or more compounds of Formula I alone as the active ingredient or in combination with other active ingredients.</p><p id="p-0277" num="0219">In some embodiments, there is provided a food product comprising a compound of Formula I, or a pharmaceutically acceptable salt, solvate or prodrug thereof. In some embodiments, there is provided a supplement or feed additive product comprising a compound of Formula I, or a pharmaceutically acceptable salt, solvate or prodrug thereof. In some embodiments, there is provided a beverage comprising a compound of Formula I, or a pharmaceutically acceptable salt, solvate or prodrug thereof.</p><p id="p-0278" num="0220">It will be appreciated that administration of the compound may be provided in various forms depending on the application and subject.</p><heading id="h-0019" level="1">EXAMPLES</heading><heading id="h-0020" level="2">General: Materials and Methods</heading><p id="p-0279" num="0221">Formulations comprising a compound of Formula Ia were tested on human subjects to evaluate the use in preventing and/or treating cognitive decline or improving cognitive ability.</p><p id="p-0280" num="0222">The compound of Formula Ia, as described herein, was synthesised and characterised according to the procedure described in WO2011135276.</p><p id="p-0281" num="0223">The compound of Formula Ia is also known as UE2343 or (5-(1H-pyrazol-4-yl)thiophen-3-yl)(3-hydroxy-3-(pyrimidin-2-yl)-8-azabicyclo[3.2.1]octan-8-yl)methanone. Xanamem&#x2122; contains the compound of Formula Ia as an active ingredient.</p><p id="p-0282" num="0224">The test was aimed at assessing if, and to what extent, Xanamem&#x2122; 20 mg a day may improve performance in healthy elderly subjects from Baseline (Week 0) to Weeks 2, 4, 6, 8, 10, 12 (End of Treatment) and 16 (Follow-up), as measured by changes in the Cogstate Test Battery. 42 subjects were randomised in which 30 subjects received 20 mg Xanamem&#x2122; once a day and 12 subjects received matching placebo once a day.</p><p id="p-0283" num="0225">For each visit, excluding the Screening visit and safety visits (Week 6 and Week 10), subjects arrived at the study site having fasted for at least 10 hours. The subjects took Xanamem&#x2122; at site after all the pre-dose blood samples had been taken. Xanamem&#x2122; was taken 30 minutes after the start of a meal. On non-study visit days, the subjects took Xanamem&#x2122; at the same time each morning with food (30 minutes after the start of the meal).</p><p id="p-0284" num="0226">One capsule of Xanamem&#x2122;, or the matching placebo, was administered orally with approximately 200 mL of warm water once a day and with food in the morning, to the subjects from Baseline (Week 0) to End of Treatment (Week 12) for a total of 12 weeks.</p><p id="p-0285" num="0227">Xanamem&#x2122; was formulated in green and cream-coloured size 3, Coni-Snap shaped gelatin capsules as an excipient blend at a dose of 20 mg. The components in 20 mg Xanamem&#x2122; and Placebo used in the test, and their contents and % w/w are shown in Tables 1 and 2, respectively.</p><heading id="h-0021" level="2">Formulations of Xanamem&#x2122; and Placebo</heading><p id="p-0286" num="0228"></p><p id="p-0287" num="0000"><tables id="TABLE-US-00001" num="00001"><table frame="none" colsep="0" rowsep="0"><tgroup align="left" colsep="0" rowsep="0" cols="1"><colspec colname="1" colwidth="217pt" align="center"/><thead><row><entry namest="1" nameend="1" rowsep="1">TABLE 1</entry></row></thead><tbody valign="top"><row><entry namest="1" nameend="1" align="center" rowsep="1"/></row><row><entry>Xanamem&#x2009;&#x2122; 20 mg formulation</entry></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="4"><colspec colname="offset" colwidth="14pt" align="left"/><colspec colname="1" colwidth="84pt" align="left"/><colspec colname="2" colwidth="35pt" align="center"/><colspec colname="3" colwidth="84pt" align="center"/><tbody valign="top"><row><entry/><entry/><entry>Weight </entry><entry>Formulation </entry></row><row><entry/><entry>Component</entry><entry>per unit</entry><entry>percentage % w/w</entry></row><row><entry/><entry namest="offset" nameend="3" align="center" rowsep="1"/></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="4"><colspec colname="offset" colwidth="14pt" align="left"/><colspec colname="1" colwidth="84pt" align="left"/><colspec colname="2" colwidth="35pt" align="center"/><colspec colname="3" colwidth="84pt" align="char" char="."/><tbody valign="top"><row><entry/><entry>UE2343 powder</entry><entry>&#x2009;&#x2002;20 mg</entry><entry>10.53</entry></row><row><entry/><entry>Lactose</entry><entry>160.5 mg&#x2002;</entry><entry>84.47</entry></row><row><entry/><entry>Croscarmellose Sodium</entry><entry>&#x2002;7.6 mg</entry><entry>4.00</entry></row><row><entry/><entry>Talc</entry><entry>0.95 mg</entry><entry>0.50</entry></row><row><entry/><entry>Magnesium Stearate</entry><entry>0.95 mg</entry><entry>0.50</entry></row><row><entry/><entry>Total</entry><entry>&#x2009;190 mg</entry><entry>100%</entry></row><row><entry/><entry namest="offset" nameend="3" align="center" rowsep="1"/></row></tbody></tgroup></table></tables></p><p id="p-0288" num="0000"><tables id="TABLE-US-00002" num="00002"><table frame="none" colsep="0" rowsep="0"><tgroup align="left" colsep="0" rowsep="0" cols="1"><colspec colname="1" colwidth="217pt" align="center"/><thead><row><entry namest="1" nameend="1" rowsep="1">TABLE 2</entry></row></thead><tbody valign="top"><row><entry namest="1" nameend="1" align="center" rowsep="1"/></row><row><entry>Placebo formulation</entry></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="4"><colspec colname="offset" colwidth="14pt" align="left"/><colspec colname="1" colwidth="84pt" align="left"/><colspec colname="2" colwidth="35pt" align="center"/><colspec colname="3" colwidth="84pt" align="center"/><tbody valign="top"><row><entry/><entry/><entry>Weight </entry><entry>Formulation </entry></row><row><entry/><entry>Component</entry><entry>per unit</entry><entry>percentage % w/w</entry></row><row><entry/><entry namest="offset" nameend="3" align="center" rowsep="1"/></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="4"><colspec colname="offset" colwidth="14pt" align="left"/><colspec colname="1" colwidth="84pt" align="left"/><colspec colname="2" colwidth="35pt" align="center"/><colspec colname="3" colwidth="84pt" align="char" char="."/><tbody valign="top"><row><entry/><entry>Lactose</entry><entry>180.5 mg&#x2002;</entry><entry>95</entry></row><row><entry/><entry>Croscarmellose Sodium</entry><entry>&#x2002;7.6 mg</entry><entry>4.00</entry></row><row><entry/><entry>Talc</entry><entry>0.95 mg</entry><entry>0.50</entry></row><row><entry/><entry>Magnesium Stearate</entry><entry>0.95 mg</entry><entry>0.50</entry></row><row><entry/><entry>Total</entry><entry>&#x2009;190 mg</entry><entry>100%</entry></row><row><entry/><entry namest="offset" nameend="3" align="center" rowsep="1"/></row></tbody></tgroup></table></tables></p><p id="p-0289" num="0229">To assess the efficacy of Xanamem&#x2122; 20 mg once a day in improving cognitive ability in the subjects, the Cogstate Test Battery of the subjects were checked at Baseline (Week 0), Weeks 2, 4, and 8, Week 12 (End of Treatment) and Week 16 (Follow-up).</p><p id="p-0290" num="0230">The Cogstate Test Battery included the following tests: detection test, identification test, one card learning test, one back working memory test, and the continuous paired associate learning test (CPAL; paired associate learning).</p><heading id="h-0022" level="2">Detection Test</heading><p id="p-0291" num="0231">The Cogstate Detection test is a measure of simple reaction time and has been shown to provide a valid assessment of psychomotor function. For this test, the subject pressed a &#x201c;YES&#x201d; response key as soon as they detected an event (a card turning face up presented in the centre of the computer screen). The software measured the response time to detect each event.</p><heading id="h-0023" level="2">Identification Test</heading><p id="p-0292" num="0232">The Cogstate Identification test is a measure of choice reaction time and has been shown to provide a valid assessment of visual attention. In this test an event (a card turning face up) occurred in the centre of the computer screen and the subject decided &#x201c;YES&#x201d; or &#x201c;NO&#x201d; as to whether this event met a predefined and unchanging criterion (i.e. is the color of the card red?). The software measured the speed and accuracy of each response.</p><heading id="h-0024" level="2">One Card Learning Test</heading><p id="p-0293" num="0233">The One Card Learning test is a continuous visual recognition learning test that assesses visual learning within a pattern separation model (Yassa et al., 2010). Theoretical models of the pattern separation model specify that information is organized in orthogonal and distinct non-overlapping representations so that new memories can be stored rapidly without interference. The One Card Learning test has been shown to be a valid test of learning and memory.</p><p id="p-0294" num="0234">In this test, the participant attended to the card in the centre of the screen and responded to the question &#x201c;have you seen this card before in this test?&#x201d; If the answer was yes, participants were instructed to press the &#x201c;YES&#x201d; button, otherwise they were to press the &#x201c;NO&#x201d; button if the answer was no. Normal playing cards were displayed (without joker cards).</p><p id="p-0295" num="0235">In this test, six cards were drawn at random from the deck and were repeated throughout the test. These four cards were interspersed with distractors (non-repeating cards). The test ended after 50 trials, without rescheduling for post-anticipatory correct trials. The primary performance measure for this test was the proportion of correct answers (accuracy), which was normalized using an arcsine square root transformation.</p><heading id="h-0025" level="2">One Back Working Memory Test</heading><p id="p-0296" num="0236">The Cogstate One Back memory test is a valid measure of working memory. On this test the subject was shown a single stimulus in the centre of the computer screen (a card turns face up). The subject decided &#x201c;YES&#x201d; or &#x201c;NO&#x201d; as to whether the current card matched the card that had been seen on the immediately previous trial. The software measured the speed and accuracy of each response.</p><heading id="h-0026" level="2">Continuous Paired Associate Learning Test (CPAL; Paired Associate Learning)</heading><p id="p-0297" num="0237">The Continuous Paired Associate Learning test is a measure of visual associate memory and uses a well-validated paired associate learning paradigm in which the subject must learn the locations of a number of amoeba-like shapes on the computer screen.</p><p id="p-0298" num="0238">This test consisted of a single amoeboid shape displayed in the centre of the screen surrounded by a number of blue-filled circles. Beneath all but two of the blue spheres were amoeboid shapes, one of which matched the central display; the two remaining circles were distractors. In the exposure phase of the test all of the to-be-remembered pattern-location associations were presented on the computer screen simultaneously.</p><p id="p-0299" num="0239">After a five second delay, a pattern was shown in the central location and this signals that the subject should touch the location in the periphery that contained the same pattern. This process continued until the participant had acknowledged all of the pattern-location associations. The learning phase began with the same test display presented during the exposure phase except that now all of the peripheral locations were shown as blue spheres. One of the patterns presented in the exposure phase was presented in the centre location. With the presentation of this pattern, the subject was required to select the peripheral location where an identical pattern was hidden beneath the blue sphere. This process continued until the correct location of each pattern was found.</p><p id="p-0300" num="0240">Finding the correct location for all patterns in the set was defined as a learning trial. There were six learning trials. A single trial delayed recall condition was available for this test after a 10-30 minute delay. The software recorded each move as an error or as a correct move.</p><heading id="h-0027" level="2">Timing of Cogstate Test Battery</heading><p id="p-0301" num="0241">The timing of the Cogstate Test Battery is shown in Table 3.</p><p id="p-0302" num="0000"><tables id="TABLE-US-00003" num="00003"><table frame="none" colsep="0" rowsep="0"><tgroup align="left" colsep="0" rowsep="0" cols="1"><colspec colname="1" colwidth="217pt" align="center"/><thead><row><entry namest="1" nameend="1" rowsep="1">TABLE 3</entry></row></thead><tbody valign="top"><row><entry namest="1" nameend="1" align="center" rowsep="1"/></row><row><entry>Trials and timing for each test in the cognitive battery</entry></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="4"><colspec colname="1" colwidth="105pt" align="left"/><colspec colname="2" colwidth="28pt" align="center"/><colspec colname="3" colwidth="42pt" align="left"/><colspec colname="4" colwidth="42pt" align="left"/><tbody valign="top"><row><entry/><entry>N </entry><entry>Maximum </entry><entry>Average </entry></row><row><entry/><entry>Trials/</entry><entry>Time</entry><entry>time</entry></row><row><entry>Test</entry><entry>Screens</entry><entry>Allowed</entry><entry>Required</entry></row><row><entry namest="1" nameend="4" align="center" rowsep="1"/></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="4"><colspec colname="1" colwidth="105pt" align="left"/><colspec colname="2" colwidth="28pt" align="char" char="."/><colspec colname="3" colwidth="42pt" align="left"/><colspec colname="4" colwidth="42pt" align="left"/><tbody valign="top"><row><entry>Subject demographic screen</entry><entry>1</entry><entry>Unlimited</entry><entry>~1 minute</entry></row><row><entry>Detection test instructions &#x26;</entry><entry>1</entry><entry>Unlimited</entry><entry>~1 minute</entry></row><row><entry>demo</entry><entry/><entry/><entry/></row><row><entry>Detection test</entry><entry>35</entry><entry>5 minutes</entry><entry>~2 minutes</entry></row><row><entry>Identification test instructions</entry><entry>1</entry><entry>Unlimited</entry><entry>~1 minute</entry></row><row><entry>&#x26; demo</entry><entry/><entry/><entry/></row><row><entry>Identification Test</entry><entry>30</entry><entry>5 minutes</entry><entry>~2 minutes</entry></row><row><entry>One Card Learning test</entry><entry>1</entry><entry>Unlimited</entry><entry>~1 minute</entry></row><row><entry>instructions &#x26; demo</entry><entry/><entry/><entry/></row><row><entry>One Card Learning Test</entry><entry>80</entry><entry>5 minutes</entry><entry>~4 minutes</entry></row><row><entry>One Back test instructions &#x26;</entry><entry>1</entry><entry>Unlimited</entry><entry>~1 minute</entry></row><row><entry>demo</entry><entry/><entry/><entry/></row><row><entry>One Back test</entry><entry>31</entry><entry>5 minutes</entry><entry>~3 minutes</entry></row><row><entry>Continuous Paired Associate</entry><entry>1</entry><entry>5 minutes</entry><entry>~1 minute</entry></row><row><entry>Learning Test instructions &#x26;</entry><entry/><entry/><entry/></row><row><entry>demo</entry><entry/><entry/><entry/></row><row><entry>Continuous Paired Associate</entry><entry>7</entry><entry>Unlimited</entry><entry>~7 minutes</entry></row><row><entry>Learning Test</entry><entry/><entry/><entry/></row><row><entry>Continuous Paired Associate</entry><entry>1</entry><entry>2 minutes</entry><entry>~1 minute</entry></row><row><entry>Learning Test-Delayed</entry><entry/><entry/><entry/></row><row><entry>Recall</entry><entry/><entry/><entry/></row><row><entry>Estimated total time cognitive</entry><entry/><entry/><entry>25 minutes</entry></row><row><entry>battery</entry></row><row><entry namest="1" nameend="4" align="center" rowsep="1"/></row></tbody></tgroup></table></tables></p><heading id="h-0028" level="2">Cognitive Outcome Measures</heading><p id="p-0303" num="0242">Although each of the cognitive tests to be used yields multiple outcome measures, research by Cogstate identified a set of measures that were optimal for the detection of cognitive change in clinical trials at both the group and individual level.</p><p id="p-0304" num="0243">For each cognitive test, a single outcome measure was selected from each test in the battery to minimize experiment-wise error rates. Each outcome measure was selected because it was shown to be optimal for the detection of change because:<ul id="ul0001" list-style="none">    <li id="ul0001-0001" num="0000">    <ul id="ul0002" list-style="none">        <li id="ul0002-0001" num="0244">it was drawn from a data distribution that contained only a small probability of floor or ceiling effects and no restriction in the range of possible performance values; and</li>        <li id="ul0002-0002" num="0245">it was drawn from a distribution that is normal or which can be corrected to normal through the use of appropriate mathematical transformation (e.g., logarithmic base 10, or arcsine).</li>        <li id="ul0002-0003" num="0246">The outcome measures for the test used are summarized in Table 4.</li>    </ul>    </li></ul></p><p id="p-0305" num="0000"><tables id="TABLE-US-00004" num="00004"><table frame="none" colsep="0" rowsep="0"><tgroup align="left" colsep="0" rowsep="0" cols="1"><colspec colname="1" colwidth="217pt" align="center"/><thead><row><entry namest="1" nameend="1" rowsep="1">TABLE 4</entry></row></thead><tbody valign="top"><row><entry namest="1" nameend="1" align="center" rowsep="1"/></row><row><entry>Recommended outcome measures for the cognitive battery</entry></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="5"><colspec colname="1" colwidth="49pt" align="left"/><colspec colname="2" colwidth="42pt" align="left"/><colspec colname="3" colwidth="49pt" align="left"/><colspec colname="4" colwidth="28pt" align="center"/><colspec colname="5" colwidth="49pt" align="left"/><tbody valign="top"><row><entry/><entry/><entry/><entry>Range</entry><entry/></row><row><entry/><entry>Cognitive</entry><entry>Unit of</entry><entry>of</entry><entry/></row><row><entry>Test name</entry><entry>domain</entry><entry>measurement</entry><entry>scores</entry><entry>Description</entry></row><row><entry namest="1" nameend="5" align="center" rowsep="1"/></row><row><entry>Detection </entry><entry>Psychomotor</entry><entry>Log<sub>10</sub></entry><entry>0 to</entry><entry>Speed of </entry></row><row><entry>Test</entry><entry>function</entry><entry>milliseconds</entry><entry>3.69*</entry><entry>performance; </entry></row><row><entry/><entry/><entry/><entry/><entry>mean of </entry></row><row><entry/><entry/><entry/><entry/><entry>the log<sub>10</sub></entry></row><row><entry/><entry/><entry/><entry/><entry>transformed </entry></row><row><entry/><entry/><entry/><entry/><entry>reaction </entry></row><row><entry/><entry/><entry/><entry/><entry>times for</entry></row><row><entry/><entry/><entry/><entry/><entry>correct </entry></row><row><entry/><entry/><entry/><entry/><entry>responses</entry></row><row><entry>Identi- </entry><entry>Visual</entry><entry>Log<sub>10</sub></entry><entry>0 to</entry><entry>Speed of </entry></row><row><entry>fication</entry><entry>attention</entry><entry>milliseconds</entry><entry>3.69*</entry><entry>performance; </entry></row><row><entry>Test</entry><entry/><entry/><entry/><entry>mean of </entry></row><row><entry/><entry/><entry/><entry/><entry>the log<sub>10 </sub></entry></row><row><entry/><entry/><entry/><entry/><entry>transformed </entry></row><row><entry/><entry/><entry/><entry/><entry>reaction </entry></row><row><entry/><entry/><entry/><entry/><entry>times for</entry></row><row><entry/><entry/><entry/><entry/><entry>correct </entry></row><row><entry/><entry/><entry/><entry/><entry>responses</entry></row><row><entry>One Card </entry><entry>Visual</entry><entry>Arcsine</entry><entry>&#x2009;0-1.57</entry><entry>Accuracy of </entry></row><row><entry>Learning </entry><entry>learning</entry><entry>proportion</entry><entry/><entry>performance; </entry></row><row><entry>Test</entry><entry/><entry>correct</entry><entry/><entry>arcsine</entry></row><row><entry/><entry/><entry/><entry/><entry>transformation </entry></row><row><entry/><entry/><entry/><entry/><entry>of the </entry></row><row><entry/><entry/><entry/><entry/><entry>proportion of</entry></row><row><entry/><entry/><entry/><entry/><entry>correct </entry></row><row><entry/><entry/><entry/><entry/><entry>responses</entry></row><row><entry>One Back </entry><entry>Working</entry><entry>Log<sub>10</sub></entry><entry>&#x2009;0-3 69</entry><entry>Speed of </entry></row><row><entry>Test</entry><entry>memory</entry><entry>milliseconds</entry><entry/><entry>performance: </entry></row><row><entry/><entry/><entry/><entry/><entry>mean of </entry></row><row><entry/><entry/><entry/><entry/><entry>the log<sub>10 </sub></entry></row><row><entry/><entry/><entry/><entry/><entry>transformed </entry></row><row><entry/><entry/><entry/><entry/><entry>reaction </entry></row><row><entry/><entry/><entry/><entry/><entry>times for</entry></row><row><entry/><entry/><entry/><entry/><entry>correct </entry></row><row><entry/><entry/><entry/><entry/><entry>responses</entry></row><row><entry>Continuous </entry><entry>Hippocampal</entry><entry>Number of</entry><entry>0-999</entry><entry>Number of </entry></row><row><entry>Paired</entry><entry>dependent</entry><entry>errors across</entry><entry/><entry>errors </entry></row><row><entry>Associate </entry><entry>learning and</entry><entry>all learning</entry><entry/><entry>remembering </entry></row><row><entry>Learning </entry><entry>memory</entry><entry>trials</entry><entry/><entry>the </entry></row><row><entry>Test</entry><entry/><entry/><entry/><entry>associations</entry></row><row><entry>Continuous </entry><entry>Hippocampal</entry><entry>Number of</entry><entry>0-999</entry><entry>Number of </entry></row><row><entry>Paired</entry><entry>dependent</entry><entry>errors across</entry><entry/><entry>errors </entry></row><row><entry>Associate </entry><entry>learning and</entry><entry>single </entry><entry/><entry>remembering </entry></row><row><entry>Learning </entry><entry>memory</entry><entry>delayed</entry><entry/><entry>the</entry></row><row><entry>Test-</entry><entry/><entry>trial</entry><entry/><entry>associations </entry></row><row><entry>Delayed </entry><entry/><entry/><entry/><entry>after a delay</entry></row><row><entry>Recall</entry></row><row><entry namest="1" nameend="5" align="center" rowsep="1"/></row><row><entry namest="1" nameend="5" align="left" id="FOO-00001">*Reaction times longer than 5 seconds (i.e. log10 [5000]) were excluded as reflecting responses that were abnormally slow.</entry></row><row><entry namest="1" nameend="5" align="left" id="FOO-00002"># for this test total n errors in a single administration was controlled so that patients who did not understand the test were not tested unnecessarily.</entry></row></tbody></tgroup></table></tables></p><p id="p-0306" num="0247">The outcomes of each of the Tests included in the Cogstate Test Battery are described below.</p><heading id="h-0029" level="1">Example 1: Detection Test</heading><p id="p-0307" num="0248">Compared to the placebo subject group, the subject group administered Xanamem&#x2122; showed improved psychomotor function. This is demonstrated by the improved speed of performance of the subjects administered Xanamem&#x2122;, which was measured by means of the log<sub>10 </sub>transformed reaction times for correct responses by the subjects.</p><p id="p-0308" num="0249">The test scores from the Detection Test are shown in <figref idref="DRAWINGS">FIG. <b>1</b>A</figref>(<b>1</b>) and <figref idref="DRAWINGS">FIG. <b>1</b>A</figref>(<b>2</b>) for all of the subjects, <figref idref="DRAWINGS">FIG. <b>1</b>B</figref>(<b>1</b>) and <figref idref="DRAWINGS">FIG. <b>1</b>B</figref>(<b>2</b>) for all of the female subjects, and <figref idref="DRAWINGS">FIG. <b>1</b>C</figref>(<b>1</b>) and <figref idref="DRAWINGS">FIG. <b>1</b>C</figref>(<b>2</b>) for all of the male subjects. A linear plot of mean (&#xb1;SD) Detection Test results over visit by treatment group is shown in <figref idref="DRAWINGS">FIG. <b>1</b>D</figref>.</p><heading id="h-0030" level="1">Example 2: Identification Test</heading><p id="p-0309" num="0250">Compared to the placebo subject group, the subject group administered Xanamem&#x2122; showed improved visual attention. This is demonstrated by the improved speed of performance of the subjects administered Xanamem&#x2122;, which was measured by means of the log<sub>10 </sub>transformed reaction times for correct responses by the subjects.</p><p id="p-0310" num="0251">The test scores from the Identification Test are shown in <figref idref="DRAWINGS">FIG. <b>2</b>A</figref>(<b>1</b>) and <figref idref="DRAWINGS">FIG. <b>2</b>A</figref>(<b>2</b>) for all of the subjects, <figref idref="DRAWINGS">FIG. <b>2</b>B</figref>(<b>1</b>) and <figref idref="DRAWINGS">FIG. <b>2</b>B</figref>(<b>2</b>) for all of the female subjects, and <figref idref="DRAWINGS">FIG. <b>2</b>C</figref>(<b>1</b>) and <figref idref="DRAWINGS">FIG. <b>2</b>C</figref>(<b>2</b>) for all of the male subjects. A linear plot of mean (&#xb1;SD) Identification Test results over visit by treatment group is shown in <figref idref="DRAWINGS">FIG. <b>2</b>D</figref>.</p><heading id="h-0031" level="1">Example 3: One Card Learning Test</heading><p id="p-0311" num="0252">Compared to the placebo subject group, the subject group administered Xanamem&#x2122; showed improved visual learning in week 8. This is demonstrated by the improved accuracy of performance in week 8 of the subjects administered Xanamem&#x2122;, which was measured by arcsine transformation of the proportion of correct responses by the subjects.</p><p id="p-0312" num="0253">The test scores from the One Card Learning Test are shown in <figref idref="DRAWINGS">FIG. <b>3</b>A</figref>(<b>1</b>) and <figref idref="DRAWINGS">FIG. <b>3</b>A</figref>(<b>2</b>) for all of the subjects, <figref idref="DRAWINGS">FIG. <b>3</b>B</figref>(<b>1</b>) and <figref idref="DRAWINGS">FIG. <b>3</b>B</figref>(<b>2</b>) for all of the female subjects, and <figref idref="DRAWINGS">FIG. <b>3</b>C</figref>(<b>1</b>) and <figref idref="DRAWINGS">FIG. <b>3</b>C</figref>(<b>2</b>) for all of the male subjects. A linear plot of mean (&#xb1;SD) One Card Learning Test results over visit by treatment group is shown in <figref idref="DRAWINGS">FIG. <b>3</b>D</figref>.</p><heading id="h-0032" level="1">Example 4: One Back Working Memory Test</heading><p id="p-0313" num="0254">Compared to the placebo subject group, the subject group administered Xanamem&#x2122; showed improved working memory. This is demonstrated by the significantly improved speed of performance of the subjects administered Xanamem&#x2122;, which was measured by means of the log<sub>10 </sub>transformed reaction times for correct responses by the subjects.</p><p id="p-0314" num="0255">The test scores from One Back Working Memory test are shown in <figref idref="DRAWINGS">FIG. <b>4</b>A</figref>(<b>1</b>) and <figref idref="DRAWINGS">FIG. <b>4</b>A</figref>(<b>2</b>) for all of the subjects, <figref idref="DRAWINGS">FIG. <b>4</b>B</figref>(<b>1</b>) and <figref idref="DRAWINGS">FIG. <b>4</b>B</figref>(<b>2</b>) for all of the female subjects, and <figref idref="DRAWINGS">FIG. <b>4</b>C</figref>(<b>1</b>) and <figref idref="DRAWINGS">FIG. <b>4</b>C</figref>(<b>2</b>) for all of the male subjects. A linear plot of mean (&#xb1;SD) One Back Test results over visit by treatment group is shown in <figref idref="DRAWINGS">FIG. <b>4</b>D</figref>.</p><heading id="h-0033" level="1">Example 5: Continuous Paired Associate Learning Test</heading><p id="p-0315" num="0256">Compared to the placebo subject group, the subject group administered Xanamem&#x2122; showed improved Hippocampal dependent learning and memory. This is demonstrated by the improved performance of the subjects administered Xanamem&#x2122;, which was measured by a number of errors remembering the associations by the subjects.</p><p id="p-0316" num="0257">The test scores from the Continuous Paired Associate Learning Test are shown in <figref idref="DRAWINGS">FIG. <b>5</b>A</figref>(<b>1</b>) and <figref idref="DRAWINGS">FIG. <b>5</b>A</figref>(<b>2</b>) for all of the subjects, <figref idref="DRAWINGS">FIG. <b>5</b>B</figref>(<b>1</b>) and <figref idref="DRAWINGS">FIG. <b>5</b>B</figref>(<b>2</b>) for all of the female subjects, and <figref idref="DRAWINGS">FIG. <b>5</b>C</figref>(<b>1</b>) and <figref idref="DRAWINGS">FIG. <b>5</b>C</figref>(<b>2</b>) for all of the male subjects. A linear plot of mean (&#xb1;SD) Continuous Paired Associated Learning Test results over visit by treatment group is shown in <figref idref="DRAWINGS">FIG. <b>5</b>D</figref>.</p><heading id="h-0034" level="1">Example 6: Continuous Paired Associate Learning-Delayed Test</heading><p id="p-0317" num="0258">Compared to the placebo subject group, the subject group administered Xanamem&#x2122; showed improved Hippocampal dependent learning and memory. This is demonstrated by the improved performance of the subjects administered Xanamem&#x2122;, which was measured by number of errors remembering the associations after a delay by the subjects.</p><p id="p-0318" num="0259">The test scores from the Continuous Paired Associate Learning-Delayed Test are shown in <figref idref="DRAWINGS">FIG. <b>6</b>A</figref>(<b>1</b>) and <figref idref="DRAWINGS">FIG. <b>6</b>A</figref>(<b>2</b>) for all of the subjects, <figref idref="DRAWINGS">FIG. <b>6</b>B</figref>(<b>1</b>) and <figref idref="DRAWINGS">FIG. <b>6</b>B</figref>(<b>2</b>) for all of the female subjects, and <figref idref="DRAWINGS">FIG. <b>6</b>C</figref>(<b>1</b>) and <figref idref="DRAWINGS">FIG. <b>6</b>C</figref>(<b>2</b>) for all of the male subjects. A linear plot of mean (&#xb1;SD) Continuous Paired Associated Learning-Delayed Test results over visit by treatment group is shown in <figref idref="DRAWINGS">FIG. <b>6</b>D</figref>.</p><heading id="h-0035" level="1">Example 7: Conclusions of Cogstate Test Battery</heading><p id="p-0319" num="0260">Statistically significant and large effects (&#x3e;0.6) of 12 weeks treatment with Xanamem&#x2122; 20 mg versus placebo were observed for speed of performance on both the Identification and One-back tests, which measure attention and working memory, respectively. These positive effects were evident both at Week 12 (EOT) and also at the earlier post-Baseline assessment time points. Together, they suggest a beneficial effect on cognition of Xanamem&#x2122; 20 mg when compared to placebo, and include reducing or preventing performance decrements over time in healthy, elderly subjects. Further, support for this was evident in the data for the Detection test, which measures psychomotor speed. The positive effect from Xanamem&#x2122; 20 mg was evident at week 8, and this may have been due, at least in part, to performance differences at Baseline, through effect sizes in favour of Xanamem&#x2122; 20 mg were evident at all time points in sensitivity analysis.</p><p id="p-0320" num="0261">Other additionally statistically significant differences in data were in favour of Xanamem&#x2122; 20 mg on the Continuous Paired Associates Learning Test outcomes. The effect size difference also favoured Xanamem&#x2122; 20 mg at Week 4 in the sensitivity analysis. Overall, the effect size (ES) data for One Card Learning and Continuous Paired Associates outcomes tended to favour Xanamem&#x2122; 20 mg.</p><p id="p-0321" num="0262">Importantly, no systemic evidence of impairment in any respect of cognition was observed to be associated with treatment with Xanamem&#x2122; 20 mg when compared to placebo over the 12 weeks of this study.</p><heading id="h-0036" level="1">Example 8: Pharmacokinetics</heading><p id="p-0322" num="0263">The mean Xanamem&#x2122; plasma concentration at 3-5 hours after the first dose of the study was 169 ng/mL. Trough and 3-5 hour concentrations were consistent across Weeks 2, 4, and 8, suggesting that steady state had been achieved by Week 2. The mean trough concentration at Weeks 2, 4, and 8, was 89, 73, and 78 ng/mL, and the mean 3 to 5 hour concentration was 353. 331, and 330 ng/mL for weeks 2, 4, and 8, respectively.</p><p id="p-0323" num="0264">The ratio of Xanamem&#x2122; CSF to plasma concentrations in the four CSF samples taken at the EOT visit ranged from 0.028 to 0.421; the range of CSF concentrations was 3.48 to 6.25 ng/mL, compared to 11.6 to 126 ng/mL for the corresponding plasma concentrations.</p><p id="p-0324" num="0265">The pharmacokinetics of Xanamem&#x2122; were well described using a one-compartment model with first-order absorption and elimination. Only body weight was identified as a covariate impacting PK in this model, confirming that the PK of Xanamem&#x2122; are consistent between healthy volunteers, patients with Alzheimer's Disease, and healthy elderly subjects. The results are shown in <figref idref="DRAWINGS">FIG. <b>7</b></figref>.</p><p id="p-0325" num="0266">It will be appreciated by persons skilled in the art that numerous variations and/or modifications may be made to the above-described embodiments, without departing from the broad general scope of the present disclosure. The present embodiments are, therefore, to be considered in all respects as illustrative and not restrictive.</p><?detailed-description description="Detailed Description" end="tail"?></description><us-chemistry idref="CHEM-US-00001" cdx-file="US20230000843A1-20230105-C00001.CDX" mol-file="US20230000843A1-20230105-C00001.MOL"/><us-chemistry idref="CHEM-US-00002" cdx-file="US20230000843A1-20230105-C00002.CDX" mol-file="US20230000843A1-20230105-C00002.MOL"/><us-chemistry idref="CHEM-US-00003" cdx-file="US20230000843A1-20230105-C00003.CDX" mol-file="US20230000843A1-20230105-C00003.MOL"/><us-chemistry idref="CHEM-US-00004" cdx-file="US20230000843A1-20230105-C00004.CDX" mol-file="US20230000843A1-20230105-C00004.MOL"/><us-chemistry idref="CHEM-US-00005" cdx-file="US20230000843A1-20230105-C00005.CDX" mol-file="US20230000843A1-20230105-C00005.MOL"/><us-chemistry idref="CHEM-US-00006" cdx-file="US20230000843A1-20230105-C00006.CDX" mol-file="US20230000843A1-20230105-C00006.MOL"/><us-chemistry idref="CHEM-US-00007" cdx-file="US20230000843A1-20230105-C00007.CDX" mol-file="US20230000843A1-20230105-C00007.MOL"/><us-chemistry idref="CHEM-US-00008" cdx-file="US20230000843A1-20230105-C00008.CDX" mol-file="US20230000843A1-20230105-C00008.MOL"/><us-chemistry idref="CHEM-US-00009" cdx-file="US20230000843A1-20230105-C00009.CDX" mol-file="US20230000843A1-20230105-C00009.MOL"/><us-chemistry idref="CHEM-US-00010" cdx-file="US20230000843A1-20230105-C00010.CDX" mol-file="US20230000843A1-20230105-C00010.MOL"/><us-chemistry idref="CHEM-US-00011" cdx-file="US20230000843A1-20230105-C00011.CDX" mol-file="US20230000843A1-20230105-C00011.MOL"/><us-chemistry idref="CHEM-US-00012" cdx-file="US20230000843A1-20230105-C00012.CDX" mol-file="US20230000843A1-20230105-C00012.MOL"/><us-chemistry idref="CHEM-US-00013" cdx-file="US20230000843A1-20230105-C00013.CDX" mol-file="US20230000843A1-20230105-C00013.MOL"/><us-chemistry idref="CHEM-US-00014" cdx-file="US20230000843A1-20230105-C00014.CDX" mol-file="US20230000843A1-20230105-C00014.MOL"/><us-chemistry idref="CHEM-US-00015" cdx-file="US20230000843A1-20230105-C00015.CDX" mol-file="US20230000843A1-20230105-C00015.MOL"/><us-chemistry idref="CHEM-US-00016" cdx-file="US20230000843A1-20230105-C00016.CDX" mol-file="US20230000843A1-20230105-C00016.MOL"/><us-chemistry idref="CHEM-US-00017" cdx-file="US20230000843A1-20230105-C00017.CDX" mol-file="US20230000843A1-20230105-C00017.MOL"/><us-chemistry idref="CHEM-US-00018" cdx-file="US20230000843A1-20230105-C00018.CDX" mol-file="US20230000843A1-20230105-C00018.MOL"/><us-chemistry idref="CHEM-US-00019" cdx-file="US20230000843A1-20230105-C00019.CDX" mol-file="US20230000843A1-20230105-C00019.MOL"/><us-chemistry idref="CHEM-US-00020" cdx-file="US20230000843A1-20230105-C00020.CDX" mol-file="US20230000843A1-20230105-C00020.MOL"/><us-chemistry idref="CHEM-US-00021" cdx-file="US20230000843A1-20230105-C00021.CDX" mol-file="US20230000843A1-20230105-C00021.MOL"/><us-chemistry idref="CHEM-US-00022" cdx-file="US20230000843A1-20230105-C00022.CDX" mol-file="US20230000843A1-20230105-C00022.MOL"/><us-chemistry idref="CHEM-US-00023" cdx-file="US20230000843A1-20230105-C00023.CDX" mol-file="US20230000843A1-20230105-C00023.MOL"/><us-chemistry idref="CHEM-US-00024" cdx-file="US20230000843A1-20230105-C00024.CDX" mol-file="US20230000843A1-20230105-C00024.MOL"/><us-chemistry idref="CHEM-US-00025" cdx-file="US20230000843A1-20230105-C00025.CDX" mol-file="US20230000843A1-20230105-C00025.MOL"/><us-chemistry idref="CHEM-US-00026" cdx-file="US20230000843A1-20230105-C00026.CDX" mol-file="US20230000843A1-20230105-C00026.MOL"/><us-chemistry idref="CHEM-US-00027" cdx-file="US20230000843A1-20230105-C00027.CDX" mol-file="US20230000843A1-20230105-C00027.MOL"/><us-chemistry idref="CHEM-US-00028" cdx-file="US20230000843A1-20230105-C00028.CDX" mol-file="US20230000843A1-20230105-C00028.MOL"/><us-chemistry idref="CHEM-US-00029" cdx-file="US20230000843A1-20230105-C00029.CDX" mol-file="US20230000843A1-20230105-C00029.MOL"/><us-chemistry idref="CHEM-US-00030" cdx-file="US20230000843A1-20230105-C00030.CDX" mol-file="US20230000843A1-20230105-C00030.MOL"/><us-chemistry idref="CHEM-US-00031" cdx-file="US20230000843A1-20230105-C00031.CDX" mol-file="US20230000843A1-20230105-C00031.MOL"/><us-chemistry idref="CHEM-US-00032" cdx-file="US20230000843A1-20230105-C00032.CDX" mol-file="US20230000843A1-20230105-C00032.MOL"/><us-chemistry idref="CHEM-US-00033" cdx-file="US20230000843A1-20230105-C00033.CDX" mol-file="US20230000843A1-20230105-C00033.MOL"/><us-chemistry idref="CHEM-US-00034" cdx-file="US20230000843A1-20230105-C00034.CDX" mol-file="US20230000843A1-20230105-C00034.MOL"/><us-chemistry idref="CHEM-US-00035" cdx-file="US20230000843A1-20230105-C00035.CDX" mol-file="US20230000843A1-20230105-C00035.MOL"/><us-chemistry idref="CHEM-US-00036" cdx-file="US20230000843A1-20230105-C00036.CDX" mol-file="US20230000843A1-20230105-C00036.MOL"/><us-chemistry idref="CHEM-US-00037" cdx-file="US20230000843A1-20230105-C00037.CDX" mol-file="US20230000843A1-20230105-C00037.MOL"/><us-chemistry idref="CHEM-US-00038" cdx-file="US20230000843A1-20230105-C00038.CDX" mol-file="US20230000843A1-20230105-C00038.MOL"/><us-chemistry idref="CHEM-US-00039" cdx-file="US20230000843A1-20230105-C00039.CDX" mol-file="US20230000843A1-20230105-C00039.MOL"/><us-chemistry idref="CHEM-US-00040" cdx-file="US20230000843A1-20230105-C00040.CDX" mol-file="US20230000843A1-20230105-C00040.MOL"/><us-chemistry idref="CHEM-US-00041" cdx-file="US20230000843A1-20230105-C00041.CDX" mol-file="US20230000843A1-20230105-C00041.MOL"/><us-chemistry idref="CHEM-US-00042" cdx-file="US20230000843A1-20230105-C00042.CDX" mol-file="US20230000843A1-20230105-C00042.MOL"/><us-chemistry idref="CHEM-US-00043" cdx-file="US20230000843A1-20230105-C00043.CDX" mol-file="US20230000843A1-20230105-C00043.MOL"/><us-chemistry idref="CHEM-US-00044" cdx-file="US20230000843A1-20230105-C00044.CDX" mol-file="US20230000843A1-20230105-C00044.MOL"/><us-chemistry idref="CHEM-US-00045" cdx-file="US20230000843A1-20230105-C00045.CDX" mol-file="US20230000843A1-20230105-C00045.MOL"/><us-chemistry idref="CHEM-US-00046" cdx-file="US20230000843A1-20230105-C00046.CDX" mol-file="US20230000843A1-20230105-C00046.MOL"/><us-chemistry idref="CHEM-US-00047" cdx-file="US20230000843A1-20230105-C00047.CDX" mol-file="US20230000843A1-20230105-C00047.MOL"/><us-chemistry idref="CHEM-US-00048" cdx-file="US20230000843A1-20230105-C00048.CDX" mol-file="US20230000843A1-20230105-C00048.MOL"/><us-chemistry idref="CHEM-US-00049" cdx-file="US20230000843A1-20230105-C00049.CDX" mol-file="US20230000843A1-20230105-C00049.MOL"/><us-chemistry idref="CHEM-US-00050" cdx-file="US20230000843A1-20230105-C00050.CDX" mol-file="US20230000843A1-20230105-C00050.MOL"/><us-chemistry idref="CHEM-US-00051" cdx-file="US20230000843A1-20230105-C00051.CDX" mol-file="US20230000843A1-20230105-C00051.MOL"/><us-chemistry idref="CHEM-US-00052" cdx-file="US20230000843A1-20230105-C00052.CDX" mol-file="US20230000843A1-20230105-C00052.MOL"/><us-chemistry idref="CHEM-US-00053" cdx-file="US20230000843A1-20230105-C00053.CDX" mol-file="US20230000843A1-20230105-C00053.MOL"/><us-chemistry idref="CHEM-US-00054" cdx-file="US20230000843A1-20230105-C00054.CDX" mol-file="US20230000843A1-20230105-C00054.MOL"/><us-chemistry idref="CHEM-US-00055" cdx-file="US20230000843A1-20230105-C00055.CDX" mol-file="US20230000843A1-20230105-C00055.MOL"/><us-chemistry idref="CHEM-US-00056" cdx-file="US20230000843A1-20230105-C00056.CDX" mol-file="US20230000843A1-20230105-C00056.MOL"/><claims id="claims"><claim id="CLM-00001" num="00001"><claim-text><b>1</b>. A method of preventing and/or treating cognitive decline in a cognitively healthy subject, comprising administering to the cognitively healthy subject a therapeutically effective amount of a compound of Formula I, or a pharmaceutically acceptable salt, solvate or prodrug thereof:</claim-text><claim-text><chemistry id="CHEM-US-00052" num="00052"><img id="EMI-C00052" he="28.45mm" wi="67.31mm" file="US20230000843A1-20230105-C00052.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry><claim-text>wherein R<sup>1 </sup>and R<sup>2 </sup>are each independently selected from the group consisting of hydrogen, halogen, C<sub>1-6</sub>alkyl, &#x2014;O&#x2014;C<sub>1-6</sub>alkyl, C<sub>1-6</sub>haloalkyl, &#x2014;O&#x2014;C<sub>1-6</sub>haloalkyl, C<sub>2-6</sub>alkenyl, C<sub>2-6</sub>alkynyl, 3-10-membered carbocyclyl, 3-10-membered heterocyclyl, &#x2014;CN, &#x2014;CF<sub>3</sub>, &#x2014;OR<sup>3</sup>, &#x2014;SR<sup>3</sup>, &#x2014;NR<sup>3</sup>R<sup>4</sup>, &#x2014;COR<sup>3</sup>, &#x2014;CO<sub>2</sub>R<sup>3</sup>, &#x2014;CONR<sup>3</sup>R<sup>4</sup>, &#x2014;NR<sup>3</sup>COR<sup>4</sup>, &#x2014;SO<sub>2</sub>R<sup>3</sup>, &#x2014;SO<sub>2</sub>NR<sup>3</sup>R<sup>4</sup>, and &#x2014;NR<sup>3</sup>SO<sub>2</sub>R<sup>4</sup>;</claim-text><claim-text>wherein R<sup>3 </sup>and R<sup>4 </sup>are each independently selected from the group consisting of hydrogen, C<sub>1-6</sub>alkyl, 3-7-membered carbocyclyl and 3-7-membered heterocyclyl;</claim-text><claim-text>wherein each 3-10-membered carbocyclyl, 3-10-membered heterocyclyl, 3-7-membered carbocyclyl, and 3-7-membered heterocyclyl, is unsubstituted or substituted with one or more substituents selected from the group consisting of hydrogen, halogen, C<sub>1-6</sub>alkyl, &#x2014;O&#x2014;C<sub>1-6</sub>alkyl, C<sub>1-6</sub>haloalkyl, &#x2014;O&#x2014;C<sub>1-6</sub>haloalkyl, C<sub>2-6</sub>alkenyl, C<sub>2-6</sub>alkynyl, &#x2014;CN, &#x2014;CF<sub>3</sub>, &#x2014;OR<sup>5</sup>, &#x2014;SR<sup>5</sup>, &#x2014;NR<sup>5</sup>R<sup>6</sup>, &#x2014;COR<sup>5</sup>, &#x2014;CO<sub>2</sub>R<sup>5</sup>, &#x2014;CONR<sup>5</sup>R<sup>6</sup>, &#x2014;NR<sup>5</sup>COR<sup>6</sup>, &#x2014;SO<sub>2</sub>R<sup>5</sup>, &#x2014;SO<sub>2</sub>NR<sup>5</sup>R<sup>6</sup>, and &#x2014;NR<sup>5</sup>SO<sub>2</sub>R<sup>6</sup>; and wherein each R<sup>5 </sup>and R<sup>6 </sup>are independently selected from the group consisting of hydrogen and C<sub>1-6</sub>alkyl.</claim-text></claim-text></claim><claim id="CLM-00002" num="00002"><claim-text><b>2</b>. (canceled)</claim-text></claim><claim id="CLM-00003" num="00003"><claim-text><b>3</b>. The method of <claim-ref idref="CLM-00001">claim 1</claim-ref>, wherein R<sup>1 </sup>and R<sup>2 </sup>are each independently selected from the group consisting of hydrogen, halogen, 3-10-membered carbocyclyl, 3-10-membered heterocyclyl, &#x2014;OH, &#x2014;CN, and &#x2014;NH<sub>2</sub>; and wherein if present, each 3-10-membered carbocyclyl and 3-10-membered heterocyclyl may be further substituted with one or more substituents selected from the group consisting of hydrogen, halogen, &#x2014;OH, &#x2014;CN, &#x2014;CF<sub>3</sub>, &#x2014;NH<sub>2</sub>, and C<sub>1-6</sub>alkyl.</claim-text></claim><claim id="CLM-00004" num="00004"><claim-text><b>4</b>. The method of <claim-ref idref="CLM-00001">claim 1</claim-ref>, wherein R<sup>1 </sup>and R<sup>2 </sup>are each independently selected from the group consisting of hydrogen, halogen, 6-membered carbocyclyl, 6-membered heterocyclyl, &#x2014;OH, &#x2014;CN, and &#x2014;NH<sub>2</sub>; and wherein if present, each 6-membered carbocyclyl and 6-membered heterocyclyl may be further substituted with one or more substituents selected from the group consisting of hydrogen, halogen, &#x2014;OH, &#x2014;CN, &#x2014;CF<sub>3</sub>, &#x2014;NH<sub>2</sub>, and C<sub>1-6</sub>alkyl.</claim-text></claim><claim id="CLM-00005" num="00005"><claim-text><b>5</b>. The method of <claim-ref idref="CLM-00001">claim 1</claim-ref>, wherein R<sup>1 </sup>is selected from the group consisting of hydrogen, halogen, &#x2014;OH, &#x2014;CN, &#x2014;CF<sub>3</sub>, &#x2014;NH<sub>2</sub>, and C<sub>1-6</sub>alkyl, and R<sup>2 </sup>is independently selected from the group consisting of:</claim-text><claim-text><chemistry id="CHEM-US-00053" num="00053"><img id="EMI-C00053" he="101.43mm" wi="50.72mm" file="US20230000843A1-20230105-C00053.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></claim-text></claim><claim id="CLM-00006" num="00006"><claim-text><b>6</b>. The method of <claim-ref idref="CLM-00001">claim 1</claim-ref>, wherein the compound of Formula I is selected from the group consisting of:</claim-text><claim-text><chemistry id="CHEM-US-00054" num="00054"><img id="EMI-C00054" he="239.61mm" wi="54.86mm" file="US20230000843A1-20230105-C00054.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry><chemistry id="CHEM-US-00055" num="00055"><img id="EMI-C00055" he="82.72mm" wi="62.74mm" file="US20230000843A1-20230105-C00055.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></claim-text></claim><claim id="CLM-00007" num="00007"><claim-text><b>7</b>. The method of <claim-ref idref="CLM-00001">claim 1</claim-ref>, wherein the compound of Formula I is:</claim-text><claim-text><chemistry id="CHEM-US-00056" num="00056"><img id="EMI-C00056" he="33.53mm" wi="54.69mm" file="US20230000843A1-20230105-C00056.TIF" alt="embedded image" img-content="chem" img-format="tif"/></chemistry></claim-text></claim><claim id="CLM-00008" num="00008"><claim-text><b>8</b>. (canceled)</claim-text></claim><claim id="CLM-00009" num="00009"><claim-text><b>9</b>. The method of <claim-ref idref="CLM-00001">claim 1</claim-ref>, wherein the cognitively healthy subject is not suffering from another, diagnosed medical condition that is associated with the central nervous system (CNS) and the subject has an increased risk of cognitive decline.</claim-text></claim><claim id="CLM-00010" num="00010"><claim-text><b>10</b>. (canceled)</claim-text></claim><claim id="CLM-00011" num="00011"><claim-text><b>11</b>. The method of <claim-ref idref="CLM-00009">claim 9</claim-ref>, wherein the increased risk of cognitive decline is provided by a risk factor selected from the group consisting of an increased risk of stroke, the presence of genetic markers associated with cognitive decline, a family history of cognitive decline, environmental factors associated with cognitive decline, societal factors associated with cognitive decline, external factors associated with cognitive decline, and side effects associated with therapeutic treatment.</claim-text></claim><claim id="CLM-00012" num="00012"><claim-text><b>12</b>. The method of <claim-ref idref="CLM-00001">claim 1</claim-ref>, wherein the administration of a compound of Formula I, or a pharmaceutically acceptable salt, solvate or prodrug thereof, provides improved cognitive ability of the treated subject relative to a non-treated subject determinable by cognitive testing.</claim-text></claim><claim id="CLM-00013" num="00013"><claim-text><b>13</b>. (canceled)</claim-text></claim><claim id="CLM-00014" num="00014"><claim-text><b>14</b>. The method of <claim-ref idref="CLM-00001">claim 1</claim-ref>, wherein the administration of a compound of Formula I, or a pharmaceutically acceptable salt, solvate or prodrug thereof, provides an improvement of psychomotor function of the treated subject relative to a non-treated subject.</claim-text></claim><claim id="CLM-00015" num="00015"><claim-text><b>15</b>. The method of <claim-ref idref="CLM-00014">claim 14</claim-ref>, wherein the improvement of psychomotor function is at least partial restoration of motor function provided by an improvement in simple reaction time.</claim-text></claim><claim id="CLM-00016" num="00016"><claim-text><b>16</b>. (canceled)</claim-text></claim><claim id="CLM-00017" num="00017"><claim-text><b>17</b>. The method <claim-ref idref="CLM-00001">claim 1</claim-ref>, wherein the administration of a compound of Formula I, or a pharmaceutically acceptable salt, solvate or prodrug thereof, provides an improvement of visual attention of the treated subject relative to a non-treated subject.</claim-text></claim><claim id="CLM-00018" num="00018"><claim-text><b>18</b>. The method of <claim-ref idref="CLM-00017">claim 17</claim-ref>, wherein the improvement in visual attention is provided by an improvement in choice retention time.</claim-text></claim><claim id="CLM-00019" num="00019"><claim-text><b>19</b>. The method of <claim-ref idref="CLM-00001">claim 1</claim-ref>, wherein the administration of a compound of Formula I, or a pharmaceutically acceptable salt, solvate or prodrug thereof, provides an improvement of learning and memory of the treated subject relative to a non-treated subject, by an improvement in visual recognition learning.</claim-text></claim><claim id="CLM-00020" num="00020"><claim-text><b>20</b>. (canceled)</claim-text></claim><claim id="CLM-00021" num="00021"><claim-text><b>21</b>. The method of <claim-ref idref="CLM-00001">claim 1</claim-ref>, wherein the administration of a compound of Formula I, or a pharmaceutically acceptable salt, solvate or prodrug thereof, provides an improvement of working memory of the treated subject relative to a non-treated subject.</claim-text></claim><claim id="CLM-00022" num="00022"><claim-text><b>22</b>. The method of <claim-ref idref="CLM-00001">claim 1</claim-ref>, wherein the administration of a compound of Formula I, or a pharmaceutically acceptable salt, solvate or prodrug thereof, provides an improvement of visual associate memory of the treated subject relative to a non-treated subject.</claim-text></claim><claim id="CLM-00023" num="00023"><claim-text><b>23</b>. The method of <claim-ref idref="CLM-00001">claim 1</claim-ref>, wherein the cognitively healthy subject is selected from one or more of the following categories;<claim-text>has age-related cognitive decline;</claim-text><claim-text>is at least 40 years of age, or between about 1 and about 20 years of age;</claim-text><claim-text>has a low IQ;</claim-text><claim-text>is male.</claim-text></claim-text></claim><claim id="CLM-24-27" num="24-27"><claim-text><b>24</b>-<b>27</b>. (canceled)</claim-text></claim><claim id="CLM-00028" num="00028"><claim-text><b>28</b>. The method of <claim-ref idref="CLM-00001">claim 1</claim-ref>, wherein the compound of Formula I, or a pharmaceutically acceptable salt, solvate or prodrug thereof, is administered in amount so as to deliver a total daily dosage of from about 20 to 40 mg of Formula I, administered as a single once-daily dosage or a twice-daily dosage.</claim-text></claim><claim id="CLM-00029" num="00029"><claim-text><b>29</b>. (canceled)</claim-text></claim><claim id="CLM-00030" num="00030"><claim-text><b>30</b>. The method of <claim-ref idref="CLM-00001">claim 1</claim-ref>, wherein the compound of Formula I, or a pharmaceutically acceptable salt, solvate or prodrug thereof, is administered as a twice-daily dosage of 10 mg per dosage.</claim-text></claim><claim id="CLM-00031" num="00031"><claim-text><b>31</b>. The method of <claim-ref idref="CLM-00001">claim 1</claim-ref>, wherein the compound of Formula I, or a pharmaceutically acceptable salt, solvate or prodrug thereof, is administered orally.</claim-text></claim><claim id="CLM-32-38" num="32-38"><claim-text><b>32</b>-<b>38</b>. (canceled)</claim-text></claim></claims></us-patent-application>